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Cynthia J. Burrows 
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ABSTRACT 
Tuberculosis (TB) remains one of the world’s deadliest infectious diseases, 
second only to Human Immunodeficiency Virus (HIV).  The alarming global 
statistics on TB has prompted a renewed interest in the discovery and development of 
antitubercular drugs in the scientific community.  As part of the growing efforts 
toward the development of new TB drugs, we have identified amicetin as a viable 
candidate for antitubercular drug discovery. A recent natural product library 
screening has identified amicetin, a ribosomal antibiotic isolated from Streptomyces 
vinaceusdrappus in 1953, to be active against TB, relatively noncytotoxic, and 
compatible with current antiretroviral therapy (ART).  Here we present synthetic and 
biological studies on amicetin and its analogues. 
A modular synthetic route towards the formation of cytimidine, a derivative 
of amicetin, as well as some analogues via a one-pot copper catalyzed N-aryl 
amidations is described.  This route allows the efficient and rapid diversification of 
the cytimidine core by  exploiting the  regioselective  coupling of a 4-iodobenzamide 
with a 2-halopyrimidine affording the union of three fragments in a single synthetic 
manipulation.  Synthetic efforts toward the synthesis of the disaccharide moiety 
using the Noyori-Achmatowicz reaction sequence were also presented. 
In line with our efforts, amicetin was expressed, isolated, and purified from 
Streptomyces vinaceusdrappus and was co-crystallized with the 70S subunit of 
Thermus thermophilus ribosome at 3.5 Å.  From our crystallographic data, amicetin 
iv 
forms a Watson-Crick base pair through its cytosine moeity with G2262 
(T. thermophilus numbering).  Its aminosugar moeity forms cation-π interactions 
with the A2450 while its p-aminobenzoyl group π-stacks with A2613.  Its 
α-methylserine moeity forms a hydrogen bond with the R18 of the ribosomal protein 
L16.  Amicetin displaces the penultimate cytosine of the conserved CCA 3’ end of 
the P-site tRNA, trapping the P-site tRNA in a nonproductive conformation, thereby 
inhibiting protein synthesis.   
Additionally, a number of synthesized analogues were found to exhibit good 
antimycobacterial property, the most potent of which, analogue 3, has an IC50 of 
0.98 µM against M. tuberculosis H37Ra and selective cytotoxicity of IC50 > 100 µM 
against CEM-TART cell line.  These active analogues were found to inhibit bacterial 
protein synthesis using luciferase assay. All amicetin analogues were found to 
exhibit a narrow spectrum of antibacterial activity and selective cytotoxicity against 
mammalian cells regardless of their antimycobacterial potency.  Crystal structures 
of analogues 1 and 5 bound to the 70S subunit of the T. thermophilus ribosome were 
obtained at 3.1 Å.  Both analogues were observed occupying the same binding site as 
amicetin.  Analogue 1, the more potent of the two, however, exhibited a closer 
binding motif to amicetin, exhibiting all key interactions aforementioned while 
analogue 5 lacks the cation-π interaction with A2450. 
These discoveries provide modular routes to amicetin analogues as well as 
key insights into their biological activity.  Current and future efforts are being 
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1.1  Tuberculosis:  A Brief History of an Ancient Disease 
 
Tuberculosis (TB) has plagued the human race throughout history and may 
be responsible for the overall highest mortality rate caused by a single pathogen.1  
The earliest known account of TB comes from 4000-5000 year old Egyptian 
mummies with characteristic Pott’s deformities associated with skeletal 
tuberculosis.2  TB was well recorded in ancient Greece, but known by a different 
name, phthisis.1 In 400 BC, in his book Of the Epidemics, Hippocrates described 
phthisis as a fatal disease with symptoms such as coughing, chest pain, and bloody 
sputum.  This is the earliest recorded diagnosis of the disease known today as TB. 3   
During the 19th century, incidence of TB or consumption, as it was known 
back then, was at its peak, especially in Europe with approximately one-quarter of 
the population infected at that time.4  It was not until the 19th century when 
modern understanding of the disease started, beginning with the pioneering work of 
René Théophile Hyacinthe Laennec, who invented the stethoscope and published 
treaties on autopsies of TB patients. 5   His work contributed greatly to the diagnosis 
and understanding of the pathology of the disease, from which we still benefit to this 
day.  Following the work of Laennec, Jean-Antoine Villemin demonstrated the 
transmissibility of TB through the inoculation of a rabbit with liquid from 
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tuberculous cavities– enlarged air spaces formed from extensive necrosis of lung 
tissues.6  A greater understanding of the etiology of TB was attributed to Hermann 
Heinrich Robert Koch. In his famous presentation to the Berlin Physiological 
Society, Die Aetiologie der Tuberculose, he reported the isolation of Mycobacterium 
tuberculosis (Mtb) from both animal and human specimens and the replication of 
the disease in guinea pigs. 7,  8  His work enabled the proper diagnosis of the most 
lethal disease in human history and won him a Noble Prize in Medicine or 
Physiology in 1905.  Koch also isolated tuberculin from the tubercle bacilli, which he 
believed at the time to be a valuable for therapy, but was later found to be more 
useful for diagnostic purposes.  In 1909, Clemens Freiherr von Pirquet followed up 
on Koch’s work and developed a diagnostic protocol known today as the tuberculin 
skin test.9, 10 
With improved diagnostics, as well as proper sanitation in hospital and 
specialized TB sanatariums, TB mortality decreased towards the end of the 19th 
century.  The discovery of the Bacille Calmette-Guérin (BCG) vaccine by Albert 
Calmette and his associate Camille Guérin in 1921 led to extensive vaccination, 
especially among children.11, 12  Introduction of TB chemotherapy culminated the 
modern era of TB management, beginning with the discovery of p-amino salicylic 
acid (PAS) by Jorgen Lehmann in 194313, 14 While PAS was found to be only 
bacteriostatic, it was the first therapeutic agent with any efficacy used in the 
treatment of tuberculosis.  Not long after in 1944, Albert Schatz, Elizabeth Bugie 
and Selman Waksman isolated and reported streptomycin as the first bactericidal 
effective against Mtb.15  Introduction of oral mycobacterial drugs, such as isoniazid 
in 1952, pyrazinamide and rifamycin in 1957, 16  allowed for home treatment, 
diminishing the need for sanatoriums. 17   Implementation of short-course 
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combination therapy in the 1970s then increased treatment success rates to 95%.18   
In the mid-1980’s the treatment success rates declined largely due to the 
emergence of drug-resistant mycobacteria and AIDS.3  First reports of multidrug-
resistant strains of TB (MDR-TB) were reported during this decade.  In 2006, a TB 
epidemic in rural South Africa exposed a new, more deadly strain of TB, which has 
since been labeled as extensively drug-resistant TB (XDR-TB).19  Deadlier strains 
have been reported in the past decade.  In 2007, totally drug-resistant strains (TDR-
TB) were first reported. 20   
TB is an ancient disease with a long history that continues to afflict 
humanity to this day. With the occurrence of TB outbreaks on the rise, the World 
Health Organization (WHO) seeks to address and eradicate this global health 
problem.21   
 
 
1.2  TB: A Global Problem 
 
TB is caused by Mycobacterium tuberculosis (Mtb), an acid-fast rod-shaped 
bacillus primarily transmitted via the respiratory route.7, 8 The bacilli most 
commonly attack the pulmonary system (pulmonary TB or more simply TB), but can 
also affect the genitourinary, vertebral, and nervous system (extra-pulmonary TB).22  
Symptoms of pulmonary TB often include chronic cough, chest pains, sputum 
production, weakness, fatigue, appetite loss, weight loss, fever, chills, night sweats, 
and hemoptysis— the expectoration of blood or blood stained sputum.23   
TB is an airborne disease– the tubercle bacilli can be easily spread through a 
simple exhale, sneeze or cough of an infected person.  A single sneeze for example, 
can release up to 40,000 aerosolized droplets.24  Each droplet, containing as few as 
1-3 bacilli, is capable of infection.25, 26  With such ease of transmission, it is estimated 
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that one-third of the world’s population, about 2 billion people, are infected with 
TB.27,	  28   
TB remains to be the world’s most prevalent infectious disease second only to 
Human Immunodeficiency Virus (HIV), with over 9 million newly reported cases and 
1.5 million TB-related deaths in 2013.27  The subsequent silent transmission of the 
bacilli from untreated patients makes this infectious disease a pressing global health 
problem.  In 2013 alone, an estimated 3 million people with TB were either 
undiagnosed or missed by the national notification systems, leaving these people to 
potentially infect others.27 For every year a single infected individual is left 
untreated, he or she can infect as many as 10-15 other people.29   When left 
undiagnosed and untreated, TB has a mortality rate of about 70% within 10 years.30   
With so many undocumented cases, it is not surprising that annual surveillance 
reports show no significant drop in the number of new cases of TB or TB mortality 
despite years of efforts.31, 32     
The majority of newly reported TB incidents are from poverty-stricken 
regions where deficient public health funding limits access to health care; including, 
but not limited to, proper diagnostic assays, vaccination and chemotherapy. 
Inadequate public health infrastructure has been a major factor in the rapid spread 
and high mortality of the disease.  Poor patient compliance in developing countries 
also presents major obstacles in the complete eradication of TB.  About 56% of newly 
reported cases in 2013 occurred in Asia, with populous countries like India and 
China having the greatest burden of the disease at 24% and 11%, respectively. 
Around 82% of the world’s TB cases are concentrated in 22 high-burden countries, 
with India, China, Nigeria, Pakistan, Indonesia, and South Africa hardest hit.27   
The fewest cases have been reported in developed and high-income regions 
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including the Eastern Mediterranean region at 8%, the European region at 4% and 
the Americas at 3%. Canada, United States of America, Japan, Australia, New 
Zealand, and countries of Western Europe reported the lowest incidence rates, with 
less than 10-50 cases per 100,000 people.27  The highest numbers of reported cases in 
these regions are among foreign-born residents and recent immigrants from 
countries where TB is endemic.33, 34, 35   
With current medical advances on diagnosis and chemotherapy, TB is now 
considered a curable disease.  However, the resurgence of drug resistant pathogens 
and subsequent rise in related morbidity and mortality across the globe presents an 
imposing threat.36  Recent reports on the rise of drug-resistant tuberculosis are 
particularly alarming, and what was considered an ancient scourge has emerged as 
a dangerous threat, especially to developing parts of the world.  The World Health 
Organization (WHO) 2014 Survey reported about 480,000 new cases27 of MDR-TB— 
a form of TB caused by Mtb exhibiting resistance to first-line drugs isoniazid and 
rifampin.37  The number of people diagnosed with MDR-TB tripled between 2009 
and 2013.  About 210,000 MDR-TB related deaths were reported in 2013 alone.27  
XDR-TB is a form of TB caused by Mtb that are not only resistant to first-line 
drugs, but also resistant to fluoroquinolones and second line injectable polypeptides 
or aminoglycosides.38   It has been estimated that the current average percentage of 
MDR-TB cases that are also XDR-TB is about 9.6%.  In 2013, at least one incidence 
of XDR-TB was reported in 100 countries, up from 92 countries in 2012; this number 
includes developed nations such as the United States where TB is not endemic.27 
The ominous progression in the evolution of deadlier strains of Mtb has been 
documented in at least three countries.  In 2007, Migliori and co-workers reported 
two cases of extremely drug-resistant TB (XXDR-TB) in Italy.20 Not long after in 
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2009, the term totally drug resistant-TB (TDR-TB) was first used to describe the 
clinical isolates from 15 patients in Iran that are resistant to all first-line and 
second-line drugs. 39   While the terminology TDR-TB has not yet been officially 
endorsed by the WHO, a published article on TDR-TB cases in India in 201240 
documenting Mtb isolates exhibiting resistance to all drugs has nevertheless 
captured international attention. The official classification of such reported cases 
remain under the XDR-TB classification in spite of their clinical differences and 
manifestations; specifically, their drug-susceptibility test results differ from cases 
that strictly follow the official definition of XDR-TB. 
Compounding the problem of TB is its co-infection with HIV.  A huge upsurge 
in TB cases has been observed since the HIV epidemic in the 1980s.  In 2014, the 
WHO estimated that at least one-third of the 35.3 million people living with HIV are 
co-infected with TB.41  In 2013, there were 1.1 million new cases of TB among HIV-
positive people.  TB remains to be the leading cause of death among people with HIV 
infection; in 2013 about 360,000 HIV-associated TB deaths were reported in that 
year alone.27  
TB has once been considered an ancient scourge, a disease of the past.  In the 
present-day era of advanced therapeutics and antibiotics, epidemiological studies 
have shown, however, that this infectious disease has resurfaced and is now a 
modern-day global problem. Overall, global statistics for both occurrence and related 
mortality for drug resistant TB have remained considerably unchanged since 
2007.27-32  Efforts from the medical and scientific community, governing bodies and 





1.3  TB Drugs and Treatment Regimen 
Currently, there are more than twenty anti-TB drugs that are used for the 
treatment of TB.42  They are classified into two main groups based on efficacy, 
potency, disease strain, and experience of use. First-line drugs have the greatest 
activity against Mtb and are the first compounds administered to new patients with 
active TB. The basic TB drugs include isoniazid, rifampin, pyrazinamide, and 
ethambutol (Table 1.1).  
Second-line drugs are usually reserved for drug-resistant cases (Table 1.2).  
Compounds in this class are  comprised of  injectable   aminoglycosides,  injectable 
Table 1.1 First-line TB drugs43 
Drug 
(Abbreviation) 
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polypeptide, oral and injectable fluoroquinolones, and various other orally 
administered compounds.  A third group of TB drugs, third-line drugs, have 
undefined roles and efficacy but are used in very special cases of drug-resistant TB 
such as XDR-TB and TDR-TB.  Third-line anti-TB drugs are more expensive and 
have more side effects than first-line and second-line drugs, and are only 
administered as a last resort.42 
TB treatment requires at least six months of two-phase short-course regimen, 
administered under direct observed therapy (DOT).  The first phase is a 2-month 
long intensive dosage of four drugs: isoniazid (INH), rifampicin (RMP), 
pyrazinamide (PZA) and ethambutol (EMB). It is followed by a 4-month course of 
isoniazid and rifampicin.42 Globally, the success rate of short course treatment is 
about 87% recovery.44   
Combination therapy for the basic treatment of   drug-susceptible TB (DS-TB) 
was introduced in the 1970’s and has been used for over fifty years.18 Regimens are 
only adjusted in cases of drug-resistant  TB.  The rationale for  combination  therapy 
is based on lowering the probability of resistance though spontaneous mutation.  For 
example, the frequency of spontaneous mutations conferring resistance for first line 
drugs ranges from 10-6 to 10-10 –  about  10-5 for PZA, 10-7 for EMB, 10-8 INH, and 10- 
10 for RMP.45  Because these mutations are independent of each other, in theory, the 
probability of developing bacillary resistance to a four-drug regimen consisting of 
INH, RMP, PZA, and EMB becomes 10-30.  The probability of simultaneous resistance 
to three anti-TB drugs would be virtually nonexistent and treatment success rate is 
increased.   
Additionally, Mtb is a complex pathogen that exists in different populations 
of varying growth rates and persistence during infection. In a single infected 
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individual, there would be rapidly growing bacilli alongside with slowly growing, as 
well as sporadically replicating populations.46  INH and STM both exhibit good 
bactericidal properties and therefore can address the rapidly growing populations.43  
However, these agents are not suitable for clearing persistent and sporadically 
multiplying population of Mtb.  PZA, a sterilizing antibiotic, effectively kills these 
persistent populations.43  Combination therapy affords access to drugs with different 
modes of action, thereby effectively addressing problems in treating TB infection.  
 
 
1.4  TB Pathogenesis 
 
TB infection begins when droplet nuclei containing the mycobacteria are 
inhaled and enter the lungs (Figure 1.1).  Most of the tubercle bacilli will remain in 
the lungs; however, a small amount of tubercle bacilli may enter the bloodstream 
and spread to other parts of the body, such as in the case of extra-pulmonary TB.  In 
the lungs, the bacilli travel to the alveoli, where macrophages engulf them by 
phagocytosis.47  Inside the macrophage, the bacilli replicate exponentially before 
reaching a plateau.48  In addition to macrophages, lymphocytes and dendritic cells 
are recruited to the primary site of infection.49  The immune cells, macrophages and 
fibroblasts aggregate and eventually form nodules and lesions called granulomas, 
the hallmark of TB.50  Granulomas act as a form of physical barrier preventing 
further dissemination of the mycobacterium to the remainder of the lung and other 
organs.  Additionally, they act as a local communication site for the dendritic cells 
and the local lymph nodes.  
Upon containment in granulomas, the progression of tuberculosis is largely 
influenced by the host’s immune system. Under optimal circumstances, the human 









vation and maturation of macrophages to phagolysosomes– a cytoplasmic body 
formed by the fusion of the phagosome with a lysosome, subsequently elicits an 
arsenal of host defense mechanisms against the   bacilli.52   Increase in acidity in the 
phagosomal environment has been observed, simultaneously facilitating the 
enzymatic degradation of bacterial lipids arresting microbial metabolism. 53  
Production of reactive oxygen and nitrogen species (ROS and RNS) by phagosomal 
enzymes are responsible for further damage of primary bacterial metabolites.54, 55  
Lymphatic T cells (CD4 and CD8) are also primed as part of the body’s innate and 
adaptive immune response to TB infection. 56   T-lymphocytes secrete cytolytic 
proteins such as perforin and granulysin that directly kill the infected cells.57, 58  
Interferon gamma (IFNγ), a cytokine secreted by T lymphocytes, is known to play a 
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critical role in suppressing bacterial  burden  and  inflammation  by  inducing 
autophagy,59 a catabolic mechanism wherein unnecessary or dysfunctional cellular 
components are degraded through lysosomal processes for cell survival.  In the case 
of TB, autophagy also facilitates the maturation of phagosomes to phagolysosomes, 
and suppresses mycobacterial growth and damaging inflammation responses.59  
Ultimate clearance of the bacilli requires this maturation process.60  Phagolysosomes 
release hydrolytic enzymes and cationic antimicrobial peptides (CAMPs), such as 
defensins, which permeabilize the bacillus’ cell membrane, making it more 
susceptible to complete degradation.61  
While macrophages act as the primary effector cell for bacterial clearance, 
they also provide a habitat for mycobacteria to persist and develop host-defense 
mechanisms to counter every immune response.  For example, reactive oxidative 
species are known to modify bacterial proteins leading to eventual bacterial death; 
Mtb has developed in vitro tolerance to ROS and RNS.62, 63  Mtb has developed the 
ability to arrest phagosomal maturation, averting the bacilli’s destruction causing 
infection.64  To avoid detection and degradation, Mtb can translocate from inside the 
phagolysosome to the cytosol.65  Propagation of infection can also happen through 
host macrophage necrosis, characterized by disruption of the host surface 
membrane, allowing the escape of Mtb to the surrounding tissue.66  
The interplay between bacterial persistence and host-immune response 
determines whether a primary infection will progress into active TB or not.  If the 
immune system is incapable of containing and clearing the bacilli, and they 
disseminate and multiply, then active TB infection has begun.  If the bacilli is 
contained but not eradicated, latent TB infection (LTBI) is established in the 
patient, who may or may not develop active TB at some point in their lifetime.  
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While TB pathogenesis has been studied for decades, it is impossible to predict, upon 
primary infection, which course will it take.  
1.5 Latency and Biofilm Formation 
Statistically speaking, primary infection often does not progress to active 
TB.67   More than 90% of people infected with TB are asymptomatic, and are 
clinically categorized as having the latent form of TB infection (LTBI) 68. During this 
dormant state, patients are noninfectious but remain a reservoir for potential 
transmission.69  Latent infection arises from the mycobacteria’s innate ability to 
enter a state of dormancy and subclinical persistence within the host as a 
mechanism of survival.  This is a direct result of host’s immune response to primary 
infection to quarantine the bacteria. 
Formation of granuloma is the primary mechanism by which the host isolates 
the bacilli from the rest of the lung tissue and the body.  In latent TB, granulomas 
sequester the bacteria for a long period of time, forcing the bacteria to enter a 
dormant and noninfective state.3  Solid granulomas formed during latency are 
encircled by a fibrotic wall, which limits resources by separating them from the 
surrounding tissues.  Low nutrient and oxygen supply inside the granuloma triggers 
a global down regulation of metabolic genes, causing Mtb to transition to a low-
metabolic, non- or low-replicating, but persistent state. 70  Such bacilli are found to 
be resistant to TB drugs.71  This drug resistance is exclusively a physiologic state 
resulting from the down-regulation of Mtb growth functions during dormancy, and is 
independent from genetic mutations.72   
A new school of thought on TB pathogenesis suggests that Mtb’s persistence 
is not only due to its ability to enter latency but also due to its ability to form 
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biofilms.  Clinical features and mechanisms involved in the persistence of the 
tubercle bacilli bear similarities to biofilm-associated infections.73  Several species of 
mycobacteria, including Mtb, are known to form biofilms in vitro . 74 , 75 , 76  
A pathological study on the surviving population of bacilli in a post-treated guinea 
pig infection model has shown evidence of microcolonies of bacteria concentrated 
around the acellular rim in the granulomas.77  A protein similar to pilin, a fibrous 
protein involved in cell adhesion mechanism, is found in Mtb’s genetic code, and 
expressed in vivo . 78   The protein binds strongly to the eukaryotic extracellular 
matrix; supporting the idea that pathogen’s surface could be actively engaged in 
surface attachment. In another study, nonreplicating Mtb accumulated an 
extracellular matrix that is, in part, composed of carbohydrates and free mycolic 
acid, characteristic of biofilm formation in bacterial survival.79  Drug tolerance is 
also observed during pellicle-biofilm formation of drug-hypersensitive mycobacteria 
strains. 80   The observed conferred resistance was reversible upon the addition of 
agents that disrupt Mtb biofilm formation in conjunction with conventional 
antibiotics.  
Whether as independent or cooperative mechanisms of survival, both latency 
and biofilm formation in Mycobacterium tuberculosis elicit antibiotic recalcitrance. 
This conferred phenotypic resistance is one reason for prolonged chemotherapy and 
one of the major hurdles to overcome in TB therapy.   
1.6  Latent TB Progression 
While most cases of TB are asymptomatic, LTBI cases have a significant risk 
for disease development within a finite time frame.  Within a period of 1 to 2 years, 
5-10% of patients with latent infections will develop an active form of the disease.67 
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Progression of latent to active TB varies greatly from patient to patient and is 
dictated by the individual’s immune system.81  
Cytokine imbalance can cause the latent bacilli to be released from solid 
granulomas, triggering disease activation.82  Therapeutic neutralization of tumor 
necrosis factor (TNF) in treating autoimmune diseases can also account for LTBI 
activation.83  Upon TNF neutralization, decreased macrophage activity, macrophage 
death, and granulysin-containing T-cells depletion have been observed.84, 85 
Immunocompromised patients such as those infected with HIV have a much 
higher risk of developing active TB. 86, 87  The depletion in CD4 T-cells, lymphatic 
cells involved in tubercle clearance during primary and latent infection, accounts for 
activation of TB among HIV patients.88  HIV also preferentially targets and depletes 
Mtb specific CD4 T-cells.89 Overall, the activation of dormant Mtb is controlled by 
the increase in HIV viral load and its subsequent effect on T cells and cytokine 
production.90, 91  HIV increases the probability of not only contracting a primary 
infection but also activating latent TB.92, 93   
 
 
1.7  Recurrent TB 
TB recurrence after a full or partial treatment is a pervasive problem. 94 
Overall, the risk of reactivation is estimated to be about 10% within a patient’s 
lifetime.95  People who have contracted TB once are at a greater risk of developing 
TB than those who never had the disease in the first place.96  Both HIV-positive and 
HIV-negative hosts are subject to relapse and re-infection, the two main causes of 
recurrent TB. 97  By definition, relapse of TB infection is the recurrence of the 
disease with the same endogenous Mtb strain, while re-infection is caused by a new 
exogenous strain.98  
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Re-infection is associated with a weakened immune system as HIV-positive 
patients are more prone to reinfection than HIV-negative patients.99  Most cases of 
TB relapse, on the clinical level, are attributed to poor and inadequate therapy.97 
On the cellular level, it is suggested that Mtb’s ability to form biofilms can also 
account for the relapse of previously treated TB,100 as reactivation of the disease was 
found to occur in residual necrotic cells harboring live bacilli.101 
Recurrence creates setbacks for clinicians formulating therapies.  Recurrent 
tuberculosis necessitates another cycle of treatment that is usually more toxic, 
takes longer to complete, and is largely unavailable in most parts of the world.97 
Additionally, recurrent TB poses the threat of drug resistance.102  
1.8  Mechanisms of TB Drug Resistance 
Mycobacterium tuberculosis has acquired and intrinsic mechanisms for drug 
resistance as an evolutionary measure of survival.  Acquired resistance is said to 
occur when a particular strain of Mtb obtains the ability to resist a particular 
antibiotic to which they were previously susceptible.  Intrinsic resistance is Mtb’s 
endowed ability to actively neutralize the actions of certain antibiotics. 
Like other microorganisms, Mtb has acquired the ability to undergo 
spontaneous chromosomal mutations resulting in genetic drug-resistance, which 
happens at a frequency of 10-6 to 10-8 mycobacterial replications.103 Horizontal gene 
transfer via plasmids and transposons does not mediate drug resistance in Mtb 
unlike other microorganisms.104  All known acquired resistance to anti-TB drugs is 
the result of spontaneous mutations (Table 1.3).  
In theory, the probability of simultaneous resistance  to  three  anti-TB drugs 
would be virtually nonexistent, about 10-18 to 10-20, a probability that is  contrary  to 
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Table 1.3  Mechanisms of drug resistance in Mtb105 
Drug Resistant gene(s) Gene function 
Mutation 
frequency (%) 
Isoniazid katG inhA 
Catalase-peroxidae 
Enoyl ACP reductase 
50-95 
8-43 
Rifampin rpoB ß subunit of RBA polymerase 95 
Pyrazinamide pncA Nicotinamidase/pyrazinamidase 72-97 
Ethambutol embB Arabinoyl transaferase 47-65 
Streptomycin rpsL rrs 




Amikacin rrs 16S rRNA 76 
Quinolones gyrA gyrB 
DNA gyrase subunit A 
DNA gyrase subunit B 75-94 
Ethionamide etaA inhA Flavin monooxygenase 
37 
56 
PAS thyA Thymidylate synthase 36 
the global presence of drug-resistant TB today.  Selection of resistant mutants is 
amplified by the human errors in the clinical practice of TB treatment.  Extensive 
drug use due to increasing infection rates lengthy regimens creates a positive 
pressure on the selective evolution of progressively resistant strains.106  Exposure to 
sub-lethal levels of bactericidal antibiotics has been implicated in inducing 
mutagenesis though the production of reactive oxygen species (ROS).107 
Aside from acquired resistance, Mtb is known to have an intrinsic passive 
drug resistance attributed to its thick cell wall, composed of arabinogalactan, 
mycolic acid, and a periplasm-like interlayer similar to that of gram-negative 
bacteria, which limits the permeability of antibiotics.106  For instance, Mtb’s 
multilayered cell wall hinders ß-lactam antibiotic diffusion by two orders of 
magnitude in mycobacteria.108   
Mtb has also developed other specialized active intrinsic mechanisms. 
Enzyme-mediated chemical modification and degradation of antibiotics confers 
resistance in Mtb. Acetylation by acetyltransferases prevents aminoglycoside to bind 
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to ribosomes. 109   Expression of hydrolases mainly account for Mtb’s intrinsic 
resistance to ß-lactam antibiotics. 110   Target modification, i.e., methylation of 
ribosomes, prevents efficient binding macrolides and lincosamide antibiotics.111, 112 
Target mimicry, i.e., formation of DNA-mimics, sequesters the inhibitory action of 
fluoroquinolones on DNA replication. 113   Efflux pumps allow Mtb to expel 
antibiotics.114  These are few examples of Mtb’s specialized mechanisms for drug 
resistance. 
1.9  TB-HIV Co-infection and Highly Active 
Antiretroviral Treatment 
TB and HIV, the top infectious diseases in the world today, overlap not only 
in their epidemiology but also in their bi-directional interaction on pathogenesis, 
progression and drug treatment interaction.  The current standard treatment of 
HIV, highly active antiretroviral therapy (HAART), is composed of a triple-drug 
therapy: two nucleoside or nucleotide reverse transcriptase inhibitors (NRTI/NtRTI) 
alongside with a non-nucleoside reverse transcriptase inhibitor (NNRTI) or protease 
inhibitor (PI).115  HIV’s triple-drug combination along with the cocktail of drugs used 
for the treatment of TB, presents the problem of opposing pharmacokinetic 
interactions, as with any multidrug therapy.  Interactions between rifampin (RMP), 
a key first-line TB drug, and PIs and NNRTIs are largely responsible for the 
challenges encountered during HAART.116   
Antiretrovirals such as PIs and NNRTIs are metabolized through the 
cytochrome P450 (CYP) enzymes, primarily through its 3A4 and 2C9 isoforms.117 
RMP activates and induces the expression of hepatic cytochromes CYP3A4 
rendering the plasma levels of the antiretrovirals subtherapeutic.  Rifampin reduces 
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the plasma levels of NNRTIs efavirenz and nevirapine by 22-26% and 31%, 
respectively.118, 119  RMP reduces PIs’ plasma concentration significantly by 35-92% 
and induces the activity of the efflux multidrug transporter P-glycoprotein (P-gp), 
subsequently decreasing the cellular concentration of PIs.120, 121  The anatoginstic 
effects of co-treating a patient with HAART and rifamycins has been correlated with 
HIV treatment failure116  
1.10  TB Drug Development 
Most of the current TB drugs were developed and approved for use as part of 
combination therapy several decades ago.  The research and development of new TB 
drugs has been dormant for nearly fifty years, but there has been a resurgence of 
interest in the scientific community that began nearly ten years ago122  With support 
from WHO’s Stop TB campaign, investment from funding agencies, and research 
efforts by scientists, a number of new drug candidates have entered the  pipeline 
(Table 1.4, Figure 1.2). 123, 124  Most compounds are currently in the hit-to-lead and 
lead optimization stages, while some of the candidates are in Phase II and Phase III 
clinical trials. 
A number of these compounds are repurposed antibiotics previously 
developed and used for treating other infectious diseases and have been approved for 
the treatment of special cases of drug-resistant TB.122  Fluoroquinolones such as 
gatifloxacin and moxifloxacin, have been approved as second-line drugs for the 
treatment of MDR-TB. 125  These compounds are now being tested against DS-TB. 
Rifapentine, a member of the rifamycin family of antibiotics, has a longer half-life 
than rifampicin and is being developed, together with isoniazid,  as  part  of  a three- 
























































































































































































































































































































































































































































































































Figure 1.2 TB drugs in the pipeline122-124 
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currently employed in a randomized clinical trial in patients with XDR-TB.127 The 
efficacy of clavulanic acid-meropenem combination therapy for XDR-TB is also 
currently under investigation.128  
New chemical entities (NCEs) as TB drugs have also been discovered in the 
past decade. 122, 129  Bedaquiline (Sirturo) is a diarylquinoline that inhibits ATP 
synthase, decreasing intracellular ATP levels.130  In December 2012, through a fast-
track approval process, bedaquiline was approved by the Food and Drug 
Administration (FDA) for the treatment of MDR-TB. 131   It is the first TB drug to be 
approved in forty years,132 and is currently in Phase 3 clinical trials for DS-TB. 
Otsuka’s delamanid (Deltyba), a nitro-dihydro-imidazooxazole that inhibits mycolic 
acid biosynthesis, 133  was approved by European Medicines Agency (EMA) in 
November 2013 and is currently under FDA and WHO pre-qualification status.134 
Another mycolic acid synthesis inhibitor, Q109 is an ethylenediamine developed by 
Suquella.135  Pre-clinical candidate PBTZ169, is a benzothiazinone antibiotic that 
inhibits decaprenylphosphoryl-beta-D-ribose 2’-epimerase (DprE1), an enzyme 
involved in the synthesis of key mycobacterial cell wall components.136  These novel 
and repurposed TB drugs have been integrated into multidrug regimens in clinical 
trials. 
1.11  Amicetin as a Potential Lead for Antitubercular 
Drug Discovery 
The alarming global statistics on TB along with the inadequacy of current 
treatments has prompted a recent interest in the discovery and development of 
drugs.  While most big pharmaceutical companies have yet to actively re-engage in 
the research and development of new compounds, the scientific community at large, 
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particularly academic and research institutions are spearheading the resurgence in 
TB drug discovery. After almost half a century of research hiatus, a promising 
pipeline for new antitubercular drugs has emerged through a multifaceted approach; 
including but not limited to, the discovery of new compounds, the repurposing of 
existing drugs, and the re-evaluation and re-engineering of existing antibacterial 
compounds.137   
Over the past half-century, a myriad of natural products with antibiotic 
activity have been discovered. 138 , 139   Most of the antibiotics used in clinical 
treatment today are either natural products, derivatives, or  analogues of a 
compound expressed by bacteria.140  It can be argued that compounds produced by 
bacteria have been, and could still be, the best source for potent antibiotic scaffolds. 
This rationale has inspired a number of research laboratories, including the Looper 
group and the Barrows group at the University of Utah, to start re-evaluating 
existing natural product libraries.  Through this approach amicetin (Figure 1.3) was 
re-identified as a viable candidate for antitubercular drug discovery.  Initial 
compound screening identified amicetin to be active against TB, selective against 
prokaryotic cells, and compatible with highly active antiretroviral therapy (HAART).  
Research efforts and collaborative work from the Steitz, Barrows, and Looper 
research groups have been aimed towards the synthesis, re-isolation, analogue 
design and development, and biological evaluation of amicetin analogues. 
1.11.1 Amicetin: Isolation and Biological Activity 
Amicetin (Figure 1.3), also known as allomycin and sacromycin, is an 
aminohexopyranose nucleoside antibiotic isolated from Streptomyces 
vinaceusdrappus141, 142 and Streptomyces fasciculatis143 in 1953.   The antibiotic  has  
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Figure 1.3  Amicetin 
been  isolated  by other  research  groups  from  other  Streptomyces species.144, 145, 146  
The chemical structure of amicetin was proposed, initially, through classical pre- 
NMR techniques of chemical degradation and derivatization (Scheme 2.1).147, 148, 149  
Its gross chemical structure was obtained through hydrolysis reactions, specific 
configuration and stereochemistry of the sugar components were established by 
synthesis and NMR studies on amicetin derivatives and degradation 
products.150,  151, 152  The crystal structure of amicetin was published later, affirming 
the results of the seminal works.153   
Amicetin has antimicrobial activity against a number of acid-fast gram 
positive bacteria (Table 1.5), including Staphylococcus aureus (FDA-209), with a 
minium inhibitory concentration (MIC) of 2.0 µg/mL, and Mycobacterium 
tuberculosis (H37Rv), with an MIC of 0.5 µg/mL.141  It is also found to be active 
against Mycobacterium smegmatis, with an MIC of 8 µg/mL. 154   Amicetin is 
ineffective against gram-negative species, except for mutant species of Eschericia 
coli. 155  It is about ten-fold less active against E. coli with a half maximal inhibitory 
concentration (IC50) of 0.3 µM compared to Enterococcus faecalis where it exhibits an 
IC50 of 0.02 µM.156  In a disk diffusion assay, mutant strain E. coli H135 is found to 
be sensitive to amicetin at 50 µg/disk concentration.  Amicetin is active in vivo 




















Table 1.5 Antibacterial spectrum of amicetin compared with streptomycin157
Test organisms* MIC (µg/mL) Amicetin Streptomycin 
Staphylococcus aureus FDA-209 0.2 2.0 
Mycobacterium tuberculosis H37Rv 0.5 1.0 
Mycobacterium tuberculosis ATCC-607 1.0 1.0 
Bacillus subtilis I11 4.0 0.1 
Klebseilla pneumoniae PCI-602 >20 0.2 
Escherichia coli ATCC-26 >20 1.0 
Bodenheimer’s coco-bacillus PCI-3 >20 1.0 
same species, amicetin is found to be less  effective  than  streptomycin  sulfate  on a 
weight basis. 158 
Amicetin also exhibits in vitro antiviral activity, measured as the number of 
plaque forming units (PFU) per 0.5 mL after 24 hours of incubation, against 
deoxyribonucleic acid viruses herpes, vaccinia, and pseudorabies.159  The replication 
of herpes virus in chick embroyo monolayers is inhibited by about four log units 
using a 100 µg/ml concentration of amicetin.  At 160 µM, it inhibits the replication of 
vaccinia and pseudorabies by one log unit and two and a half log units, respectively, 
compared to the control.  
The potency-toxicity ratio of amicetin is favorable compared to other 
antibiotics.  Cytotoxicity of amicetin towards mammalian cells is lower than other 
antibiotics of its class.159  It has an intermediate activity against KB strain of human 
epidermoid carcinoma cells, with a reported IC50 of 7 µg/mL,160  and has been 
reported to prolong the survival time of mice with leukemia-82.161  Another clinical 
study showed that amicetin was inactive against acute leukemia in children who 
had previously developed resistance to chemotherapy.162 Interestingly, amicetin’s 
toxicity across test species varies significantly.141  Its acute intravenous LD50 is 90 
mg/kg for mice and 200 mg/kg for rats.  Subcutaneous LD50 values for  mice  and  
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rats   are  approximately  600-700 mg/kg  and 600 mg/kg, respectively.  When 
administered subcutaneously in guinea pigs,  amicetin is forty times more toxic than 
streptomycin, but only one-tenth as toxic  as  penicillin.   When tested for ototoxicity, 
unlike streptomycin, amicetin was found to not cause eighth nerve damage, an 
adverse effect common to aminoglycoside antibiotics.141, 163, 164 
Early biochemical studies have shown amicetin to be a protein synthesis 
inhibitor.165  Since other cytosine nucleoside antibiotics are known to be peptidyl 
tranferase inhibitors, it has been suggested that perhaps amicetin has the same 
mode of action as well. The exact process through which amicetin inhibits the 
transpeptidation process has been extensively studied and will be discussed in the 
following chapters. 
1.12  Natural Products Related to Amicetin: Pyrimidine 
Nucleoside Antibiotics Type I 
In the past 50 years a number of pyrimidine nucleoside antibiotics have been 
isolated and studied.  Most of these compounds are produced by the Streptomyces 
species.  Among them, are a number of antibiotics that are structurally similar to 
amicetin, featuring a cytosine group, a sugar moeity, and two basic centers.  For the 
purpose of this review, these compounds will be referred to as type-I pyrimidine 
nucleoside antibiotics.  Some compounds are almost identical in structure to 
amicetin, while some others have been co-isolated with amicetin suggesting a shared 
biosynthetic pathway.  Type-I compounds are generally active against gram-positive 
bacteria and are less toxic than other pyrimidine nucleoside antibiotics. 
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1.12.1 Bamicetin 
Bamicetin (Figure 1.4) was co-isolated with amicetin in 1958 by Haskell from 
Streptomyces plicatus. 166    It was isolated as both the free base and the 
hydrochloride salt.  Preliminary proposals on the structure of bamicetin were based 
on data from initial degradation studies.  Results from the acid hydrolysis of 
bamicetin identified cytimidine as one of the fragments, indicating that both 
amicetin and bamicetin have the same aglycone component.  Glycosidic fragments 
obtained from the aforementioned antibiotics, however, differ on the number of 
carbons.  Amicetin yielded a 14-carbon aminosugar, while bamicetin yielded a 13-
carbon aminosugar.  Respective periodate oxidation of the sugars gave a mixture of 
formic acid, glyoxal and methylamine for bamicetin, and dimethylamine for 
amicetin, suggesting that amicetin’s structure differs from bamicetin by one methyl 
group.167  
Bamicetin is also reported to be active against M. tuberculosis H37Rv (data 
not shown).166  Bamicetin is twice as active as amicetin against E. coli P-D 04863.166 
Bmicetin exhibited an MIC of 16 µg/mL against Mycobacterium smegmatis, only 
half as active as amicetin.154  Translational studies done by Lovett and co-workers 
reported inhibition of peptidyl transferase activity of B. subtilis and E. coli 70S 
ribosomes to be nearly twice as strong as amicetin’s,166, 168  Cerna and co-workers 
Figure 1.4 Bamicetin 
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have   previously noted that with respect to the inhibition of specific steps in the 
peptidyl transferase, bamicetin has a similar inhibitory property as that exhibited 
by amicetin.169  For both bamicetin and amicetin, complete inhibition of  Ac-Phe  
transfer  to puromycin was achieved at millimolar concentrations of the antibiotics. 
Lovett’s report also presented the selective inhibition of translation on prokaryotic 
ribosomes of B. subtilis and E. coli, over eukaryotic ribosomes Saccaromyces 





 Oxamicetin (Figure 1.5) is an antibiotic isolated from the fermentation broth 
of Arthrobacter oxamicetus sp. nov.  from a soil sample collected at Kominato, 
Chiba, Japan by Konishi and co-workers in 1973.170   Structural elucidation of 
oxamicetin was achieved through a combination of degradation studies and 
spectroscopic methods.171   
Not surprisingly, oxamicetin exhibited an antibacterial spectrum comparable 
to amicetin (Table 1.6).  It is less active than amicetin with respect to activity 
against Gram-positive species like Staphylococcus, as well as acid-fast species 
likeMycobacterium, but is slightly more active against Gram-negative bacteria like 
Escherichia.  When tested in vivo on mouse infection models  S. aureus   Smith and 
mg/kg respectively.  On the other hand, oral administration of the antibiotic did not 
produce any valuable in vivo activity.  In mouse models, oxamicetin exhibited lower 
acute toxicity relative to amicetin, with an intravenous  LD50 of about 200 mg/kg 
compared to the latter’s 68-90 mg/kg.  It was also reported to be nontoxic at 400 







Table 1.6 Antibacterial spectrum of oxamicetin in comparison to amicetin172 
Test organisms* MIC (µg/mL) Oxamicetin Amicetin 
Micrococcus flavus 1.6 3.1 
Sarcina lutea PCI 1001 1.6 1.6 
Staphylococcus aureus Terajima 1.6 0.8 
Mycobacterium 607 (KM-R/SM-R) 3.1 1.6 
Mycobacterium phlei 3.1 0.8 
Salmonella typhosa Yale 3.1 3.1 
Escherichia coli A 15169 6.3 6.3 
Bacillus subtilis PCI-219 6.3 12.5 
Streptococcus pyogenes S-23 6.3 3.1 
Mycobacterium 607 12.5 3.1 
Mycobacterium 607 (KM-R) 12.5 3.1 
Mycobacterium ranae 12.5 3.1 
Staphylococcus aureus # 193 (PC-R/TC-R) 12.5 6.3 
Staphylococcus aureus Russell (PC-R) 12.5 6.3 
Staphylococcus aureus Smith 12.5 6.3 
Bacillus anthracis 115 25 12.5 
Diplococcus pneumonia Type 2 25 3.1 
Escherichia coli NIHJ 25 50 
Escherichia coli A 20365 (KM-R/NM-R/SM-R) 25 50 
Proteus vulgaris A 9526 25 100 
Streptococcus pyogenes Digonet 25 3.1 
Klebsiella pneumonia D11 50 100 
Proteus morganii A 20031 50 >100 
Proteus vulgaris A 9436 50 50 
Shigella sonnei Yale 50 100 
Salmonella enteritidis A 9531 50 100 
Escherichia coli Juh1 100 >100 
Shigella flexneri A 9684 100 100 
Streptococcus pyogenes Dick 100 50 
Proteus mirabilis A 9554 >100 >100 
Pseudomonas aeruginosa D15 >100 > 100 
 
 





 SF2457 (Figure 1.6) is a closely related aminohexopyranose nucleoside 
isolated by Itoh and Miyadoh in 1992.173  Unlike other antibiotics in the amicetin 
family produced by Streptomyces and Arthrobacter species, SF2457 was isolated 
from the fermentation broth of Nocardia brasiliensis SF2457, from the soil sample 
collected at Toba City, Mie Prefecture, Japan.  SF2457 was isolated and purified as a 
free base, and was described as a water soluble, colorless and amorphous powder.  
The structure of SF2457 was determined from spectroscopic analysis of the molecule 
itself, as well as from its degradation products.  These experiments identified 
SF2457 as a close analogue of oxamicetin, containing a D-alanine rather than an 
α-methylserine moiety.   
Similar to other analogues, it exhibited strong activity against Gram-positive 
bacteria such as subspecies of Staphylococcus aureus and some species of Salmonella 
(Table 1.7).  However, the antibiotic was also found to be inactive against Gram-
negative bacteria.  Aside from the initial report on its isolation, there have been no 





Haneda and co-workers isolated four active compounds from the fermentation 
broth of Streptomyces amakusaensis KO-8119 and designated the isolates as 
cytosaminomycins A, B, C and D (Figure 1.7).174  Cytosaminomycin A and B were 
reported as a pale yellow powder and crystal, respectively, while cytosaminomycin C 
and D were reported as white powders.  
The structures of the cytosaminomycins were determined by both one and 







Table 1.7 Antibacterial spectrum of SF2457175 
Test organisms MIC (µg/mL) 
Staphylococcus aureus 209P JC-1 1.56 
Staphylococcus aureus Smith S-424 1.56 
Staphylococcus aureus No. 26 1.56 
Staphylococcus epidermidis ATCC 14990 1.56 
Staphylococcus epidermidis 109 1.56 
Bacillus anthracis No. 119 1.56 
Salmonella typhi O-901-W 1.56 
Salmonella enteritidis No. 11 1.56 
Enterococcus faecium ATCC 8043 12.5 
Shigella sonnei EW33 Type I 25 
Proteus vulgaris OX19 50 
Salmonella sp. D-0001 50 
Salmonella typhimurium LT-2 50 
Escherichia coli JR66/W677 50 
Escherichia coli JC-2 100 
Escherichia coli No. 29 100 
Escherichia coli W3630 RGN823 100 
Morganella morganii Konno 100 
Kleibsiella pneumoniae PCI602 100 
Kleibsiella pneumoniae 22#3038 100 
Serratia marcanscens MB-3848 100 
Citrobacter freundii GN346 >100 
Proteus mirabilis GN310 >100 
Providencia rettgeri J-0026 >100 
Pseudomonas aeruginosa MB-3829 > 100 
Pseudomonas cepacia M-0527 > 100 




Figure 1.6 SP2457 
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Figure 1.7 Cytosaminomycins 
spectrometry.176  Cytosaminomycins were shown to be related to oxyplicacetin186 and 
contain the same hydroxycytosamine nucleoside fragment but differ at the N6-
acylation of the cytosine moiety.  The acyl groups contained were (E)-3-
(methylthio)acrylic acid, 4-methylaminobenzoic acid, 3-methylcrotonic acid, and 
tiglic acid for cytosaminomycins A, B, C, and E respectively. 
Coccidiosis is a parasitic disease common in poultry and is caused by a group 
of protozoans including Eimeria tenella.  It is common practice in the poultry 
business to use polyether ionophores such as monensin, 177  salinomycin, 178  and 
lasalocid in combatting coccidiosis. 179   Recent reports have stated that such 
ionophores have become progressively ineffective due to resistant Eimeria sp.180  The 
cytosaminomycins were tested primarily for their anticoccidial activity against 
monensin-resistant E. tenella using an in vitro assay that employs primary chicken 
embryonic cells  and BHK-21 cells as hosts (Table 1.8).  Anticoccidial  activity was 
measured using minimum effective concentrations; determining the lowest 
concentration at which no schizont formation was observed.  Cytosaminomycin A 











































































Cytosaminomycin A Cytosaminomycin B
Cytosaminomycin DCytosaminomycin C
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Table 1.8 Anticoccidial activity of cytosaminomycins181 
Compound 
MEC (µg/mL) 






Cytosaminomycin A 0.31 10 0.16 0.31 
Cytosaminomycin B 0.62 5 1.25 2.5 
Cytosaminomycin C 0.62 5 1.25 5.0 
Cytosaminomycin D 2.5 10 10 > 10 
Monensin --- 0.03 --- 0.03 
by cytosaminomycin D.  The observed cytotoxicity of cytosaminomycins B, C, and D 
against the host cells was about the same.  Cytosaminomycin A, on the other hand, 
showed the highest selectivity index in the chicken embryonic cell assay with respect 
to minimum effective dose for cytotoxicity versus anticoccidial activity among its co-
isolates.  Additionally, the antimicrobial activity of cytosaminomycins was tested 
using disk diffusion assay (Table 1.9) at  a  concentration  of  5  mg on a 6 mm paper 
disk cytosaminomycins showed antibacterial activity against gram-positive, gram-
negative and wall-less bacteria.  Cytosaminomycin A and C exhibited better 
biological activities  than  cytosaminomycins  B  and  D.   At  these specific 
concentrations none of compounds exhibited  activity  against  Candida  albicans, 
Saccharomyces sake, Aspergillus niger and Mucor racemosus. 
Table 1.9 Antimicrobial activity of cytosaminomycins A-D182 
Inhibition Zone Diameter (mm) 
Organism       A     B    C D 
Micrococcus luteus PCI1001 20 14 21 10 
Escherichia coli NIHJ 14 7 14 0 
Xanthomonas oryzae 14 0 17 16 
Acholeplasma laidlawi PG-8 24 14 24 11 
Bacteroides fragilis 10 0 12 0 
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1.12.5  Streptcytosines 
Streptcytosines A–E (Figure 1.8) were isolated from a culture broth of 
Streptomyces sp. TPU1236A collected in Okinawa, Japan by Bu and co-workers in 
2014.154 Streptcytosine A closely resemble amicetin’s structure, while 
streptcytosines B–E where close deoxy-analogues of cytosaminomycins A, C, and D. 
Streptcytosine A inhibited the growth of Mycobacterium smegmatis (MIC = 32 
µg/mL), while streptcytosine B-E were not active at 50 µg/disc.  It is less active than 
bamicetin and amicetin, with MICs of 16 µg/mL and 8 µg/mL, respectively.  To date, 
no further studies on the streptocytocines have been made. 





























































































1.12.6  Plicacetin 
 
Haskell and co-workers reported a third antibiotic isolated from the same 
culture filtrates of Streptomyces plicatus that produced amicetin and bamecin, and 
named the compound plicacetin (Figure 1.9).145  The same antibiotic was 
independently reported by Sensi and co-workers a few months earlier  in  1957 and 
was named “amicetin B”.  It was isolated from an actinomycete species arbitrarily 
designated as Streptomyces sp. 285.183  Like amicetin and bamicetin, plicacetin’s 
structure was determined through degradation studies.167 It was concluded that 
plicacetin had the same overall structure as amicetin minus its amino acid moeity, 
and is probably a biosynthetic precursor of amicetin.145   
 Initial studies reported plicacetin’s biological activity against M. tuberculosis 
H37Rv, both in vitro and in vivo, to be much lower than that of amicetin and 
bamicetin, and thus were not investigated further at the time.145  Two decades later 
this observation was supported by studies on plicacetin’s effect on the peptidyl 
transferase reaction of E. coli B 70S ribosomes.169  Plicacetin does not inhibit 
peptidyl transferase even at concentrations wherein amicetin and bamicetin showed 
complete inhibition.  For example, with respect to its inhibitory effect on puromycin 
reaction with either AcPhe-tRNA or poly-Lys-tRNA as donor substrates, plicacetin  
displayed only about 1% of the activity exhibited by amicetin and bamicetin at 
millimolar concentrations.  When comparing concentrations at 50% inhibition of 
	  
	  	  
Figure 1.9 Plicacetin  
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puromycin reaction with CACCA-Leu-Ac as a donor substrate, plicacetin is ten times 
less active than amicetin.  It also does not inhibit the binding of donor and acceptor 
substrates to the peptidyl transferase center of the ribosome.169, 184  Examining 
plicacetin’s structural features and biological activity, strongly indicates that an 
aminoacyl moiety, a D-a-methylserine in the case of amicetin and bamicetin, is 
essential for intercepting ribosomal transpeptidation reactions.   
1.12.7 Norplicacetin 
In 1977, Evans and Weare reported a fourth antibiotic isolated from 
Streptomyces plicatus from fermentation cultures of a soil sample obtained from 
Ghana.185  The antibiotic was described as white needles that exhibited an identical 
UV spectrum with known compound, plicacetin.  Additional spectroscopic data 
obtained from mass spectrometry and NMR spectroscopy further suggested that its 
structure is closely related to plicacetin, minus a methyl group on the latter’s 
aminosugar moiety.   The compound was named norplicacetin (Figure 1.10) and was 
assigned as the mono-methyl analogue of plicacetin and possible precursor to 
bamicetin.  The antibiotic spectrum and activity of norplicacetin (Table 1.10) resem 
bles the activity of plicacetin. It is moderately active against Gram−positive bacteria 
and acid-fast mycobacteria.   
1.12.8 Oxyplicacetin 
Oxyplicacetin (Figure 1.11) was isolated from the fermentation cultures of 
Streptomyces ramulosus Tu-34 by Yongle and co-workers in 1985.186  Little  is 
known about this compound except for studies done by  Haneda   and   co-workers in 







Figure 1.10 Norplicacetin 
 
Table 1.10 Antibacterial spectrum of norplicacetin187 
 
Test organisms MIC (µg/mL) 
Mycobacterium bovis BCG 1077 0.5 
Mycobacterium bovis BCG 1173 0.5 
Staphylococcus aureus Glaxo 618 4 
Streptococcus pneumoniae  4 
Haemophilus influenzae Glaxo 1184E 8 
Escherichia coli Glaxo 573 16 
Staphylococcus aureus Glaxo 663 and 853-E 31 
Mycobacterium smegmatis ATCC 607 62 
Mycobacterium smegmatis NCTC 8158 62 
Escherichia coli 1161 >500 
Klebsiella aerogenes Glaxo 1082E >500 
Pseudomonas aeruginosa Glaxo 1371E >500 










Table 1.11 Antimicrobial activity of oxyplicacetin188 
 
Organism Inhibition Zone Diameter (mm) 
Micrococcus luteus PCI1001      18 
Escherichia coli NIHJ      12 
Xanthomonas oryzae      16 


































using 6 mm paper disk in disk diffusion assays. Oxyplicacetin also showed 
anticoccidial activity against Eimeria tenella, with MEC values of 5.0 and 
1.25 µg/mL for chicken embryonic cells and BHK-21 cells. The same study reported 
complete cytotoxicity against BHK-21 at 5.0 µg/mL but no apparent cytotoxicity 
against chicken embryonic cells at 10 µg/mL for oxyplicacetin. 
 
 
1.13  Natural Products Related to Amicetin: Pyrimidine  
Nucleoside Antibiotics Type II 
The second type of pyrimidine nucleoside antibiotics have only one basic 
terminal group, either an amino group or an aminoacyl moeity, attached to a sugar 
moeity that is bound to the cytosine group.  Most of these antibiotics closely 
resemble the structure of blasticidin S (Figure 1.12), the first discovered antibiotic of 
its type and the most explored member of this group.  For the purposes of this 
section, the following compounds are classified as Type-II or blasticidin-type 
pyrimidine nucleoside antibiotics.  Not only do these compounds share the same 
bonding arrangement with blasticidin S, but also exhibit similar antimicrobial and 
toxicity properties. These compounds typically have broad but modest antibacterial 




Figure 1.12 Blasticidin S 	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1.13.1 Blasticidin S 
 
 Blasticidin S (Figure 1.12, vide infra) was isolated from the fermentation 
broth of Streptomyces griseochromogenes by Takeuchi and co-workers in 1958. 189  
Its discovery was part of the screening initiative at the National Institute of 
Agricultural Science, Tokyo, in search of compounds that were active against 
Piricularia oryzae, the cause of rice blast disease, hence the parent name blasticidin.  
The compound is, however, not structurally related to blasticidin A, B, 
and C.189, 190, 191   
The biological activity profile of blasticidin S was examined by agar streak 
dilution method and broth dilution methods against a number of microorganisms.  
Blasticidin S was found to be moderately active against a number of bacteria 
including species of Mycobacterium tuberculosis and Pseudomonas fluorescens 
(Table 1.12).   It is also reported to be active against a number of pytopathogens with 
MICs ranging from 5-50 µg/ml, (Table 1.13).  At 5 µg/ml. (MIC) it displays the most 
activity against Bacterium aroideae, Bacterium citri, Pseudomonas tobaci, and 
Piricularia oryzae. The modest activity demonstrated by blasticidin S against gram-
negative bacteria is over shadowed by animal toxicity; when injected intravenously 
to mice, it was found to have an LD50 of 2.82 mg/kg.189   
It has antitumor activity against transplantable animal tumor.192  Blasticidin 
S displayed 30-68% tumor growth inhibition against Walker adenocarcinoma 256 in 
rats, about 60-70% inhibition in Ehrlich carcinoma inhibition and 40% sarcoma 180 
in mice through intraperitoneal injection of 1.5 to 3 mg, twice daily over two weeks. 
It is also worth noting that none of the animals died of toxicity during the course of 
the experiment. 








Table 1.12 Antimicrobial spectrum of blasticidin S193 
 
Test organisms MIC (µg/mL) 
Pseudomonas fluorescens 5 
Mycobacterium tuberculosis H37RA 10 
Mycobacterium tuberculosis ATCC 607 50 
Mycobacterium phlei 50 
Micrococcus pyogenes var. aureus 209 P 50 
Bacillus subtilis 50 
Sacrina lutea 50 
Escherichia coli 50 
Penicillium notatum >100 
Penicillium chrysogenum Q176 >100 
Aspergillus oryzae  >100 
Trichophytone purpureum  >100 
Candida albicans >100 
Pseudosaccharomyces samtacruxensis >100 
Saccharomyces cerevisiae >100 
Torula albia >100 




Table 1.13 Antipytopathogenic spectrum of blasticidin S194 
 
Test organisms MIC (µg/mL) 
Bacterium citri 5 
Bacterium aroideae 5 
Pseudomonas tobaci 5 
Piricularia oryzae 5-10 
Sclerotinia mali 10 
Alternaria kikuchiana 50 
Erwinia aroidae 50 
Gloeosporium kaki 50 
Gloeosporium lacticolor  50 
Pseudomonas solanacearum 50 




reported interesting observations.  Kinetic  studies  have  shown  blasticidin  S both 
enhancing P-site binding and inhibiting the A-site binding of aminoacyl- 
CACCA.195, 196  It doesn’t promote the premature release of  peptides from the ribo 
somes unlike puromycin, an A-site  inhibitor,  suggesting  a  different  mechanism of 
action.  Blasticidin S,  however, was  later  reported  to   compete   with  A-site 
binding antibiotic puromycin and sparsomycin.197, 198  It was further suggested that 
its mode of action may involve binding to the A site based on results from resistance 
studies wherein strains resistant to sparsomycin and puromycin are found to be co-
resistant to blasticidin S and vice versa.199  
The crystal structure of blasticidin S bound to the 50S ribosome subunit of 
Haloarcula marismortui (Figure 1.13) has been solved by Steitz and published in 
2003,200 and shows two copies of blasticidin S bound to the P site of the ribosome. 
Both copies interact with the highly conserved P loop of the ribosome but with 
different affinities.  The stronger site (Figure 1.13A) shows both the cytosine and the 
sugar moeity of blasticidin S perfectly aligns with the corresponding cytidine, C74, of 
a P-site substrate.  The cytosine of blasticidin forms a Watson-Crick base pair with 
G2251 (E. coli numbering), while its pyranose ring superimposes with the 
corresponding ribose of C74.  The guanidinium tail was originally described as 
forming hydrophobic interactions with A2439, although stronger forces such as 
cationic-π interactions would have played a greater role.  The guanidinium tail also 
hydrogen bonds with the phosphates of A2439 and A2600.  In the weaker site 
(Figure 1.13B), blasticidin base pairs with G2252, in place of C75 of the P-site 
substrate but without the superimposing of its sugar to its ribose equivalent. Both 
guanines, G2251 and G2252, are critical to the proper positioning of the conserved 
CCA  terminus   of   the   P-site   bound   tRNA.   Overall,   the   data   suggests  that 
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Figure 1.13  Blasticidin S binding to 50S ribosome subunit of H. marismortuii 
A) Stronger binding site and B) Weaker binding site: blasticidin S (green), ribosome
residues (yellow), water (red), second blasticidin S molecule (green, line). 
blasticidin S competes with the P-site substrate binding, thereby inhibiting protein 
synthesis. 
The work provided insight, at the molecular level, as to how cytosine nucleo 
side antibiotics possibly elicit their biological activity.  However, it neither provides 
a detailed mechanism by which it inhibit the peptidyl transferase reaction, nor does 
it provide an explanation to the previously reported nuances and apparent 
contradictory observations in its mechanism of action, i.e., its co-resistance and 
competition with known A-site antibiotics and stabilization of the binding of P-site 
substrates.  
Korostelev and co-workers sought to answer this conundrum using biological 
assays, X-ray crystallography, and single-molecule Förster resonance energy 
transfer (smFRET). 201   In their published work, Korostelev re-examined how 
blasticidin S stabilizes the binding of P-site substrates.  Monitoring the binding of 
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N-formyl-methionyl-tRNA to the P-site of E. coli 70S ribosomes pre-incubated with 
varying concentrations of blasticidin, he showed that it only interferes with P-site 
substrate [35S]-fMet-tRNAfMet binding  at  high  millimolar  concentrations 
(IC50 ~20 mM).   This exceeds the inhibition constant for peptidyl transfer up to five 
orders of magnitude, which is about 200-400 nM,202, 203 and is is also about four 
orders of magnitude higher than the concentration needed to inhibit bacterial 
growth.  It is proposed that the observed competition with the P-site substrate is 
only effected by blasticidin S binding to the second low-affinity site as observed in 
the crystal structure of H. marismortui co-crystallized with millimolar 
concentrations of the antibiotic.189  Blasticidin is therefore not an effective P-site 
inhibitor despite binding to the P-site.  It was then suggested that perhaps it affects 
another facet of protein synthesis. 
Single molecule FRET experiments were employed to monitor the inter-
subunit dynamics of the ribosomal complex during the translocation process. 204  
Fluorophores were attached to proteins S6 and L9 of the 30S and 50s subunit 
respectively to monitor.  How blasticidin affects the affinity of tRNA to the 50S P-
site is monitored by measuring the fluctuations between conformations of the 
ribosomal units.  In the absence of the antibiotic, the ribosomes maintained its 
rotated hybrid state 70% of the time.  Upon addition of blasticidin, 80% of the 
ribosomes remained in the nonrotated conformation. Blasticidin was found to slow 
down the counterclockwise rotation of the 30S subunit during the translocation 
process by up to five-fold.  It is suggested that blasticidin stabilizes the acceptor end 
of the P-site tRNA preventing the rotation of the 30S subunit and the shifting of the 
deacylated tRNA into the hybrid states, corresponding to previous reports on 
blasticidin’s stabilization P-site substrates.169, 196, 201   
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Blasticidin is also found to inhibit peptide release and peptidyl transfer 
during termination and elongation steps, respectively, supporting the seminal works 
on its biological activity.195, 196, 201   Peptide release during the termination step is 
catalyzed by release factors 1 and 2 (RF1 and 2), proteins that bind to the A-site and 
facilitate the peptidyl-tRNA hydrolysis.  Blasticidin inhibits RF1-mediated release of 
[35S]-fMet release from P-site bound [35S]-fMet-tRNAfMet.  The apparent inhibition 
constant (Ki) is 32 ± 18 nM for the RF1-mediated release.  For the inhibition of 
peptidyl transfer of [35S]-fMet to puromycin, the values are much higher at 182 ± 39 
nM.  Blasticidin has been cited as a peptidyl transaferase inhibitor but its strong 
inhibition of the termination step is particularly noteworthy since no specific 
inhibitors for this step have been previously identified.205  
Korostelev also presented a 3.4 Å crystal structure  of  blasticidin S  bound to 
the 70S Thermus thermophilus ribosome complex (Figure 1.14).201 Compared to the 
previous work of Steitz, wherein two molecules of blasticidin S were bound to the 
vacant 50S subunit, only one copy is found in the 70S-tRNA complex.  The 
conformation and the binding site of blasticidin S in the more recent published 
crystallographical data, however, is very similar to that described for the higher 
affinity site, with an all-atom rms difference of 0.57 Å, which is within the boundary 
of acceptable coordinate error for a 3.4 Å resolution.   The guanidinium group of 
blasticidin stacks with A2439, possibly forming cation-π interactions with the 
adenine.  A hydrogen bond network formed with the guanidine tail and the 
phosphate groups of A2439, A2600, and C2601 further stabilizes the structure.   The 
cytosine moeity base pairs with G2251, replacing the pairing between G2251 and 
C75 in antibiotic-free 70S-tRNA complexes.  It also intercalates between C74 and 
A76 of the CCA terminus of the P-site tRNA.  These interactions displaces the  CCA 
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Figure 1.14 Blasticidin S bound to the 70S T. thermophilus ribosome complex 
terminus of the P-site tRNA toward the A-site dramatically, by about 7Å.  This 
observed shift of P-site tRNA towards the A-site explains the reported effect of 
blasticidin on A-site substrates.195  201   The protrusion of the CCA end may have also 
led to steric interference with the highly conserved GGQ region known to bind 
release factors, mediating the premature release of peptide described earlier.  In 
addition, the distortion may also result in the poor positioning of substrates for 
nucleophilic attack during peptidyl transfer.   
1.13.2 Gougerotin 
Gougerotin (Figure 1.15) is an antibiotic that was isolated from Streptomyces 
gougerotii No. 21544 by Kanzaki and co-workers in 1962.206  It has been isolated 
independently by another research group from other species of Streptomyces and 
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also has been assigned a different name, yungumycin. 207, 208 The initial structure of 
gougerotin was proposed by Iwasaki from a series of classical chemical studies,209 
but was reinvestigated and revised by Fox and co-workers in 1965 through 
derivitization and synthetic studies.210, 211   
 Gougerotin is active against a number of gram-positive, gram-negative  bacte- 
ria and mycobacteria (Table 1.14).206  It was also reported to reduce the growth of 
rice seedlings by 60% and 100% at 0.1 mM and 0.3 mM respectively.207  Gougerotin 
is known to be toxic to mammalian systems, with an LD50 of 57 mg/kg for mice via 
intravenous injection.  However, the toxicity of the compound is delayed. 
Gougerotin belongs to the cytosine nucleoside family of antibiotics known to 
inhibit protein synthesis.212  Initial experiments have shown gougerotin inhibits the 
amino acid transfer in the polyuridylic acid-dependent synthesis of 
polyphenylalanine in cell-free E. coli systems. It was also shown that gougerotin 
inhibits protein synthesis by inhibiting the transfer reaction of amino acids from 
aminoacyl-tRNA to the nascent peptide.  Gougerotin inhibits the   transfer   reaction  
in both cell-free systems obtained from murine liver samples and rabbit 
reticulocytes.213, 214, 215  It was originally proposed that   gougerotin    and puromycin 
may have the same mechanism of action based  on  their  structural  similarities. 
Subsequently,  it  was  shown  that gougerotin’s specific mode  of action  to  be 
	  	  
Figure 1.15 Gougerotin 	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Table 1.14 Antimicrobial spectrum of gougerotin216 
Test organisms MIC (µg/mL) 
Micrococcus flavus 40 
Mycobacterium tuberculosis H37Rv 100 
Escherichia coli 200 
Brevibacillus brevis 200 
Staphylococcus aureus 209 P  400 
Bacillus subtilis PCI 219 400 
Alternaria kikuchiana >500 
Candida albicans  >500 
Colleto lagernarium >500 
Gibberella fujikuroi >500 
Glomerella cingulate >500 
Penicillium chrysogenum Q 176 >500 
Phytophytophora infestans >500 
Piricularia oryzae >500 
Saccaromyces cerevisiae >500 
Mycobacterium avium 800 
Mycobacterium avium Streptomycin-fast 800 
Mycobacterium 607 800 
Pseudomonas aeruginosa 800 
Sarcina lutea 800 
Brevibacillus cereus >800 




different from that of puromycin.  Gougerotin does not compete with the binding of 
the aminoacyl-tRNA in the ribosome complex, nor does it act as an aminoacyl-tRNA 
analogue that terminates the  peptide  elongation  process  like  puromycin.215, 214 To 
date, the  detailed  mechanism  of  action  has  not been  completely  and  specifically  
elucidated for gougerotin.  Much  of  what is known is based on the aforementioned 
seminal  work  in  the  1960s.    However, its mechanism  of  action  can be inferred 
from studies done on other closely related cytidine antibiotics such as blasticidin S. 
 
 
1.13.3  Anthelmycin/Hikizimycin 
 
Anthelmycin (Figure 1.16) was isolated from Streptomyces longissimus 









1964.217  Its hydrochloride salt was obtained as white crystals that are stable in 
solution from pH 1 to 10 at and 25 °C.  Like other related cytosine antibiotics, it does 
not exhibit a distinct melting point but decomposes above 200 °C.  It is reported to 
be very soluble in water,  acidic  aqueous  solutions,  in  methanol,  but  is practically 
insoluble in other organic solvents.  
The cytosine antibiotic hikizimycin was independently isolated from the 
fermentation broth of Streptomyces sp. strain A-5, found in the soil sample collected 
at the Hikizi river-side, Kanagawa Prefecture, Japan by Uchida and co-workers in 
1971.218  It was obtained as obtained as a colorless hydrobromide crystalline salt 
exhibiting similar physical properties to that of anthelmycin.  Initial studies on the 
structure of the two antibiotics reported that both contained cytosine and 3-amino-3-
deoxy-D-glucose.219, 220, 221  Common physical properties and structural features lead 
to the re-examination of the identities of both antibiotics and have confirmed the 
intimation that anthelmycin and hikizimycin are the same antibiotics.   
Anthelmycin exhibited a broad but weak antimicrobial activity profile 
(Table 1.15).217 While hikizimycin exhibited moderate activity against certain 
species of Pseudomonas and Xanthomonas, it is notably active against 























Table 1.15 Antimicrobial spectrum of anthelmycin/hizikimycin222 
Test organisms MIC (µg/mL) 
Pseudomonas syringae 2 
Pseudomonas fluorescens 10 
Alternaria solani 12.5 
Ceratostomella ulmi 12.5 
Helminthosporium sativum 25 
Mycobacterium avium  25 
Pseudomonas tabaci 40 
Aerobacter aerogenes 50 
Klebsiella pneumonia 50 
Mycobacterium tuberculosis ATCC 607 50 
Pseudomonas solanacearum 50 
Shigella paradysenteriae 50 
Xanthomonas oryzae 50 
Xanthomonas phaseoli 50 
Agrobacterium tumefaciens 55 
Penicillium chrysogenum 80 
Aspergillus niger 100 
Bacillus subtilis 100 
Colletotrichum pisi 100 
Endoconidiopora fagacearum 100 
Erwinia amylovora 100 
Penicillium expansum 100 
Pseudomonas aeruginosa 100 
Salmonella enteritidis 100 
Pullularia sp. 100 
Aspergillus oryzae 150 
Trichophyton rubrum 150 
Escherichia coli 200 
Corynebacterium michiganese 200 
Proteus vulgaris 200 
Staphylococcus aureus  200 
Xanthomonas campestri  200 
Candida albicans >200 
Candida utilis >200 







Table 1.16 Antipytopathogenic spectrum of Anthelmycin/Hikizimycin223 
Test organisms MIC (µg/mL) 
Alternaria kikuchiana 1 
Alternaria tenius 2 
Ascochyta sojaecola 2 
Curvularia lunata 2 
Sclerotium bataticola 2 
Stemphylium lotii 5 
Botrytis tulipae 10 
Carvularia geniculate 10 
Helminthosporium sativum 10 
Helminthosporium oryzae 10 
Rhizoctonia solani 10 
Botrytis cinerae 20 
Sclerotium rolfisii 20 
Colletotrichum linicolum 20 
Piricularia oryzae 100 
Fusarium oxysporium >200 
Trichoderma viridi >200 
properties were closely similar to that of blasticidin S.  Anthelmycin also exhibited 
antiviral activity by protecting HeLa cells from herpes simplex and  inhibiting 
production of encephalomyocarditis (EMC) virus.224, 225  
When tested for its in vivo activity, anthelmycin was found to be an effective 
anthelmintic agent against a number of  parasites such  as  pinworms,  roundworms, 
whipworms, and strongyles.  Oral administration of anthelmycin at a dosage of 12 g 
per ton of normal swine ration eliminated 100% of the total population of 
Oesopagostumum sp. (nodular worms), 100% of Trichuris suis (whipworms), and 
80% of Ascaris suis (roundworms).  In addition, anthelmycin also exhibited housefly 
larvacidal activity217 and notable toxicity towards green peach aphids.226  The acute 
toxicity (LD50) of anthelmycin in mouse models, was about 5 mg/kg and 150 mg/kg 
via intravenous administration and oral administration, respectively.   
Seminal studies on the biological activity of anthelmycin have reported it to 
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be a protein synthesis inhibitor, specifically the peptidyl transferase reaction, in 
both prokaryotic and eukaryotic ribosomes.227  However, while being structurally 
similar to amicetin and blasticidin S, anthelmycin lacked the aminoacyl moeity 
other members of the cytosine nucleoside family of antibiotics possess.  Footprinting 
studies showed that anthelmycin inhibits the peptide bond formation by binding to 




1.13.4  Mildiomycin 
 
Mildiomycin (Figure 1.17) was isolated from Streptoverticillium rimofaciens 
B-98891 found in a soil sample collected in Papua New Guinea, as part of the 
agricultural antibiotic screening program of Takeda Chemical Industries.229   It was 
isolated as a white formate salt and was immediately identified as structurally 
similar to blasticidin S and gougerotin.   Initial physico-chemical studies done on the 
antibiotic determined it to be a new compound with a novel 5-hydroxymethyl 
cytosine, which has never been reported within its class of nucleoside antibiotics.  
The structure of mildiomycin was established by spectroscopic studies on its free 
base and x-ray crystallography on its benzoate derivative.230, 231 




















and fungus Rhodotorula rubra, a form of powdery mildew that causes extensive 
damage to a number of essential   agricultural   crops.    Similar   to   gougerotin and 
blasticidin S, it exhibited weak antimicrobial activity on gram-positive, gram-
negative bacteria, and fungi (Table 1.17). 
Compared to blasticidin S, mildiomycin  is  relatively  nontoxic.   The acute 
mammalian toxicity of mildiomycin in female mice (LD50) was determined to be 
599 mg/kg  by  intravenous  administration,  which   is   200-fold   less   toxic than 
blasticidin S.232   The LD50 values for the same species measured via subcutaneous, 
intraperitoneal, and oral routes were 1150 mg/kg, 1050 mg/kg and 5250 mg/kg, 
respectively.    In   female   rats   the  LD50   values  were   measured   as  684 mg/kg, 
70 mg/kg, 842 mg/kg, and 4120 mg/kg via  subcutanoues, intravenous, 
interperitoneal and oral routes respectively, which are all at least 100-fold less toxic 
than related cytosine nucleoside antibiotics.232 
Table 1.17 Antimicrobial spectrum of mildiomycin233 
Test organisms MIC (µg/mL) 
Rhodotorula rubra IFO 0870 50 
Mycobacterium phlei IFO 3158 50 
Guignardia laricina IFO 7888  100 
Alternaria kikuchiana IFO 8414  250 
Botrytis cinerea TFK 12  250 
Cochliobolus miyabeanus IFO 5277  250 
Mycobacterium smegatis ATCC 607 250 
Escherichia coli IFO 12734 500 
Pseudomonas aeruginosa IFO 3449  500 
Sclerotinia sclerotiorum IFO 9395 500 
Trichopython mentagrophytes IFO 5809 500 
Bacillus brevis IFO 3331  >500 
Bacillus cereus IFO 3466  >500 
Bacillus subtilis IFO 3513  >500 
Proteus vulgaris IFO 3045 >500 
Sarcinia lutea IFO 3232  >500 
Staphylococcus aureus IFO 3061  >500 
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Adverse allergic effects of mildiomycin were also tested on rabbit skin and 
cornea.232  No irritation was observed during a dosing period of 10 days, at 1,000 
ppm concentration.  No significant effect was observed in a toxicity test using 
killifish, water fleas and carps at a dosage of 20 ppm for 7 days.  Chronic toxicity of 
mildiomycin was also measured over a period of 30 days.  Daily dosing of 200 mg/kg 
in mice or rats produced no adverse effects.  The study was extended over a three-
month period and no significant adverse effects were observed, leading to the 
conclusion that mildiomycin is considered to have low toxicity.229 
When the mechanism of action was probed, mildiomycin was found to be a 
selective protein synthesis inhibitor in human HeLa cells (Table 1.18).234  It was 
found to be more potent and selective inhibitor of mammalian protein synthesis than 
blasticidin S, gougerotin and anthelmycin.  The activity, however, is reversed with 
respect to bacterial and fungal protein synthesis. It was also found to be less active 
in  the  inhibition  of  RNA or DNA  synthesis.234   Nucleoside antibiotics like 
mildiomycin are molecules across the cellular membrane, owed to their very 
hydrophilic nature.  However, when paired with animal viruses that permeabilize 
cell membranes the antibiotic can cross the membrane.235  An increase in potency 
was observed when HeLa cells are transfected  with encephalomyocarditis virus. 
 
 




% Control  
Yeast HeLa E. coli	  
None 100 100 100	  
Mildiomycin (50 µM) 19 0 0	  
Mildiomycin (20 µM) 86 0 53	  
Mildiomycin (10 µM) 92 0 90	  
Anthelmycin (10 µM) 109 103 25	  
Gougerotin (10 µM) 64 84 24	  
Blasticidin S (10 µM) 5 20 6	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In vitro experiments on the direct effect of mildiomycin in the protein 
synthesis machinery, using S-30 rabbit reticulocyte lysate, determined the IC50 to be 
0.5 µM.  Mildiomycin has no effect on the binding of Phe-tRNA (P-site substrate) and 
N-Ac-Phe-tRNA (A-site substrate) to the ribosome in a poly-(U) system.  Similar to 
blasticidin S, mildiomycin inhibits the  peptidyl  transferase  reaction  of 
3H]-puromycin  using   yeast  polysomes.234, 237   It  exhibited  43%  inhibition  of the 
puromycin reaction at a concentration of 100 µM, which is considerably lower than 
anisomycin’s (90% inhibition) and trichodermin’s (80% inhibition)  activities  at the 
same antibiotic concentration.234   
 
 
1.13.5  Ezomycins A1 and A2  
 
 Ezomycins A1 and A2 (Figure 1.18) were isolated by Sakata and co-workers in 
1974 from the fermentation broths of Streptomyces found in samples collected in 
Hokkaido. 238   Ezomycin A1 was isolated as a white amorphous powder, while 
Ezomycin A2 was obtained as a crystalline solid. Ezomycin A1 is highly soluble in 
water while ezomycin A2 is partially soluble in water, but easily soluble in acidic and 
basic conditions.  Both antibiotics are practically insoluble in most organic 
solvents.238  





Figure 1.18 Ezomycins A1 and A2 
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experiments 239 , 240 , 241  and spectrometric studies.242 , 243   Their structures feature 
aunique octosyl cytosine nucleoside, a deoxyglycoside (ezoaminuroic acid) and an N-
linked pseudopeptide (L-cystathionine) for ezomycin A1.  Other ezomycins have been 
co-isolated with A1 and A2 such as ezomycins B1 and B2, which are uracil analogues 
of A1 and A2 respectively.  Ezomycin A1 was found to be inactive against most 
microbes  except  for  Sclerotina   and   Botrytis   (Table 1.19).   On  the  other hand, 
ezomycin A2, lacking the L-cystathioninyl, was devoid of any significant 
antimicrobial activity.238  To date no additional study has been done on ezomycins. 
Table 1.19 Antimicrobial spectrum of Ezomycin A1 244 
Test organisms MIC (µg/mL) 
Sclerotinia sclerotiorum 6.3 
Botrytis cinerea  6.3 
Sclerotinia libertiana  50 
Botrytis alli  50 
Bacillus subtilis PCI 219  >100 
Blastomyces brasiliensis OUT 4210 >100 
Candida albicans YU 1200 >100 
Candida tropicalis IAM 4862 >100 
Cornyebacterium xerosis  >100 
Escherichia coli NIHJ JC-2  >100 
Gloesporum kaki #KYU: 438 >100 
Klebsiella pneumoniae PCI 602  >100 
Mycobacterium smegmatis ATCC 607 >100 
Proteus vulgaris OX-19  >100 
Pseudomonas aeruginosa IAM 1095  >100 
Saccharomyces cervisiae ATCC 9736  >100 
Sarcina lutea PCI 1001  >100 
Trichophyton mentagrophytes  >100 
Trichophyton interdigiate  >100 
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 Pyrimidine nucleosides (Figure 2.1) are a class of ribosomal antibiotics 
primarily derived from fermentation broths of Streptomyces species.1, 2  Amicetin, a 
member of this class, is of particular interest to us for its potent antibacterial 
activity against Mycobacterium tuberculosis H37Rv (MIC 0.5 µg/mL) and good 
selectivity index against mycobacteria over mammalian cells.3, 4 With the resurgence 
of drug resistant strains of M. tuberculosis (MDR-TB, XDR-TB, and TDR-TB),5 the 
need for more efficient therapeutics prompted us to develop a convergent approach 
 
 




towards the synthesis of amicetin and its derivatives.  
 
 
2.2 Retrosynthesis  
 
A convergent retrosynthesis of amicetin is proposed (Figure 2.2).  Examining 
the structure of amicetin 1, the molecule can be synthesized from the N-glycoside 
coupling 6  of the amicetamine 2 and cytimidine 3.  The disaccharide can be 
synthesized from the Tsuji-Trost coupling of pyranones derived from the Noyori 
reduction-Achmatowicz rearrangement sequence on acylfuran 4.7   We envision the 
synthesis of the whole eastern unit of amicetin from the copper catalyzed amidation 






Figure 2.2  Retrosynthetic analysis 
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2.3  Results and Discussion 
2.3.1  Synthesis of Cytimidine Through a One-Pot Copper  
Amidation Cascade  
We began our efforts toward the total synthesis of amicetin by developing a highly 
efficient route to cytimidine. We sought to prepare cytimidine from a one-pot 
regioselective coupling of halopyrimidine 5 to 4-iodobenzamide 6, and carboxamide 
7, via copper catalyzed N-aryl amidation reactions (Figure 2.3).  Our strategy 
highlights the use of and inexpensive coupling chemistry and avoids a series of 
protection-deprotection chemistries normally employed in peptide synthesis.  We 
hypothesized that the differences in bond strength and steric constraints among the 
coupling partners would produce different rates of amidation, enabling us to unite 
these fragments via a one-pot, three component tandem N-aryl amidation.  We 
expected 5 and 6 to undergo a faster amidation because the carbon-halogen bond of 
a halopyrimidine is weaker than an arylhalide bond.  In addition, the coupling 
with 7 would be slower due to the steric hindrance afforded by the quaternary 
α-stereocenter. To explore our hypothesis and learn more about the subtleties that 





































Our synthesis began with the the synthesis of the carboxamide 7 
(Figure 2.4), which corresponds to the α-methylserine moiety, we began with the 
pivaldehyde condensation and subsequent Boc-protection of serine methyl ester 8 to 
form oxazolidine ester 9 as a single diasteromer.9 Oxazolidine ester 9 was alkylated 
employing Seebach’s memory of chirality,10 giving the α-methylated oxazolidine ester 
10 in excellent yield and >95:5 dr.  The alkylated product was saponified to the acid 
11, then converted to carboxamide 7 by treating the corresponding acid chloride 
(formed in situ) with concentrated ammonia. 
We proceed with formation of 4-halopyrimidines 5a-c (Figure 2.5).  These 
halides were prepared by the reaction of commercially available 4-chloro-2-
methylthiopyrimidine 12a with TMSBr or TMSI to give the corresponding bromo 
and iodopyrimidines 12b and 12c.11  Oxidation of 8a-c to the sulfone 13a-c,12 
followed by nucleophilic aromatic substitution13 with  potassium  allyloxide  gave  
5a-c,  in good to excellent yields.  The allyl protecting group was introduced to offer 
the option of selective deprotection to the cytosine moiety for N-glycosylation, or con 
currently deprotection en route to cytimidine and its analogues. 
 
  






We proceeded to screen reaction conditions for the copper catalyzed N-aryl 
amidation of 5a-c with 4-iodobenzamide 6 (Table 2.1).  The first example was from 
Buchwald who reported a the N-amidation of cyclohexanecarboxamide with 
5-bromopyrimidine using the trans-N,N′-dimethylcyclohexane-1,2-diamine ligand.8 
The second report was from Legraverend who showed the one-pot synthesis of 
purines via the amidation-condensation of 5-amino-4-iodopyrimidines with 
benzamides. 14  As a starting point, we applied Buchwald’s and Legraverend’s 
conditions to our coupling reaction (entries 1-4). To our surprise, instead of giving 
the desired pyrimidylbenzamide 14, these halopyrimidines couple with the diamine 
ligand, which had been previously described by Fukuyama in the copper-mediated 
N-aryl amination 2-iodopyridine. 15  The ligandless Goldberg protocol was also 
employed,16 (entries 5-7) but only  gave a trace of the product detected by LCMS.  We 
extended our screening to other ligands typically used in copper-mediated chemistry 
(entries 8-14). 17  The most promising ligand for the reaction was found to be 
1,10-phenanthroline giving pyrimidylbenzamide 14 in good yield.  
4-Chloropyrimidine  5a,   however,   was   unreactive   in   all   reaction  conditions  
 
 




Table 2.1 Optimization of the 1st N-aryl amidation* 
	  
Entry X Ligand Solvent Base time Yield 
1 Cl dmeda Toluene K3PO4 24h - 
2 Br dmeda Toluene K3PO4 24h - 
3 I dmeda Toluene K3PO4 24h - 
4 I diamine 2 Dioxane Cs2CO3 24h - 
5 Cl - Dioxane K3PO4 24h - 
6 Br - Dioxane K3PO4 24h <1% 
7 I - Dioxane K3PO4 24h <1% 
8 Cl 1,10-phen Toluene K3PO4 18h - 
9 Br 1,10-phen Toluene K3PO4 18h 69% 
10 I 1,10-phen Toluene K3PO4 24h 71% 
11 I 2,2'-bipy Toluene K3PO4 24h 37% 
12 I 8-hq Toluene K3PO4 24h 14% 
13 I 2,4,6-collidine Toluene K3PO4 24h 14% 
14 I 1,10-phen Dioxane K3PO4 18h 72% 
*10 mol% CuI, 20 mol% ligand, 1.0 equiv 5a-c, 1.0 equiv 6, and 2.0 equiv base 
 
 
(entry 8),while 4-bromo and 4-iodopyrimidines 5b and 5c exhibited similar yields 
(entries 9 and 10).  This suggests that the coupling process does not occur via 
nucleophilic aromatic substitution mechanism, where chlorides are known to react 
faster than bromides and iodides. 18  Our data supports the copper-mediated 
amidation going through through the ion-pair oxidative addition mechanism 
proposed by Hartwig and co-workers (Figure 2.6). 19 
After optimizing the initial coupling we applied our conditions to the 2nd N-
arylamidation (Table 2.2).  Unfortunately, 1,10-phenanthroline (phen) was found to 
be a less competent ligand for this reaction (entry 1). Using the ligand N,N’-
dimethylethylenediamine (dmeda) affords the coupled product in excellent yields.  It 
















Table 2.2 Optimization of the 2nd N-aryl amidation* 
Entry Ligand solvent Base temp Time Yield 
1 1,10-phen dioxane K3PO4 120 ºC 48h 20% 
2 dmeda dioxane K3PO4 100 ºC 60h 93% 
* 10 mol% CuI, 20 mol% ligand, 1.0 equiv 14, 1.0 equiv 7, and 2.0 equiv base.
ling of a sterically demanding substrate such as carboxamide 7; however, the more 
flexible Cu(dmeda)2 complex is well tolerated.  
Unfortunately, our initial goal of presenting a three-component tandem route 
towards cytimidine was not feasible due to the differences in reactivities of the 
Cu(phen)2 and Cu(dmeda)2 ligand systems with respect to the 1st and 2nd N-aryl 
amidations (Figure 2.3, vide infra).  The competing reactions (amination vs. 
amidation) of 4-halopyrimidines 5a-c in the 1st coupling reaction and the 
incompatibility of the Cu(phen)2 in the sterically hindered 2nd amidation led us to 





























Figure 2.6 Hartwig’s proposed mechanism for copper catalyzed amidation 
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sequential amidation of cytimidine (Figure 2.7). The N-aryl amidation of 
bromopyrimidine 5b with 4-iodobenzamide 14 followed by coupling of carboxamide 
7 gave masked cytimidine 15 in overall 53% yield.  Final deprotection sequences20 
afforded cytimidine in 34% overall yield in 5 steps from the commercially available 
4 chloro-2-methylthiopyrimidine. 
We also applied our method towards the synthesis of a number of masked 
cytimidine analogues from simple precursors (Figure 2.8).21 However, the yields 
obtained in these Cu-amidation cascades  were  unsatisfactory. Possible 
decomposition of the corresponding coupled intermediate or incomplete conversion 
maybe the reason for the obtained yields. Conducting the two amidation sequences 
separately gave cleaner reactions and better overall yields for the analogues. 
Οverall, we have developed an efficient route to cytimidine via a one-pot sequential 




Figure 2.7  One-pot Cu-mediated N-aryl amidation and  
completion of cytimidine synthesis  
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homocoupled halobenzamide and Ullmann22 product in our reactions by LCMS.  The 
methodology we have developed exploits the regioselective coupling of a 




2.3.2  Efforts Towards the Synthesis of Amicetamine 
 
Continuing on our divergent synthetic strategy, we proceeded with the 
synthesis of the disaccharide of moiety of amicetin,  amicetamine  2 by utilizing the 
strategy developed by O’ Doherty and co-workers in the synthesis of deoxysugars 
from  acylfuran  (Figure 2.9).  We  started our  synthesis  of  amicetose (Figure 2.10) 
with the asymmetric reduction of acylfuran  4 using  the Noyori catalyst  and  formic  
acid/triethylamine complex as a hydride source, yielded the corresponding  enantio- 
 
*10-30 mol% CuI, 20-40 mol% ligand, 1.0 equiv 5b or 16, 1.0 equiv 6 or 
1.5 equiv 17, 1.0-1.5 equiv 7 or 1821 
 
















enriched furfuryl alcohol.24  The alcohol was obtained in high enantiomeric excess (> 
96% ee), however, its exact yield was difficult to determine due its low boiling point.  
So after aqueous workup, we subjected the semi-crude furfuryl alcohol to the 
Achmatowicz rearrangement 25 , 26  to give pyranose 25 in 61% over two steps.  
Protection of the hemiacetal with benzoic anyhydride at low temperatures gave the 
α-Boc-pyranone 26 in 49% isolated yield.  Tsuji-Trost reaction was employed on 26 
to install the benzyloxy group in excellent yield and complete anomeric selectivity.  
Controlled low temperature reduction of the Tsuji-Trost product 27 with NaBH4 
selectively formed allyl alcohol 27 in excellent isolated yield. Alkene reduction of 27 
was achieved by 2-Nitrobenzenesulfonylhydrazide (NBSH) giving 

































1. Noyori (R, R), HCOOH/Et3N (5:2), rt, 24 h
2. NBS, THF/H2O (4:1), 0 °C, 1 h O
O
Me
OH96% ee (1st step)
61%, 2 steps
Boc2O, DMAP

































We envisioned that the aminopyranoside amosamine 23 could come from  the 
same strategy. We began our synthesis  (Figure 2.11) with the Boc protection of the 
equatorial alcohol 28, which gave carbonate 29 in good yields. Unfortunately, the 
attempted Tsuji-Trost reaction with dimethylamine on 29 was unsuccessful.  We 
then proceed with the Tsuji-Trost reaction using di-Cbz imide27 as our nitrogen 
nucleophile, which then gave the protected aminodihydropyran 30 in modest yields.  
We attempted the Prevost reaction28 on 30, but instead of the dihydroxylation 
product, iodopyran 31 was formed.  From here, we decided to access the diol from 
the epoxide.  Solvolysis of the cyclic carbamate29 in 31, gave an isolatable mixture of 
benzyl and ethyl carbamate epoxides 32 and 33 in modest yields. At this point, we 
have reached a major roadblock in our synthesis to open epoxide, however, we only 
found tosic acid to work to give a mixture of diols as all attempts in transforming our 
tosylated products 34 and 35 only lead to undesired transformations. While we 
































































 We were able to synthesize cytimidine, the eastern half of amicetin through a 
one-pot copper-catalyzed amidation cascade. Our efforts towards the synthesis of 
amicetamine, the disaccharide portion of amicetin, resulted in the completion of the 
dideoxy sugar amicetose, but not the aminosugar amosamine. During our attempts 
to complete the synthesis of amicetin, we also sought other more viable ways of 
producing the compound for further studies. It was then we opted to produce the 
natural product through actinomycete fermentation and isolation procedures. 
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2.6  Supplemental Information 
2.6.1 General Experimental Considerations 
All reactions requiring anhydrous conditions were conducted in flame-dried 
glassware under a positive pressure of either nitrogen or argon. Commercially 
available reagents were used as received; otherwise, materials were purified 
according to Purification of Laboratory Chemicals.1 Dichloromethane (CH2Cl2), 
N,N’-dimethylformamide (DMF), and tetrahydrofuran (THF) were degassed with 
nitrogen and passed through a solvent purification system (Innovative Technologies 
Pure Solv). Dry 1,4-dioxane was purchased from Acros Organics in a Acros Seal™ 
bottle.  Triethylamine (Et3N) was distilled from CaH2 immediately prior to use.  
Microwave reactions were done in CEM Discover System Model 908005.  Reactions 
were monitored by TLC and visualized by a dual short wave/long wave UV lamp and 
stained with ethanolic solution of 12-phosphomolybdic acid and p-anisaldehyde.  
Flash chromatography was performed on Merck silica gel Kieselgel 60 (230-400 
mesh) from EM Science with the indicated HPLC grade solvent.  
Melting points were determined using Mel-Temp® Capillary Melting Point 
Apparatus.  Infrared spectra were obtained using Nicolet 380-FT IR spectrometer 
fitted with a Smart Orbit sample system. Optical rotations were obtained at ambient 
temperature on a Perkin Elmer Model 343 polarimeter (Na D line) using a microcell 
with a 1 decimeter path length. Mass spectra were determined on a Micromass 
Quattro II (ESI/APCI-TOF) for HRMS at the University of Utah Mass Spectrometry 
Facility.  1H NMR spectra were recorded at 300 MHz and 500 MHz. and 13C NMR 
                                                
 
1 Purification of Laboratory Chemicals. 2003, 5th Ed. Armarego, W. L. F.; 
Chai, C. L. L. 
  
92 
spectra were recorded at 125 MHz. Proton resonances were reported relative to the 
deuterated solvent peak: 7.27 ppm for CDCl3 and 3.31 ppm  (center line signal) for 
CD3OD using the following format: chemical shift (δ) [multiplicity (s= singlet, bs= 
broad singlet, d= doublet, dd= doublet of doublet, dd= doublet of triplet, dq= doublet 
of quartet, ddd=doublet of doublet of exitdoublet, t= triplet, tdd= triplet of doublet of 
doublet, q= quartet, m= multiplet), coupling constant(s) J in Hz, integration].2  
Carbon resonances were reported as chemical shifts (δ) in parts per million, relative 
to the center line signal of the respective solvent peak: 77.23 ppm for CDCl3 and 
49.15 ppm for CD3OD. 
 
 











3-(tert-butyl) 4-methyl (2R ,4S)-2- ((tert-butyl)oxazolidine-3,4-
dicarboxylate (9). In a round bottom flask, Et3N (5.75 mL, 41.3 mmol, 100 mol) 
was added to a suspension of commercially available serine methyl ester 
hydrochloride 8 (5.83 g, 37.5 mmol, 1 equiv) in pentane (50 mL), after which 
pivaldehyde (4.54 mL, 41.25 mmol, 1.1 equiv) was added to the mixture.  A reflux 
condenser and Dean-Stark trap was then attached to the flask and the reaction was 
heated to 45 ˚C for about 6h, until no further water was collected in the Dean-Stark 
trap. The reaction was allowed to cool down to room temperature. The precipitated 
                                                
 
2 Hoye, T.R.; Hansen, P.R.; Vyvyan, J.R. J. Org. Chem. 1994, 59, 4096-4103. 
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Et3N·HCl salt was filtered, washed with Et2O (3 × 30 mL) and the organic layer 
dried over Na2SO4. The yellow filtrate was concentrated under reduced pressure and 
to give a yellow oil (6.6 g) containing a 1:1 mixture of epimers.  The condensation 
product was subjected to Boc-protection without further purification.  
Afterwards, the condensation product (6.6 g, 35.2 mmol, 1 equiv) was 
dissolved in THF (20 mL) and was cooled to 0 °C. (Boc)2O (14.6 mL, 71.8 mmol, 2 
equiv) was added dropwise. The reaction mixture was allowed to warm to room 
temperature overnight and was then poured into a mixture of ice (ca. 10 g) and 
saturated NaHCO3 solution (50 mL). The product was extracted with Et2O (50 mL) 
and was washed with saturated NaHCO3 solution (4 × 20 mL) and dried over 
Na2SO4. Excess solvent was removed under reduced pressure giving the crude 
product. Further purification by flash chromatography using 15% ether/hexanes 
gave a single isomer of the title compound 9 as a colorless oil (9.37 g, 87% yield over 
two steps). Rf = 0.31 (15% Et2O /hexanes).  [α]20D  -28.45 (c = 4.67, CHCl3). 1H NMR 
(500 MHz, CDCl3): δ 5.01 (s, 1H), 4.68 (bs, 1H), 4.26 (dd, J = 8.3, 5.9 Hz, 1H), 4.12 
(dd, J = 8.8, 8.8 Hz, 1H), 3.73 (s, 1H), 1.46 (s, 9H), 0.92 (s, 9H) ppm.  13C NMR 
(125 MHz, CDCl3) δ 171.2, 155.3, 97.8, 81.5, 68.5, 59.9, 52.5, 37.9, 28.4, 25.9 
ppm.13C DEPT (125 MHz, CDCl3) δ CH3: 52.5, 28.4, 25.9; CH2: 68.5; CH: 97.8, 59.9; 
CH0: 171.2, 155.3, 81.5, 37.9 ppm. IR (neat) 2974, 2906, 1761, 1704 cm-1. HRMS 











(2R ,4S)-3-tert-Butyl 4-methyl 2-(tert-butyl)-4-methyloxazolidine-3,4-
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dicarboxylate (10). A 100 mL flask under N2 was charged with THF (1 mL) and 
was cooled to -78 °C.  1M LHMDS in THF (1.60 mL, 1.60 mmol, 1.2 equiv) was 
added.  A solution of oxazolidine 9 (0.377 g, 1.31 mmol, 1.0 equiv) in THF (4 mL) 
was slowly added to the solution, maintaining the internal temperature of the 
reaction mixture at -78 °C.  The reaction was allowed to stir for another 30 min at 
-78 °C.  Iodomethane (0.250 mL, 4.00 mmol, 3.1 equiv) was added dropwise.  After 
stirring for another 6h at -78 °C, the solution was allowed to warm to room 
temperature.  The reaction mixture was then poured into a mixture of saturated 
solution of NH4Cl (15 mL) and EtOAc (50 mL).  The organic layer was separated, 
washed with distilled H2O (15 mL) and brine (15 mL), dried over anhydrous Na2SO4, 
filtered and concentrated under reduced pressure.  The crude product was purified 
by flash chromatography using 10% EtOAc/hexanes, giving the alkylated product 10 
(0.365 g, 92% yield) as a colorless oil.  Rf = 0.32 (10% EtOAc/hexanes).  [α]20D = -3.9, 
(c = 0.4, CHCl3).  1H NMR (500 MHz, CDCl3): δ 5.11 (s, 1H), 4.25 (d, J = 8.3 Hz, 1H), 
3.82 (d, J = 8.3 Hz, 1H), 3.77 (s, 3H), 1.64 (s, 3H), 1.44 (s, 9H), 1.01 (s, 9H) ppm.  
13C NMR (125 MHz, CDCl3) δ 172.7, 153.9, 97.2, 81.0, 77.3, 66.6, 52.6, 39.4, 28.3, 
26.8 21.4 ppm. 13C DEPT (125 MHz, CDCl3) δ CH3: 52.6, 28.3, 26.8, 21.4; CH2: 77.3; 
CH 97.2; CH0: 172.7, 153.9, 81.0, 66.6, 39.4 ppm.  IR (neat) 2976, 2907, 1744, 1713, 














carboxylic acid (11). To a stirring solution of alkylated oxazolidine 10 (0.847 g, 
2.81 mmol, 1.0 equiv) in THF (16 mL), LiOH • H2O (1.18 g, 28.1 mmol, 10.0 equiv) 
was added.  Distilled H2O (4 mL) was added to the mixture.  The reaction was 
allowed to stir at 50 ºC over 36h.  The reaction mixture was poured into a mixture of 
diethyl ether (30 mL) and distilled H2O (20 mL).  The aqueous layer was separated, 
carefully acidified to pH 3 with 1N HCl solution, extracted with EtOAc (3 Î 20 mL), 
dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure.  
The crude product was purified by flash chromatography using 50% EtOAc/hexanes, 
giving the acid oxazolidine 11 (0.797 g, 99% yield) as a white solid.  Rf = 0.41 
(50% MeOH/hexanes). Mp 117-118 °C. [α]20D = -104.5 (c = 0.4, CHCl3).  1H NMR 
(500 MHz, CDCl3): δ 5.13 (s, 1H), 4.60 (bs, 1H), 3.88 (d, J = 9.3 Hz, 1H), 1.68 (s, 3H), 
1.49 (s, 9H), 0.93 (s, 9H) ppm.  13C NMR (125 MHz, CDCl3) δ 174.3, 156.4, 97.4, 83.5, 
76.5, 66.5, 39.0, 28.1, 26.4, 21.5 ppm. 13C DEPT (125 MHz, CDCl3) δ CH3: 28.1, 26.4, 
21.5; CH2: 76.5; CH 97.4; CH0: 174.3, 156.4, 83.5, 66.5, 39.0 ppm.  IR (neat) 2978, 
2957, 1729, 1648, 1365 cm-1.  HRMS (ESI) Calculated for C14H25NO5Na m/z 320.1630 












carboxylate (7). To a stirring solution of acid oxazolidine 11 (0.344 g, 1.20 mmol, 
1.0 equiv) in CH2Cl2 (10 mL) at 0 °C under N2, dry Et3N (0.84 mL, 6.0 mmol, 
5.0 equiv) was added dropwise.  A few drops of dry DMF were added into the 
mixture.  Afterwards, Oxalyl chloride  (0.16 mL, 1.84 mmol, 1.5 equiv) was added 
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dropwise into the reaction.  The reaction was allowed to warm slowly to room 
temperature and was stirred for another 2 h.  Excess concentrated NH4OH solution 
(2 mL) was slowly added to the reaction mixture and was stirred for another 6h at 
room temperature.  The reaction mixture was quenched with saturated solution of 
NH4Cl (30 mL) and extracted with EtOAc (3 Î 20 mL).  The combined organic layers 
was washed with brine (20 mL), dried with anhydrous Na2SO4, filtered and 
concentrated under reduced pressure.  The crude product was purified by flash 
chromatography using 40% EtOAc/hexanes giving the carboxamide 7 
(0.263 g, 77% yield) as a white solid. Rf = 0.32 (40% EtOAc/hexanes). Mp 101-102 °C.  
[α]20D = -68.8 (c = 0.4, CHCl3).  1H NMR (500 MHz, CDCl3): δ 6.16 (bs, 1H), 
5.16 (s, 1H), 4.57 (d, d, J = 5.9 Hz, 1H), 3.76 (d, J = 8.8 Hz, 1H), 1.64 (s, 3H), 
1.47 (s, 9H), 0.91 (s, 9H) ppm.  13C NMR (125 MHz, CDCl3) δ 176.5, 155.3, 98.1, 82.2, 
76.8, 67.5, 38.5, 28.3, 26.4, 22.3 ppm.  13C DEPT (125 MHz, CDCl3) δ CH3: 28.3, 26.4, 
22.3; CH2: 76.8; CH: 98.1; CH0: 176.5, 153.3, 82.2, 67.5, 38.8 ppm.  IR (neat) 3485, 
3350, 2975, 1688, 1680, 1365 cm-1.  HRMS (ESI) Calculated for C14H26NO4Na m/z  








4-Bromo-2-(methylthio)pyrimidine (12b). Trimethylsilyl bromide (3.10 mL, 
23.4 mmol, 13.6 equiv) was added to a stirring solution of 4-Chloro-2-
(methylthio)pyrimidine 12a (0.200 mL, 1.72 mmol, 1.0 equiv) in CH3CN (20 mL) 
under N2 atmosphere.  The mixture was heated to 40 ºC and was stirred for 24h.  
The reaction mixture was quenched with a saturated solution of NaHCO3 (20 mL) 
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and was extracted with EtOAc (50 mL).  The organic layer was washed with distilled 
H2O (30 mL) and brine solution (30 mL), dried with anhydrous Na2SO4, and 
concentrated under reduced pressure.  The crude orange oil was purified by flash 
chromatography using 10% EtOAc/hexanes giving the title compound 12b (0.335 g, 
95% yield) as a colorless oil.  Rf = 0.26 (10% EtOAc/hexanes). 1H NMR 
(500 MHz, CDCl3): δ 8.18 (d, J = 5.4 Hz, 1H), 7.09 (d, J = 4.9 Hz, 1H), 2.56 (s, 3H) 
ppm. 13C NMR (125 MHz, CDCl3) δ 173.7, 157.2, 152.3, 120.3, 14.3 ppm. 13C DEPT 
(125 MHz, CDCl3) δ CH3: 14.3; CH: 157.2, 120.3; CH0: 173.7, 152.5 ppm. IR (neat)  
3096, 2926, 1537, 1393, 1331, 1304cm-1.  HRMS (ESI) Calculated for C5H6N1OxSBr 








4-Iodo-2-(methylthio)pyrimidine (12c). Trimethylsilyl iodide (10.0 mL, 10.3 
mmol, 20.0 equiv) was added to a stirring solution of 4-Chloro-2- 
(methylthio)pyrimidine 12a (0.400 mL, 3.43 mmol, 1.0 equiv) in CH3CN (12 mL) 
under N2 atmosphere.  The mixture was heated to 40 ºC and was stirred for 24h.  
The mixture was then cooled down to 0 ºC.  The reaction mixture was carefully 
quenched with a saturated solution of NaHCO3 (20 mL) and was extracted with 
EtOAc (50 mL).  The organic layer was washed with distilled H2O (30 mL) and brine 
solution (30 mL), dried with anhydrous Na2SO4, filtered through silica and 
concentrated under reduced pressure giving a brown crude product.  The crude 
product was then dry packed into silica gel and purified using flash chromatography 
using 10% EtOAc/hexanes giving the title compound 12c (0.163 g, 18% yield) as 
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colorless solid.  Rf = 0.26 (10% EtOAc/hexanes). Mp 38-39 °C. 
1H NMR (500 MHz, CDCl3): δ 8.00 (d, J = 5.4 Hz, 1H), 7.41 (d, J = 4.9 Hz, 1H), 
2.54 (s, 3H) ppm. 13C NMR (125 MHz, CDCl3) δ 173.5, 156.0, 129.5, 127.5, 14.5 ppm. 
13C DEPT (125 MHz, CDCl3) δ CH3: 14.5; CH: 156.0, 127.5; CH0: 173.5, 129.5 ppm. 
IR (neat) 3089, 3009, 2923, 1526, 1387 cm-1.  HRMS (ESI) Calculated for C5H6N2OSI 








4-Chloro-2-(methylsulfonyl)pyrimidine (13a). Ammonium molybdate 
tetrahydrate (0.218 g, 0.187 mmol, 0.03 equiv) was added to a 30% solution of 
Hydrogen peroxide (1.44 mL, 18.7 mmol, 3.0 equiv).  The mixture was then cooled to 
0 °C and slowly added to a stirring solution of 4-Chloro-2-(methylthio)pyrimidine 
12a (0.725 mL, 6.23 mmol, 1.0 equiv) in 95% ethanol (10 mL) at 0 °C.  The reaction 
was allowed to stir for another 24h at 0 °C, at which time, the bulk of the solvent 
was removed from the reaction mixture under reduced pressure.  The remaining 
crude reaction mixture was diluted with H2O (20 mL) and CH2Cl2 (20 mL).  The 
layers were separated and the aqueous layer was extracted with CH2Cl2 
(3 Î 20 mL).  The combined organic layers were washed with 5% H2SO4, dried with 
anhydrous Na2SO4, filtered, and concentrated under reduced pressure.  The crude 
product was purified by flash chromatography using 30% EtOAc/hexanes giving the 
chlorosulfone 13a (1.19 g, 99% yield) as a white solid. Rf = 0.21 
(50% EtOAc/hexanes). Mp 88-89 °C (lit. 87-89 °C). 1H NMR (500 MHz, CDCl3): 
δ 8.82 (d, J = 5.4 Hz, 1H), 7.63 (d, J = 4.9 Hz, 1H), 3.33 (s, 3H) ppm. 13C NMR 
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(125 MHz, CDCl3) δ 166.0, 163.3, 159.7, 124.9, 39.3 ppm. 13C DEPT (125 MHz, 
CDCl3) δ CH3: 39.3; CH: 159.7, 124.9; CH0: 166.0, 163.3 ppm. IR (neat) 3077, 3013, 
2931, 1307, 1162 cm-1.  HRMS (ESI) Calculated for C5H6N2O2SCl m/z 192.9839 








4-Bromo-2-(methylsulfonyl)pyrimidine (13b). Ammonium molybdate 
tetrahydrate (0.258 g, 0.0221 mmol, 0.03 equiv) was added to a 30% solution of 
Hydrogen peroxide (0.154 mL, 2.21 mmol, 3.0 equiv).  The mixture was then cooled 
to 0 °C and slowly added to a stirring solution of 4-Bromo-2-(methylthio)pyrimidine 
12b (0.151 g, 0.738 mmol, 1.0 equiv) in 95% ethanol (5 mL) at 0 °C.  The reaction 
was allowed to stir for another 24 h at 0 °C, at which time, the bulk of the solvent 
was removed from the reaction mixture under reduced pressure.  The remaining 
crude reaction mixture was diluted with H2O (20 mL) and CH2Cl2 (20 mL).  The 
layers were separated and the aqueous layer was extracted with CH2Cl2 
(3 Î 20 mL).  The combined organic layers were washed with 5% H2SO4, dried with 
anhydrous Na2SO4, filtered, and concentrated under reduced pressure.  The crude 
product was purified by flash chromatography using 30% EtOAc/hexanes giving the 
bromosulfone 13b (0.163 g, 93% yield) as a white solid. Rf = 0.21 
(50% EtOAc/hexanes). Mp 111-112 °C.  1H NMR (500 MHz, CDCl3): 
δ 8.69 (d, J = 5.4 Hz, 1H), 7.79 (d, J = 4.9 Hz, 1H), 3.35 (s, 3H) ppm. 13C NMR 
(125 MHz, CDCl3) δ 166.0, 158.8, 154.8, 128.9, 39.3 ppm. 13C DEPT (125 MHz, 
CDCl3) δ CH3: 39.3; CH: 158.8, 128.9; CH0: 166.0, 154.8 ppm. IR (neat) 3058, 2910, 
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1523, 1333, 1309 cm-1.  HRMS (ESI) Calculated for C5H5N2O2BNaSBr m/z 258.9153 








4-Iodo-2-(methylsulfonyl)pyrimidine (13c). Ammonium molybdate 
tetrahydrate (0.182 g, 0.0156 mmol, 0.03 equiv) was added to a 30% solution of 
Hydrogen peroxide (1.20 mL, 15.6 mmol, 3.0  equiv).  The mixture was then cooled to 
0 °C and slowly added to a stirring solution of 4-Iodo-2-(methylthio)pyrimidine 12c 
(1.31 g, 5.21 mmol, 1.0 equiv) in 95% ethanol (10 mL) at 0 °C.  The reaction was 
allowed to stir for another 24h at 0 °C, at which time, the bulk of the solvent was 
removed from the reaction mixture under reduced pressure.  The remaining crude 
reaction mixture was diluted with H2O (50 mL) and CH2Cl2 (50 mL).  The layers 
were separated and the aqueous layer was extracted with CH2Cl2 (3 Î 25 mL).  The 
combined organic layers were washed with 5% H2SO4, dried with anhydrous Na2SO4, 
filtered, and concentrated under reduced pressure.  The crude product was purified 
by flash chromatography using 30% EtOAc/hexanes giving the iodosulfone 13c 
(1.38 g, 93% yield) as a white solid. Rf = 0.21 (50% EtOAc/hexanes).  Mp 130-131 °C. 
1H NMR (500 MHz, CDCl3): d 8.44 (d, J = 4.9 Hz, 1H), 8.02 (d, J = 5.4 Hz, 1H), 
3.37 (s, 3H) ppm. 13C NMR (125 MHz, CDCl3) δ 165.8, 157.3, 135.7, 131.0, 39.3 ppm. 
13C DEPT (125 MHz, CDCl3) δ CH3: 39.3; CH: 157.3, 135.7; CH0: 165.8, 131.0 ppm. 
IR (neat) 3100, 3010, 2927, 1534, 1516, 1403, 1304 cm-1.  HRMS (ESI) Calculated for 







2-(Allyloxy)-4-chloropyrimidine (5a). To a stirring solution of allyl alcohol 
(0.25 mL, 2.86 mmol, 1.1 equiv) in THF (5 mL) at 0 °C, 1M KOBut in THF (4.0 mL, 
4.0 mmol, 1.2 equiv) was slowly added.  The reaction was allowed to stir for 15 min 
and was cooled to -78 °C.  The resulting potassium salt of allyl alcohol was added 
dropwise to a stirring suspension of chlorosulfone 13a (0.650 g, 3.37 mmol, 1 equiv) 
in THF (5 mL) at -78 °C.   The internal temperature during addition was maintained 
around -78 °C to prevent the formation of 2,4-bis(allyloxypyrimidine).  The reaction 
was allowed to react for another 2 h at -78 °C. The mixture was diluted with diethyl 
ether (25 mL) and was washed with distilled H2O (2 Î 20 mL) and brine (20 mL). 
The organic layer was then dried with anhydrous sodium sulfate, filtered, and 
concentrated under reduced pressure.  The crude product was further purified by 
flash chromatography using 30% EtOAc/hexanes affording allyloxypyrimidine 5a 
(0.490 g, 85% yield) as a yellow oil, which was stored at sub-zero temperatures to 
avoid decomposition. Rf = 0.34 (30% EtOAc/hexanes). 1H NMR (500 MHz, CDCl3): 
δ 8.38 (d, J = 5.4 Hz, 1H), 6.97 (d, J = 5.4 Hz, 1H), 6.05 (tdd, J = 17.6, 10.3, 5.4 
Hz, 1H), 5.42 (tdd, J = 17.6, 1.5, 1.0 Hz, 1H), 5.27 (tdd, J = 10.7, 2.0, 1.5 Hz, 1H), 
4.88 (ddd, J = 5.9, 2.0, 2.0 Hz, 2H) ppm. 13C NMR (125 MHz, CDCl3) δ 164.9, 162.6, 
160.2, 132.1, 118.6, 115.2, 68.9 ppm. 13C DEPT (125 MHz, CDCl3) δ CH2: 118.6, 68.9; 
CH: 160.2, 132.1, 115.2; CH0: 166.0, 163.3 ppm. IR (neat) 3116, 2946, 1456, 1398 









2-(Allyloxy)-4-bromopyrimidine (5b). To a stirring solution of allyl alcohol 
(0.081 mL, 1.19 mmol, 1.1 equiv) in THF (5 mL) at 0 °C, 1M KOBut in THF (1.3 mL, 
1.3 mmol, 1.2 equiv) was slowly added.  The reaction was allowed to stir for 15 min.  
The resulting potassium salt of allyl alcohol was added dropwise to a stirring 
solution of bromosulfone 13b (0.253 g, 1.07 mmol, 1.0 equiv) in THF (10 mL) at -78 
°C.  The internal temperature during addition was maintained around -78 °C to 
prevent the formation of 2,4-bis(allyloxypyrimidine).  The reaction was allowed to 
react for another 2h at -78 °C. The mixture was diluted with diethyl ether (20 mL) 
and was washed with distilled H2O (2 Î 10 mL) and brine (10 mL).  The organic 
layer was then dried with anhydrous sodium sulfate, filtered, and concentrated 
under reduced pressure.  The crude product was further purified by flash 
chromatography using 30% EtOAc/hexanes affording allyloxypyrimidine 5b 
(0.208 g, 91% yield) as a colorless oil, which was stored at sub-zero temperatures to 
avoid decomposition. Rf = 0.34 (30% EtOAc/hexanes). 1H NMR (500 MHz, CDCl3): 
δ 8.26 (d, J = 4.9Hz, 1H), 7.13 (d, J = 5.4 Hz, 1H), 6.05 (tdd, J = 17.1, 10.3, 5.9 
Hz, 1H), 5.42 (tdd, J = 17.1, 1.5, 1.5 Hz, 1H), 5.27 (tdd, J = 10.8, 1.5, 1.5 Hz, 1H), 
4.88 (ddd, J = 5.4, 1.5, 1.5 Hz, 2H) ppm. 13C NMR (125 MHz, CDCl3) δ 164.4, 159.5, 
153.9, 132.1, 119.2, 118.6, 69.0 ppm. 13C DEPT (125 MHz, CDCl3) δ CH2: 118.6, 69.0; 
CH: 159.5, 132.1, 118.2; CH0: 164.4, 153.9 ppm. IR (neat) 3110, 2987, 2946, 1558, 










2-(Allyloxy)-4-iodopyrimidine (5c). To a stirring solution of allyl alcohol 
(0.0240 mL, 0.352 mmol, 1.1 equiv) in THF (5 mL) at 0 °C, 1M KOBut in THF (0.378 
mL, 0.378 mmol, 1.2 equiv) was slowly added.  The reaction was allowed to stir for 
15 min.  The resulting potassium salt of allyl alcohol was added  dropwise to a 
stirring solution of iodosulfone 13c (0.0894 g, 0.315 mmol, 1.0 equiv) in THF (5 mL) 
at -78 °C.  The internal temperature during addtion was maintained around -78 °C 
to prevent the formation of 2,4-bis(allyloxypyrimidine).  The reaction was allowed to 
react for another 2h at -78 °C. The mixture was diluted with diethyl ether (25 mL) 
and was washed with distilled H2O (2 Î 20 mL) and brine (20 mL).  The organic 
layer was then dried with anhydrous sodium sulfate, filtered, and concentrated 
under reduced pressure.  The crude product was further purified by flash 
chromatography using 30% EtOAc/hexanes affording allyloxypyrimidine 5c 
(0.0825 g, 82% yield) as a colorless oil. Rf = 0.34 (30% EtOAc/hexanes).  1H NMR 
(500 MHz, CDCl3): δ 8.01 (d, J = 5.4 Hz, 1H), 7.38 (d, J = 5.4 Hz, 1H), 6.05 
(tdd, J = 16.6, 10.3, 5.9 Hz, 1H), 5.42 (tdd, J = 17.1, 1.5, 1.5 Hz, 1H), 5.27 (tdd, 
J = 10.3, 1.5, 1.4 Hz, 1H), 4.88 (ddd, J = 5.9, 1.5, 1.5 Hz, 2H) ppm.  13C NMR 
(125 MHz, CDCl3) δ 163.7, 158.3, 132.2, 130.7, 126.3, 118.7, 69.0 ppm. 13C DEPT 
(125 MHz, CDCl3) δ CH2: 118.7, 69.0; CH: 158.3, 132.2, 126.3; CH0: 163.7, 158.3 
ppm. IR (neat) 3099, 3019, 2942, 1548, 1529 cm-1.  HRMS (ESI) Calculated for 












N -(2-(Allyloxy)pyrimidin-4-yl)-4-iodobenzamide (14). Representative 
procedure: Under a positive pressure of argon, a dry pressure flask was charged with 
recrystallized CuI (0.0032 g, 0.0166 mmol, 0.1 equiv), 1,10-Phenanthroline (0.0066 g, 
0.0332 mmol, 0.2 equiv), anhydrous K3PO4 (0.0705 g, 0.332 mmol, 2.1 equiv), 
allyloxypyrimidine 5c (0.0408 g, 0.156 mmol, 1.0 equiv), and 4-Iodobenzamide 6 
(0.0410 g, 0.166 mmol, 1.1 equiv).  The flask was then quickly fitted with a rubber 
septum.  1,4-Dioxane (2.0 mL) was added to the mixture and was used to wash the 
walls of the pressure tube.  The rubber septum was quickly replaced with the 
pressure tube cap.  The reaction was stirred and heated at 120 oC for 18h.  The 
reaction mixture was then diluted with EtOAc (10 mL), filtered through a pad of 
celite and concentrated.  Flash chromatography (10% EtOAc/hexanes) afforded the 
title compound (0.0428 g, 72%) as white solid. Rf = 0.23 (20% EtOAc/hexanes).  Mp 
110 oC.  1H NMR (500 MHz, CDCl3) δ 8.62 (s, 1H), 8.47 (d, J = 5.4 Hz, 1H), 7.94 
(d, J = 5.4 Hz, 1H), 7.86 (d, J = 8.8 Hz, 2H), 7.61 (d, J = 8.8, Hz 2H), 
6.05 (tdd, J = 17.6, 10.8, 5.4 Hz, 1H), 5.40 (tdd, J = 17.1, 3.4, 2.0 Hz, 1H), 
5.27 (tdd, J = 10.3, 2.9, 1.5 Hz, 1H), 4.85 (ddd, J= 5.9, 1.5, 1.5 Hz, 1H).  13C NMR 
(125 MHz, CDCl3) δ 165.5, 164.7, 161.0, 159.2, 138.4, 132.8, 132.7, 128.9, 118.1, 
104.4, 100.6, 68.3 ppm. 13C DEPT (125 MHz, CDCl3) δ CH2: 118.1, 68.3; CH: 161.0, 
138.5, 132.7, 128.9, 104.4; CH0: 165.4, 164.6, 159.2, 100.6 ppm. IR (neat) 3299, 3164, 
2987, 1687, 1574, 1346, 1282 cm-1. HRMS (ESI) Calculated for C14H12N3O2NaI m/z 



















(2R ,4S)-tert-Butyl 4-((4-((2-(allyloxy)pyrimidin-4-yl)carbamoyl) phenyl) 
carbamoyl)-2-(tert-butyl)-4-methyloxazolidine-3-carboxylate (15). 
METHOD A (single N-aryl amidation reaction): Under a positive pressure of argon, a 
dry pressure flask was charged with recrystallized CuI (0.0166 g, 0.0872 mmol, 0.1 
equiv), anhydrous K2CO3 (0.2419 g, 1.75 mmol, 2.0 equiv), pyrimidylbenzamide 14 
(0.330 g, 0.865 mmol, 0.99 equiv), and carboxamide 7 (0.250 g, 0.872 mmol, 1.0 
equiv).  The flask was then quickly fitted with a rubber septum.  
N1,N2-Dimethylethane-1,2-diamine (0.019 mL, 0.175  mmol, 0.2 equiv) was added 
into the reaction mixture.  1,4-Dioxane (3.0 mL) was added to the mixture and was 
used to wash the walls of the pressure tube.  The rubber septum was quickly 
replaced with the pressure tube cap.  The reaction was stirred and heated at 100 oC 
for 60h.  The reaction mixture was then diluted with EtOAc (10 mL), washed with 
CH2Cl2 (10 mL), and filtered through a pad of celite and concentrated.  Flash 
chromatography (10% EtOAc/hexanes) afforded the title compound (0.4711 g, 92%) 
as colorless oil. 
METHOD B (one-pot sequential N-amidation):  Under a positive pressure of 
argon, a dry pressure flask was charged with recrystallized CuI (0.0046 g, 
0.0240 mmol, 0.1 equiv), 1,10-Phenanthroline (0.0095 g, 0.0480 mmol, 0.2 equiv), 
anhydrous K3PO4 (0.203 g, 0.960 mmol, 4.0 equiv), allyloxypyrimidine 5b (0.0517 g, 
0.240 mmol, 1.0 equiv), and 4-Iodobenzamide 6 (0.0593 g, 0.240 mmol, 1.0 equiv).  
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The flask was then quickly fitted with a rubber septum.  1,4-Dioxane (3.0 mL) was 
added to the mixture and was used to wash the walls of the pressure tube.  The 
rubber septum was quickly replaced with the pressure tube cap.  The reaction was 
stirred and heated at 120 oC for 18h.  The reaction was monitored by thin layer 
chromatography.  After the first reaction was done, carboxamide 7 (0.0687 g, 0.240 
mmol, 1.0 equiv) was added to the reaction mixture.  A solution of recrystallized CuI 
(0.0046 g, 0.0240 mmol, 0.1 equiv) and N1,N2-Dimethylethane-1,2-diamine (0.0052 
mL, 0.0480  mmol, 0.2 equiv)  in 1,4-Dioxane (1 mL) was added into the reaction 
mixture.  The reaction was stirred and heated at 100 oC for 60h.  The reaction cooled 
down to room temperature and was then diluted with EtOAc (10 mL), filtered 
through a pad of celite, washed with CH2Cl2 (10 mL), and concentrated.  Flash 
chromatography (10% EtOAc/hexanes) afforded the title compound (0.0685 g, 53%) 
as colorless oil. Rf = 0.23 (20% EtOAc/hexanes).  [α]20D = -67.5 (c = 0.45, CHCl3). 
1H NMR (500 MHz, CD3OD): δ 8.38 (d, J = 5.9 Hz, 1H), 7.97 (d, J = 8.3 Hz, 2H), 
7.90 (d, J = 5.4 Hz, 1H), 7.67 (d, J = 8.3 Hz, 2H), 6.08 (tdd, J = 17.6, 10.3, 
5.4 Hz, 1H), 5.41 (tdd, J = 17.6, 2.0, 1.5 Hz, 1H), 5.24 (tdd, J = 17.6, 1.5, 1.0 Hz, 
1H), 5.17 (s, 1H), 4.86 (ddd, J = 5.4, 1.5, 1.5 Hz, 2H), 4.69 (d, J = 8.3 Hz, 1H), 
3.78 (d, J = 8.8 Hz, 1H), 1.69 (s, 3H), 1.53 (s, 9H), 0.91 (s, 9H) ppm. 13C NMR 
(125 MHz, CD3OD) δ 173.2, 168.2, 165.7, 161.8, 161.3, 157.2, 143.5, 134.3, 130.6, 
130.4, 120.4, 118.3, 105.5, 99.2, 84.1, 77.0, 69.5, 69.1, 39.2, 28.6, 26.8, 22.2 ppm. 
13C DEPT (125 MHz, CDCl3) δ CH3: 28.6, 26.8, 22.2; CH2: 118.3, 77.0, 69.2; CH: 
161.3, 134.3, 130.6, 120.4, 105.5, 99.2; CH0: 173.2, 168.2, 165.7, 161.8, 157.2, 143.5, 
130.4, 99.2, 84.1, 69.6, 39.2 ppm.  IR (neat) 3260, 3052, 2975, 1689, 1587 cm-1.  



















(2R ,4S)-tert-Butyl 4-((3-((2- (allyloxy)pyrimidin-4-yl)carbamoyl)-5-
fluorophenyl)carbamoyl)-2-(tert-butyl)-4-methyloxazolidine-3-carbo-
xylate (19).  METHOD A (separate N-aryl amidation reaction) 1st Amidation 
reaction: Under a positive pressure of argon, a dry pressure flask was charged with 
recrystallized CuI (0.0045 g, 0.0236 mmol, 0.1 equiv), 1,10-Phenanthroline (0.0094g, 
0.047 mmol, 0.2 equiv), anhydrous K3PO4 (0.100 g, 0.471 mmol, 2.1 equiv), 
allyloxypyrimidine 5c (0.0510 g, 0.237 mmol, 1.0 equiv), and 3-Bromo-5-
Flurobenzamide 17 (0.0518 g, 0.237 mmol, 1.0 equiv).  The flask was then quickly 
fitted with a rubber septum.  1,4-Dioxane (4.0 mL) was added to the mixture and 
was used to wash the walls of the pressure tube.  The rubber septum was quickly 
replaced with the pressure tube cap.  The reaction was stirred and heated at 120 oC 
for 36h.  The reaction mixture was then diluted with EtOAc (10 mL), filtered 
through a pad of celite and concentrated.  Flash chromatography (10% 
EtOAc/hexanes) afforded the title compound (0.0475 g, 56%) as white solid. Rf = 0.37 
(20% EtOAc/hexanes).  The product was carried on forward without further 
characterization. 
2nd Amidation reaction: Under a positive pressure of argon, a dry pressure 
flask was charged with recrystallized CuI (0.0070 g, 0.0368 mmol, 0.2 equiv), 
anhydrous K3PO4 (0.2419 g, 1.75 mmol, 2.0 equiv), product from 1st amidation 
reaction: N-(2-(allyloxy)pyrimidin-4-yl)-3-bromo-5-fluorobenzamide (0.0673 g, 0.191 
mmol, 1.0 equiv), and carboxamide 7 (0.547 g, 0.191 mmol, 1.0 equiv).  The flask was 
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then quickly fitted with a rubber septum.  N1,N2-Dimethylethane-1,2-diamine 
(0.0080 mL, 0.0743 mmol, 0.4 equiv) was added into the reaction mixture.  1,4-
Dioxane (4.0 mL) was added to the mixture and was used to wash the walls of the 
pressure tube.  The rubber septum was quickly replaced with the pressure tube cap.  
The reaction was stirred and heated at 120 oC for 36h.  The reaction mixture was 
then diluted with EtOAc (10 mL), filtered through a pad of celite, washed with 
CH2Cl2 (10 mL), and concentrated.  Flash chromatography (10% EtOAc/hexanes) 
afforded the title compound (0.0499 g, 48%) as colorless oil. 
METHOD B (one-pot sequential N-amidation):  Under a positive pressure of 
argon, a dry pressure flask was charged with recrystallized CuI (0.0134 g, 
0.0704 mmol, 0.1 equiv), 1,10-Phenanthroline (0.0279 g, 0.141 mmol, 0.2 equiv), 
anhydrous K3PO4 (0.597 g, 2.82 mmol, 4.0 equiv), allyloxypyrimidine 5b (0.151 g, 
0.702 mmol, 1.0 equiv), and 3-Bromo-5-fluorobenzamide 17 (0.230 g, 1.51 mmol, 1.5 
equiv).  The flask was then quickly fitted with a rubber septum.  1,4-Dioxane (5 mL) 
was added to the mixture and was used to wash the walls of the pressure tube.  The 
rubber septum was quickly replaced with the pressure tube cap.  The reaction was 
stirred and heated at 120 oC for 36h.  The reaction was monitored by thin layer 
chromatography.  The reaction did not appear to go to completion; it was then 
decided to add carboxamide 7 (0.3024 g, 1.06 mmol, 1.5 equiv) was added to the 
reaction mixture.  A solution of recrystallized CuI (0.0270 g, 0.142 mmol, 0.2 equiv) 
and N1,N2-Dimethylethane-1,2-diamine (0.030 mL, 0.279  mmol, 0.4 equiv)  in 1,4-
Dioxane (1 mL) was added into the reaction mixture.  The reaction was stirred and 
heated at 120 oC for 60h.  The reaction cooled down to room temperature and was 
then diluted with EtOAc (15 mL), filtered through a pad of celite, washed with 
CH2Cl2 (10 mL), and concentrated.  Flash chromatography (10%-20% 
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EtOAc/hexanes) afforded title compound (0.080 g, 20%) as a colorless oil.  Rf= 0.43 
(30% EtOAc/hexanes). [α]20D = -17.2 (c= 0.62, CHCl3).  1H NMR (500 MHz, CD3OD): 
δ 8.45 (d, J = 5.4 Hz, 1H), 7.92 (d, J = 5.9 Hz, 1H), 7.84 (ddd, J =  9.8, 2.4, 
2.0 Hz, 1H), 7.78 (ddd, J = 10.7, 2.0, 2.0 Hz, 1H),  7.77 (dd, J =3.42, 2.0 Hz, 1H), 
 7.47 (ddd, J = 8.8, 2.0, 1.5 Hz, 1H),  6.10 (tdd, J = 17.1, 10.7, 5.1 Hz, 1H), 5.43 
(tdd, J = 17.6, 2.9, 1.5 Hz, 1H), 5.26 (tdd, J =  10.3, 2.9, 1.5 Hz, 1H), 5.18 (s, 1H), 
4.90 (tdd, J =  5.4, 1.5, 1.5 Hz, 1H),  4.68 (d, J = 8.3 Hz, 1H), 3.81 (d, J = 8.8  Hz, 1H), 
1.72 (s, 3H), 1.55 (s, 9H), 0.95 (s, 9H) ppm. 13C NMR (125 MHz, CD3OD) δ 173.5, 
167.6, 164.3 (δ, JC-F = 244.9 Hz), 163.3, 161.7, 161.6, 157.3, 141.5 (δ, JC-F = 10.7 Hz), 
137.9 (δ, JC-F = 8.4 Hz), 134.3, 118.3, 116.6, 112.1 (δ, JC-F = 26.7 Hz), 
111.7 (δ, JC-F = 23.7 Hz), 105.7, 99.3, 84.3, 77.1, 69.6, 69.3, 39.3, 28.6, 26.8, 22.1ppm. 
13C DEPT (125 MHz, CD3OD) δ CH3: 28.6, 26.8, 22.1; CH2: 118.3, 77.1, 69.3; CH: 
161.6, 134.3, 116.6, 112.1 (δ, JC-F = 26.7 Hz), 111.7 (δ, JC-F = 23.7 Hz), 105.7, 99.3; 
CH0: 173.5, 167.6, 164.3 (δ, JC-F = 244.9 Hz), 161.7, 161.6, 84.3, 69.6, 39.3 ppm.   
IR (neat)  3277, 3085, 2975, 1695, 1582 cm-1.  HRMS (ESI) Calculated for 
















(2R ,4S)-tert-Butyl 2-(tert-butyl)-4-((3-fluoro-5-(pyridin-2-ylcarbamoyl) 
phenyl)carbamoyl)-4-methyloxazolidine-3-carboxylate (20). METHOD A 
(separate N-aryl amidation reaction) 1st Amidation reaction: Under a positive 
pressure of argon, a dry pressure flask was charged with recrystallized CuI 
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(0.0291 g, 0.0153 mmol, 0.1 equiv), 1,10-Phenanthroline (0.0607g, 0.306 mmol, 
0.2 equiv), anhydrous K3PO4 (0.650 g, 3.06 mmol, 2.1 equiv), 2-Bromopyridine 16 
(0.146 mL, 0.153 mmol, 1.0 equiv), and 3-Bromo-5-Flurobenzamide 17 (0.500 g, 2.29 
mmol, 1.5 equiv).  The flask was then quickly fitted with a rubber septum.  
1,4-Dioxane (8.0 mL) was added to the mixture and was used to wash the walls of 
the pressure tube.  The rubber septum was quickly replaced with the pressure tube 
cap.  The reaction was stirred and heated at 120 oC for 36h.  The reaction mixture 
was then diluted with EtOAc (10 mL), filtered through a pad of celite and 
concentrated.  Flash chromatography (10% EtOAc/hexanes) afforded the title 
compound (0.2577 g, 57%) as white solid. Rf = 0.36 (20% EtOAc/hexanes).  The 
product was carried on forward without further characterization. 
2nd Amidation reaction: Under a positive pressure of argon, a dry pressure 
flask was charged with recrystallized CuI (0.0070 g, 0.0172 mmol, 0.2 equiv), 
anhydrous K3PO4 (0.0730 g, 0.344 mmol, 2.0 equiv), product from 1st amidation 
reaction: 3-Bromo-5-fluoro-N-(pyridin-2-yl)benzamide (0.0508 g, 0.172 mmol, 1.0 
equiv), and carboxamide 7 (0.0492 g, 0.171 mmol, 1.0 equiv).  The flask was then 
quickly fitted with a rubber septum.  N1,N2-Dimethylethane-1,2-diamine (0.0080 
mL, 0.0743  mmol, 0.4 equiv) was added into the reaction mixture.  1,4-Dioxane (4.0 
mL) was added to the mixture and was used to wash the walls of the pressure tube.  
The rubber septum was quickly replaced with the pressure tube cap.  The reaction 
was stirred and heated at 120 oC for 36h.  The reaction mixture was then diluted 
with EtOAc (10 mL), filtered through a pad of celite, washed with CH2Cl2 (10 mL), 
and concentrated.  Flash chromatography (10% EtOAc/hexanes) afforded the title 
compound (0.0509 g, 48%) as colorless oil. 
METHOD B (one-pot sequential N-amidation):  Under a positive pressure of 
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argon, a dry pressure flask was charged with recrystallized CuI (0.0133 g, 
0.0698 mmol, 0.1 equiv), 1,10-Phenanthroline (0.0277 g, 0.140 mmol, 0.2 equiv), 
anhydrous K3PO4 (0.593 g, 2.79 mmol, 4.4 equiv), 2-Bromopyridine 16 (0.060 mL, 
0.629 mmol, 1.0 equiv), and 3-Bromo-5-fluorobenzamide 17 (0.206 g, 0.0944 mmol, 
1.5 equiv).  The flask was then quickly fitted with a rubber septum.  1,4-Dioxane (5 
mL) was added to the mixture and was used to wash the walls of the pressure tube.  
The rubber septum was quickly replaced with the pressure tube cap.  The reaction 
was stirred and heated at 120 oC for 36h.  The reaction was monitored by thin layer 
chromatography.  The reaction did not appear to go to completion; it was then 
decided to add carboxamide 7 (0.2702 g, 0.943 mmol, 1.5 equiv) was added to the 
reaction mixture.  A solution of recrystallized CuI (0.0266 g, 0.140 mmol, 0.2 equiv) 
and N1,N2-Dimethylethane-1,2-diamine (0.030 mL, 0.279  mmol, 0.4 equiv)  in 1,4-
Dioxane (1 mL) was added into the reaction mixture.  The reaction was stirred and 
heated at 120 oC for 60 h.  The reaction cooled down to room temperature and was 
then diluted with EtOAc (15 mL), filtered through a pad of celite, washed with 
CH2Cl2 (15 mL), and concentrated.  Flash chromatography (10-20% EtOAc/hexanes) 
afforded the title compound (0.0595 g, 19%) as a colorless oil.  Rf= 0.38 (30% 
EtOAc/hexanes). [α]20D = -27.0, (c = 0.32 , CHCl3).  1H NMR (500 MHz, CD3OD): 
δ 8.36 (dd, J = 4.9, 1.0 Hz, 1H), 8.20 (d, J = 8.3 Hz, 1H), 7.84 (ddd, J =  10.3, 7.3, 
2.0 Hz, 1H),  7.79 (ddd, J = 10.7, 2.0, 2.0 Hz, 1H),  7.77 (dd, J =3.42, 2.0 Hz, 1H), 
 7.49 (ddd, J = 8.8, 2.4, 1.5 Hz, 1H),  7.18 (ddd, J = 7.3, 4.9, 1.0 Hz, 1H), 5.19 (s, 1H), 
4.69 (d, J = 8.8 Hz, 1H), 3.81 (d, J = 8.8  Hz, 1H), 1.71 (s, 3H), 1.55 (s, 9H), 0.95 (s, 
9H) ppm. 13C NMR (125 MHz, CD3OD) δ 173.5. 166.9, 164.3 (δ, JC-F = 244.9 Hz), 
157.3, 153.2, 149.3, 141.5 (δ, JC-F = 11.5 Hz), 139.8, 138.6 (δ, JC-F = 7.6 Hz), 121.6, 
116.6, 116.3, 111.7 (δ, JC-F = 26.7 Hz), 111.4 (δ, JC-F = 24.4 Hz), 99.3, 84.2, 77.1, 69.6, 
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39.3, 28.6, 26.8, 22.1 ppm.    13C DEPT (125 MHz, CD3OD) δ CH3: 28.6, 26.8, 22.1; 
CH2: 77.1; CH: 149.3, 139.8, 121.6, 116.6, 116.3, 111.7 (δ, JC-F = 26.7 Hz), 111.4 
(δ, JC-F = 24.4 Hz), 99.3; CH0: 173.5, 167.6, 164.3 (δ, JC-F = 244.9 Hz), 173.5, 166.9, 
164.3 (δ, JC-F = 244.9 Hz), 157.3, 84.2, 69.6, 39.3 ppm.   IR (neat)  3257, 2975, 1685, 


















(2R ,4S)-tert-Butyl 2-(tert-butyl)-4-methyl-4-((4-(pyridin-2-ylcarbamoyl) 
phenyl)carbamoyl)oxazolidine-3-carboxylate (21). METHOD A:  (separate N-
aryl  amidation reaction) 1st Amidation reaction: Under a positive pressure of argon, 
a dry pressure flask was charged with recrystallized CuI (0.0120 g, 0.0633 mmol, 0.1 
equiv), 1,10-Phenanthroline (0.0250 g, 0.131 mmol, 0.2 equiv), anhydrous K3PO4 
(0.2687 g, 0.127 mmol, 2.0 equiv), 2-Bromopyridine 16 (0.060 mL, 0.237 mmol, 1.0 
equiv), and 4-Iodobenzamide 6 (0.1564 g, 0.633 mmol, 1.0 equiv).  The flask was 
then quickly fitted with a rubber septum.  1,4-Dioxane (6.0 mL) was added to the 
mixture and was used to wash the walls of the pressure tube.  The rubber septum 
was quickly replaced with the pressure tube cap.  The reaction was stirred and 
heated at 120 oC for 36h.  The reaction mixture was then diluted with EtOAc (10 
mL), filtered through a pad of celite and concentrated.  Flash chromatography (10% 
EtOAc/hexanes) afforded the title compound (0.119 g, 58%) as white solid. Rf = 0.35 




2nd Amidation reaction: Under a positive pressure of argon, a dry pressure 
flask was charged with recrystallized CuI (0.0062 g, 0.0326 mmol, 0.1 equiv), 
anhydrous K3PO4 (0.1327 g, 0.652 mmol, 2.0 equiv), product from 1st amidation 
reaction: 4-Iodo-N-(pyridin-2-yl)benzamide (0.1057 g, 0.326 mmol, 1.0 equiv), and 
carboxamide 7 (0.0933 g, 0.326 mmol, 1.0 equiv).  The flask was then quickly fitted 
with a rubber septum.  N1,N2-Dimethylethane-1,2-diamine (0.0080 mL, 
0.0743 mmol, 0.2 equiv) was added into the reaction mixture.  1,4-Dioxane (4.0 mL) 
was added to the mixture and was used to wash the walls of the pressure tube.  The 
rubber septum was quickly replaced with the pressure tube cap.  The reaction was 
stirred and heated at 100 oC for 36h.  The reaction mixture was then diluted with 
EtOAc (10 mL), filtered through a pad of celite, washed with CH2Cl2 (10 mL), and 
concentrated.  Flash chromatography (10% EtOAc/hexanes) afforded the title 
compound (0.128 g, 81%) as colorless oil. 
METHOD B (one-pot sequential N-amidation):  Under a positive pressure of 
argon, a dry pressure flask was charged with recrystallized CuI (0.0070 g, 
0.0368 mmol, 0.1 equiv), 1,10-Phenanthroline (0.0138 g, 0.0696 mmol, 0.2 equiv), 
anhydrous K3PO4 (0.296 g, 1.39 mmol, 4.4 equiv), 2-Bromopyridine 16 (0.030 mL, 
0.314 mmol, 1.0 equiv), and 4-Iodobenzamide 6 (0.0593 g, 0.240 mmol, 1.0 equiv).  
The flask was then quickly fitted with a rubber septum.  1,4-Dioxane (3.0 mL) was 
added to the mixture and was used to wash the walls of the pressure tube.  The 
rubber septum was quickly replaced with the pressure tube cap.  The reaction was 
stirred and heated at 120 oC for 36h.  The reaction was monitored by thin layer 
chromatography.  The reaction did not appear to go to completion; it was then 
decided to add carboxamide  7 (0.150 g, 0.523 mmol, 1.5 equiv) was added to the 
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reaction mixture.  A solution of recrystallized CuI (0.014 g, 0.0735 mmol, 0.2 equiv) 
and N1,N2-Dimethylethane-1,2-diamine (0.015 mL, 0.140 mol, 0.4 equiv)  in 
1,4-dioxane (1 mL) was added into the reaction mixture.  The reaction was stirred 
and heated at 120 oC for 60h.  The reaction was cooled down to room temperature 
and then diluted with EtOAc (15 mL), filtered through a pad of celite, washed with 
CH2Cl2 (15 mL), and concentrated. Flash chromatography (10%-20% 
EtOAc/hexanes) afforded title compound (0.0548 g, 36%) as a colorless oil.  Rf= 0.26 
(30% EtOAc/hexanes). [α]20D = -25.8, (c = 0.71 , CHCl3).  1H NMR (500 MHz, CD3OD): 
δ 8.36 (d, J = 8.3, 1.0 Hz, 1H), 8.22 (d, J = 8.3 Hz, 1H), 7.99 (d, J =  8.3, Hz, 2H), 
 7.81 (ddd, J = 8.8, 8.8, 1.5 Hz, 1H), 7.68 (d, J =8.8 Hz, 2H),  7.14 (dd, J = 7.3, 5.3 
Hz, 1H),   5.18 (s, 1H), 4.69 (d, J = 8.3 Hz, 1H), 3.79 (d, J = 8.8  Hz, 1H), 1.70 (s, 3H), 
1.54 (s, 9H), 0.94 (s, 9H) ppm. 13C NMR (125 MHz, CD3OD) δ 173.3, 167.7, 157.2, 
153.4, 149.2, 143.1, 139.7, 131.3, 130.2, 121.3, 120.5, 116.4, 99.2, 84.1, 77.1, 69.6, 
39.3, 28.6, 26.8, 22.2 ppm. 13C DEPT (125 MHz, CD3OD) δ CH3: 28.6, 26.8, 22.2; CH2: 
77.1; CH: 149.2, 139.7, 130.2, 121.3, 120.5, 116.4, 99.2; CH0: 173.3, 167.7, 157.2, 
153.4, 143.1, 131.3, 84.1, 69.6, 39.2 ppm.  IR (neat)  3291, 2974, 1675, 1507, 





















-2,2-dimethyloxazolidine-3-carboxylate, (22). METHOD A (single N-aryl 
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amidation reaction): Under a positive pressure of argon, a dry pressure flask was 
charged with recrystallized CuI (0.0030 g, 0.016 mmol, 0.1 equiv ), anhydrous K2CO3 
(0.0365 g, 0.264 mmol, 2.0 equiv), pyrimidylbenzamide 14 (0.055 g, 0.131 mmol, 1.0 
equiv), and des-methyl carboxamide 18:3 (S)-Benzyl 4-carbamoyl-2,2-
dimethyloxazolidine-3-carboxylate  (0.0506 g, 0.182 mmol, 1.4 equiv).  The flask was 
then quickly fitted with a rubber septum.  N1,N2-Dimethylethane-1,2-diamine 
(0.005 mL, 0. 046 mmol, 0.35 equiv) was added into the reaction mixture.  1,4-
Dioxane (4.0 mL) was added to the mixture and was used to wash the walls of the 
pressure tube.  The rubber septum was quickly replaced with the pressure tube cap.  
The reaction was stirred and heated at 100 oC for 36h.  The reaction mixture was 
then diluted with EtOAc (10 mL), filtered through a pad of celite, washed with 
CH2Cl2 (10 mL), concentrated.  Flash chromatography (10% EtOAc/hexanes) 
afforded the title compound (0.045 g, 64%) as colorless oil. 
METHOD B (one-pot sequential N-amidation):  Under a positive pressure of 
argon, a dry pressure flask was charged with recrystallized CuI (0.0064 g, 
0.0335 mmol, 0.1 equiv), 1,10-Phenathroline (0.0133 g, 0.0676 mmol, 0.2 equiv), 
anhydrous K3PO4 (0.287 g, 1.35 mmol, 4.0 equiv), allyloxypyrimidine 5b (0.0720 g, 
0.335 mmol, 1.0 equiv), and 4-Iodobenzamide 6 (0.0827 g, 0.335 mmol, 1.0 equiv).  
The flask was then quickly fitted with a rubber septum.  1,4-Dioxane (4.0 mL) was 
added to the mixture and was used to wash the walls of the pressure tube.  The 
rubber septum was quickly replaced with the pressure tube cap.  The reaction was 
stirred and heated at 120 oC for 24h.  The reaction was monitored by thin layer 
                                                
 




chromatography.  After the first reaction was done, des-methyl carboxamide 18:5 
(S)-Benzyl 4-carbamoyl-2,2-dimethyloxazolidine-3-carboxylate (0.0930 g, 0.334 
mmol, 1.0 equiv) was added to the reaction mixture.  A solution of recrystallized CuI 
(0.0128 g, 0.0676 mmol, 0.2 equiv) and N1,N2-Dimethylethane-1,2-diamine (0.0146 
mL, 0.135  mmol, 0.4 equiv)  in 1,4-dioxane (1 mL) was added into the reaction 
mixture. The reaction was stirred and heated at 100 oC for 36 h.  The reaction was 
cooled down to room temperature and was then diluted with EtOAc (10 mL), filtered 
through a pad of celite, washed with CH2Cl2 (10 mL), and concentrated.   Flash 
chromatography (50% EtOac/hexanes) afforded title compound (0.0520 g, 29%) as a 
colorless oil.  Rf= 0.25 (50% EtOAc/hexanes). [α]20D = -63.6, (c = 0.805, CHCl3).  1H 
NMR (500 MHz, CD3OD) mixture of  rotomers (3:1), minor rotamer indicated by an 
asterisk: δ 8.40 (d, J= 5.4 Hz, 1H), 7.95 (d, J= 8.3 Hz, 2H), 7.92 (d, J= 5.7 Hz, 1H), 
7.72 (d, J= 8.3 Hz, 1H), 7.67 (d, J= 8.3 Hz, 1H), 7.41-7.35 (m, 2H),  7.21 (d, J= 6.8 Hz, 
1H), 7.15 (t, J= 6.9 Hz, 1H), 7.10 (t, J= 7.3 Hz, 1H), 6.09 (tdd, J= 17.1, 10.7, 5.4 Hz, 
1H), 5.41 (dd, J= 17.1, 1.0, 1H), 5.25 (dd, J= 10.7, 1.0 Hz, 1H), 5.17 (dd, J= 19.0, 11.7 
Hz, 1H), 5.11 (d, J= 12.2 Hz, 1H), 4.96 (d, J= 12.2 Hz, 1H), 4.89 (s, 1H), 4.61* (bs, 
1H), 4.31 (dd, J= 6.8, 3.9 Hz, 1H), 4.34* (dd, J= 8.8, 7.3  Hz, 1H), 4.30 (dd, J= 8.8, 7.3  
Hz, 1H), 4.11* (dd, J= 7.3 Hz, 3.4 Hz, 1H), 4.07 (dd, J= 8.8 Hz, 3.4 Hz, 1H), 1.73 (s, 
3H), 1.66* (s, 3H), 1.59 (s, 3H), 1.52* (s, 3H) ppm. 13C NMR (125 MHz, CD3OD) δ 
171.3, 170.9*, 168.5, 165.8, 161.9, 161.4, 154.8*, 153.8, 144.0, 137.5, 134.3, 130.4, 
130.2*, 129.8, 129.5*, 129.4*, 129.2, 128.9, 120.5, 118.3, 105.5, 96.8, 96.4*, 69.2, 68.9, 
68.9*, 68.4, 68.3, 67.9, 62.6*, 62.0*, 26.4*, 25.7*, 25.2, 24.9 ppm.  IR (neat) 2986, 
2940, 1682, 1585, 1502 cm-1.   HRMS (ESI) Calculated for C28H30N5O6 m/z (M+) 



















carbamoyl)phenyl)amino)propan-2-aminium chloride (3).  A dry microwave 
reaction tube was charged with masked cytimidine 15 (0.0306 g, 0.0567 mmol, 1.0 
equiv).  4N HCl (1 mL) was then added.  The reaction was heated to 70 ºC for 15 min 
in the microwave (200 W). The reaction was monitored every 2 minutes.  The 
reaction was allowed to cool down to room temperature and transferred to a round 
bottom flask.  Excess HCl was removed by addition of MeOH (7 Î 10 mL) and 
concentrating the mixture.  The excess H2O was then removed azeotropically by 
rotovaping the crude product with toluene (3 Î 10 mL).  The crude product was then 
washed with ether (3 Î 10 mL).   The product was then dried under reduced 
pressure to give the pure title compound 3 (0.0167 g, 80%) as a white solid. Rf = 0.22 
(50% MeOH/EtOAc).  Mp 260-262 oC.   [α]20D = -2.0 (c = 0.20, CH3OH). 1H NMR 
(500 MHz, CD3OD): δ 7.99 (d, J = 8.3 Hz, 2H), 7.77 (d, J = 8.8 Hz, 2H), 
7.74 (d, J = 6.8 Hz, 1H), 6.02 (d, J = 6.8 Hz, 2H), 4.11 (d, J = 12.1 Hz, 1H), 
3.83 (d, J = 11.7 Hz, 1H), 1.65 (s, 3H) ppm. 13C NMR (125 MHz, CD3OD) δ 170.2, 
169.4, 162.5, 149.23 148.2, 143.7, 131.8, 127.9, 121.4, 94.0, 65.5, 63.7, 19.1 ppm.  
13C DEPT (125 MHz, CD3OD) δ CH3: 19.1; CH2: 65.5; CH: 148.2, 131.8, 121.4, 94.0; 
CH0: 170.2, 169.4, 162.5, 149.3, 143.7, 127.9, 63.7 ppm. IR (neat)  3551, 3048, 2983, 













(2R)-6-hydroxy-2-methyl-2H -pyran-3(6H )-one (25). To a flask was added 
acetylfuran 4 (15.0 g, 136 mmol, 1 equiv), CH2Cl2 (240 mL), formic 
acid/triethylamine (5:2 (molar ratio), 50 mL) and Noyori asymmetric transfer 
hydrogenation catalyst (R)-Ru(η6-p-cymene)-(R,R)-TsDPEN (290 mg, 0.36 mol%). 
The resulting solution was stirred at room temperature for 24 h. The reaction 
mixture was diluted with water (500 mL) and extracted with Et2O (100 mL × 3). The 
combined organic layers were washed with saturated aqueous NaHCO3, dried over 
Na2SO4. The excess solvent was removed by carefully evaporating the solvent under 
atmospheric pressure. The resulting semi-crude furfuryl alcohol was dissolved in of 
THF/H2O (1000 mL, 3:1 (v/v)) and cooled to 0 ˚C. To this solution, solid NaHCO3 
(22.9 g, 272.4 mmol, 2 equiv), NaOAc•3H2O (18.5 g, 136.2 mmol, 1 equiv), and 
recrystallized NBS (64.3 g, 136.2 mmol, 1 equiv) were added and the mixture was 
stirred for 1h at 0 ˚C. The reaction mixture was extracted with cold Et2O (3 × 200 
mL) and the combined organic layer was washed by cold saturated brine (100 mL), 
dried over Na2SO4. The solvent was removed under reduced pressure to give a 
residue, which was rapidly subjected to purification via flash chromatography on 
silica gel. Elution with 50% EtOAc/hexane gave a diastereomeric mixture of 
pyranone hemiacetal 25 (10.6 g, 61%, α:β=2.3:1) as a yellow oil. Rf= 0.35 (50% 
EtOAc/hexanes).  1H NMR (500 MHz, CDCl3) α isomer: δ 6.90 (dd, J = 10.2, 3.4 Hz, 
1H), 6.10 (d, J = 10.3, 1H), 5.63 (dd, J = 4.4, 3.6 Hz, 1H), 4.71 (q, J = 6.8 Hz, 1H), 
3.73 (d, J = 5.1, 1H) OH, 1.38 (d, J = 6.8 Hz, 3H) ppm; β isomer: δ 6.94 (dd, J = 10.3, 
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1.47 Hz, 1H), 6.14, (dd, J = 10.3, 1.7, 1H), 5.67 (dd, J = 7.3, 1.2 Hz, 1H), 4.23 (dq, J = 
6.8, 1.2 Hz, 1H), 4.04 (d, J = 7.3, 1H) OH, 1.45 (d, J = 6.8 Hz, 3H) ppm. 13C NMR 
(125 MHz, CDCl3) α isomer: δ 197.2, 144.7, 127.4, 87.7, 70.6, 15.5 ppm; β isomer: 
196.8, 148.4, 128.7, 91.2, 75.4, 16.4 ppm. 13C DEPT (125 MHz, CDCl3) α isomer: 
δ CH3: 15.5; CH: 144.7, 127.4, 87.7, 70.6 ; CH0: 197.2 ppm; β isomer: δ CH3: 16.4; CH: 
148.4, 128.7, 91.2, 75.4 ; CH0: 196.8 ppm. IR (neat)  3388, 2987, 2940, 1691 cm-1.  









tert-butyl ((2R ,6R)-6-methyl-5-oxo-5,6-dihydro-2H -pyran-2-yl) carbo-
nate (26).  The mixture of pyranone hemiacetal 25 (0.162 g, 1.26 mmol, 1 equiv) 
was dissolved in CH2Cl2  (10 mL) and the solution was cooled to –78 ˚C. (Boc)2O 
(0.550 g, 2.82 mmol, 2.2 equiv) and DMAP (10.8 mg, 0.0882 mmol, 7 mol %) was 
added to the reaction mixture. After stirring for 12h, the reaction was quenched with 
aqueous saturated NaHCO3, extracted with Et2O, dried over Na2SO4, and 
concentrated under reduced pressure. The crude product was subjected to 
purification via flash chromatography using silica gel and eluting with 15% 
EtOAc/hexanes to give α-Boc-pyranone 26 (0.138 g, 49%) as a colorless oil. Rf= 0.48 
(20% EtOAc/hexane); [α]20D = -1.84 (c = 2.64, CHCl3). 1H NMR (500 MHz, CDCl3) δ 
6.87 (dd, J = 10.3, 3.9 Hz, 1H), 6.22 (d, J = 3.4 Hz, 1H), 6.20 (d, J = 10.3 Hz, 1H), 4.65 
(q, J = 6.8 Hz, 1H), 1.53 (s, 9H), 1.42 (d, J = 6.35 Hz, 3H) ppm. 13C NMR (125 MHz, 
CDCl3) δ 196.0, 152.1, 141.2, 128.7, 89.4, 83.9, 72.4, 27.9, 15.4 ppm.  13C DEPT 
  
120 
(125 MHz, CDCl3) δ CH3: 27.9, 15.4; CH: 141.2, 128.7, 89.4, 72.4 ; CH0: 196.0 ppm. 
IR (neat) 2983, 2941, 1748, 1701 cm-1. HRMS (ESI): Calculated for C11H16O5Na m/z 









(2R ,6S)-6-(benzyloxy)-2-methyl-2H -pyran-3(6H)-one (27) Benzyl alcohol 
(0.144 mL, 1.39 mmol, 2 equiv) was added to a solution of α-Boc pyranone 26 (0.158 
g, 0.694 mmol, 1 equiv) in CH2Cl2 (5 mL). The mixture was cooled to 0 °C. A solution 
of Pd2(dba)3 (15.9 mg, 0.01735 mmol, 2.5 mol%) and PPh3 (18.2 mg, 0.0694 mmol, 10 
mol%) in CH2Cl2 (4 mL) was added to the reaction mixture at 0 °C. The reaction was 
kept at 0 °C.  After 24 h, the reaction mixture was quenched with saturated aqueous 
NaHCO3 (10 mL), extracted with CH2Cl2 (3 × 5 mL), dried over Na2SO4, and 
concentrated under reduced pressure. The crude product was purified via silica gel 
flash chromatography eluting with 20% EtOAc/hexanes to give the title compound 
27 (0.104, 69%) as colorless oil. Rf= 0.43 (20% EtOAc/hexanes). [α]20D = -22.7 (c = 
1.35, CHCl3). 1H NMR (500 MHz, CDCl3) δ 7.39-7.32 (m, 5H), 6.85 (dd, J = 10.3, 3.9 
Hz, 1H), 6.10 (d, J = 10.3 Hz, 1H), 5.29 (d, J = 3.4 Hz, 1H), 4.83 (d, J = 11.7 Hz, 1H), 
4.70 (d, J = 11.7 Hz, 1H), 4.57 (q, J = 6.8 Hz, 1H), 1.37 (d, J = 6.4 Hz, 3H) ppm. 13C 
NMR (125 MHz, CDCl3) δ 197.2, 143.6, 137.4, 128.8, 128.8, 128.4, 128.3, 128.3, 
127.7, 92.6, 71.0, 70.7, 15.4 ppm. 13C DEPT (125 MHz, CDCl3) δ CH3: 15.4; CH2: 71.0; 
CH: 143.6, 128.8, 128.8, 128.4, 128.3, 128.3, 127.7, 92.6, 70.7; CH0: 197.2, 137.4 ppm.  
IR (neat) 3031, 2985, 2938, 1696 cm-1. HRMS (ESI): Calculated for C13H15O3 
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(2R ,3S ,6S)-6-(benzyloxy)-2-methyl-3,6-dihydro-2H -pyran-3-ol) (28) A 
solution of dihydropyranone 27 (0.1005 g, 0.46 mmol, 1 equiv)  was dissolved in 
CH2Cl2 /MeOH (6mL, 1:1 (v/v)). The solution was cooled to −78 °C, to which NaBH4 
(17.4 mg, 0.46 mmol, 1 equiv) was added. The reaction mixture was stirred at −78 °C 
for 4h. The reaction was quenched with saturated aqueous NaHCO3 (10 mL), 
extracted with EtOAc (3 × 5 mL).  The organic phase was dried over Na2SO4 and 
concentrated under reduced pressure. The product was purified using silica gel flash 
chromatography eluting with 20% EtOAc/hexanes to give allyl alcohol 28 (91.7 mg, 
91%) as a colorless oil: Rf= 0.22 (20% EtOAc/hexanes). [α]20D = +34.9 (c = 0.935, 
CHCl3). 1H NMR (500 MHz, CDCl3) δ 7.37-7.28 (m, 5H), 5.93 (dd, J = 9.8, 1.0 Hz, 
1H), 5.76 (ddd, J = 10.3, 2.9, 1.6 Hz, 1H), 5.03 (d J = 1.5, 0.97 Hz, 1H), 4.78 (d, J = 
11.7 Hz, 1H), 4.60 (d, J = 12.2 Hz, 1H), 3.84 (dt, J = 8.9, 1.5 Hz, 1H), 3.76 (dq, J = 
12.7, 6.3 Hz, 1H), 1.9 (d, J= 8.3 Hz, 1H) OH, 1.30 (d, J = 5.9 Hz, 3H) ppm. 13C NMR 
(125 MHz, CDCl3) δ 138.1, 133.8, 128.6, 128.6, 128.2, 128.2, 127.9, 126.7, 93.7, 70.2, 
69.9, 68.3, 18.1 13C DEPT (125 MHz, CDCl3) δ CH3: 18.1; CH2: 69.9; CH: 133.8, 
128.6, 128.6, 128.2, 128.2, 127.9, 126.7, 93.7, 70.2, 69.9, 68.3; CH0: 138.1 ppm.  IR 
(neat) 3386, 2973, 2931, 2877 cm-1. HRMS (ESI): Calculated for C13H16O3Na m/z 











(2R ,3S ,6S)-6-(Benzyloxy)-2-methyltetrahydro-2H -pyran-3-ol (24). 
O-nitro- benzenesulfonyl hydrazide (NBSH) (0.272 g, 1.25 mmol, 3 equiv) was added 
to a solution of allylic alcohol 28 (91.7 mg, 0.416 mmol, 1 equiv) in N-
methylmorpholine (NMM) (0.5 mL) at rt. Et3N (200 µL) was added to the reaction 
mixture and was stirred for 24h. Additional NBSH (0.181 g, 0.832 mmol, 2 equiv) 
was added to the reaction, which was stirred for another 12h. The reaction mixture 
was diluted with EtOAc (5 mL) and was quenched with NH4Cl solution (5 mL). The 
aqueous layer was extracted with ethyl acetate (2 × 5 mL). The organic layers were 
combined and were washed with saturated aqueous NaHCO3, dried over Na2SO4, 
and concentrated under reduced pressure. The product was purified by silica gel 
column chromatography eluting with 10% EtOAc/hexane afforded the benzyloxy 
amicetose 24 (80.3 mg, 83%) as a clear oil. Rf= 0.33 (30% EtOAc/hexanes. [α]20D = 
+108.3 (c = 2.21, CHCl3). 1H NMR (CDCl3, 500 MHz) δ 7.38-7.33 (m, 5H), 4.85 (dd, J 
= 3.0, 1.2 Hz, 1 H), 4.72 (d, J = 12.0 Hz, 1 H), 4.49 (d, J = 12.0 Hz, 1H), 3.67 (dq, J = 
9.3, 6.3 Hz, 1H), 3.29 (dddd, J = 9.8, 9.3, 4.9, 4.9 Hz, 1 H), 1.88 (m, 2H), 1.80 (m, 2H), 
1.45 (d, J=4.8 Hz, OH), 1.27 (d, J=6.6 Hz, 3 H) ppm. 13C NMR (CDCl3, 125 MHz) δ 
138.3, 128.6, 128.6, 128.0, 128.0, 127.8, 95.7, 72.3, 69.8, 68.8, 29.8, 27.9, 18.1 ppm. 
13C DEPT (125 MHz, CDCl3) δ CH3: 18.1; CH2: 68.8, 29.8, 27.9; CH: 128.6, 128.6, 
128.0, 128.0, 95.7, 72.3, 69.8, 68.8; CH0: 138.3 ppm. IR (neat) 3405, 2933, 2894, 1027 










tert-Butyl (2R ,3S ,6S)-6-(Benzyloxy)-2-methyl-3,6-dihydro-2H -pyran-3-
ylcarbonate (29). Boc2O (0.954 g, 4.37 mmol, 1.5 equiv) was added to a solution of 
allylic alcohol 28 (0.642 g, 2.92 mmol, 1 equiv) and DMAP (17.8 mg, 0.146 mmol, 5 
mol%) in CH2Cl2 (20 mL) at 0 ˚C. The reaction allowed to warm up to rt and was 
stirred for 1h. It was quenched with saturated aqueous NaHCO3. It was then 
extracted with CH2Cl2 (3 × 10 mL). The combined organic layer was washed with 
saturated aqueous NaHCO3, and dried over Na2SO4.  The solvent was removed 
under reduced pressure. The product was purified by silica gel flash column 
chromatography eluting with 10-20% EtOAc/hexane to afforded the carbonate 29 
(0.773 g, 83%) as a white solid. Mp. 60-62 ˚C. Rf= 0.63 (20% EtOAc/hexanes). [α]20D = 
+88.6 (c = 2.99, CHCl3). 1H NMR (500 MHz, CDCl3) δ 7.37-7.27 (m, 5H), 5.94 (ddd, 
J = 10.1, 1., 1.22 Hz, 1 H), 5.82 (ddd, J = 10.4, 2.7, 1.8 Hz, 1 H), 5.06 (bs, 1H), 4.87 
(ddd, J = 9.2, 3.1, 1.5 Hz, 1H), 4.79 (d, J = 11.9 Hz, 1H), 4.61 (d, J = 11.9 Hz, 1H), 
4.02 (dq, J = 9.2, 6.4 Hz, 1H), 1.50 (s, 9H), 1.23 (d, J = 6.0 Hz, 3 H) ppm. 13C NMR 
(125 MHz, CDCl3) δ 153.3, 138.3, 129.9, 128.6, 128.1, 128.0, 127.6, 93.9, 82.8, 73.7, 
70.3, 65.1, 28.0, 18.0 ppm. 13C DEPT (125 MHz, CDCl3) δ CH3: 28.0, 18.0; CH2: 70.3; 
CH: 129.9, 128.6, 128.1, 128.0, 127.6, 93.9, 73.7, 65.1; CH0: 153.3, 138.3 ppm. 
IR (neat) 2892, 2953, 1732 cm-1. HRMS (ESI) calculated for C18H24O5Na m/z (M+Na) 
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Amicetin is a known protein synthesis inhibitor.  In 1963, Brock compared 
the effects of various antibiotics on the growth of Streptococcus pyogenes group A 
and the synthesis of its virulence factor M protein.1  Amicetin was found to inhibit 
both growth and M protein synthesis at a concentration of 10 µg/mL.  It arrests 
microbial growth and peptide formation, while the synthesis of ribonucleic acid 
(RNA) and deoxyribonucleic acid (DNA) remain  unaffected.2  
A number of studies have been done to investigate amicetin’s mechanism of 
action; however, the exact molecular mechanism is not well understood.  Data from 
early biochemical studies, however, have narrowed down the possible mechanism of 
action.  Early studies have shown that amicetin does not facilitate the transfer of 
amino acids to tRNAs.  The transfer of phenylalanine to tRNA remained uninhibited 
even at 1 mM of antibiotic.2 It also does not inhibit the binding of L-[13C]-
phenylalanyl-RNA to E. coli ribosomes, even at 1mM of amicetin.2   However, it was 
reported to  interfere with the binding of phenylalanine oligonucleotide, a CACCA-
tRNA mimic, to the 50S ribosomal subunit, 3  which corresponds to amicetin 





formation in the elongation process.4  Additionally, amicetin inhibits fMethionine 
release from the fMet-tRNA-ribosome complex.5 
Since other cytosine nucleoside antibiotics are known to be peptidyl 
transferase inhibitors, it has been suggested that amicetin has the same mode of 
action.  Amicetin inhibits the transfer of RNA-bound amino acid to the nascent 
polypeptide.2  It also inhibits the reaction of [3H]-puromycin with nascent peptides in 
native polysomes.6  Polysomes are a group of ribosomes translating the same at the 
same time, allowing the production of multiple polypeptides simultaneously like a 
molecular assembly line that is typically found in bacteria.7 Amicetin was also found 
to stabilize polysomes in the presence of compounds that induce polysome 
breakdown, such as puromycin, rifampin, or streptogramin A.8  Peptidyl transferase 
inhibitors are known to stabilize polysomes while initiation inhibitors are known to 
induce polysome metabolism.9    
Studies on amicetin, its derivatives, and other type 1 pyrimidine nucleoside 
antibiotics (Figure 3.1) provided insight into the structure-activity relationship 
(SAR) of amicetin’s major chemical functionalities.10   Oxamicetin is a bit more 
potent than amicetin but overall they have similar activity profiles.  Removal of 
amicetin’s α-methylseryl group in plicacetin resulted in a 10-fold loss in activity.  
The absence of amicetin’s disaccharide moiety in the derivative cytimidine, resulted 
in a 50-fold loss of activity.  Cytosamine triacetate, the amicetin derivative without 
the α-methylseryl-p-aminobenzoyl group, is 100-fold less active.10  This study 
supports the early hypothesis that the presence of two basic groups in amicetin’s 
structure is required for its binding and inhibitory property.2  
For almost two decades, interest in amicetin has waned in favor of more 





amicetin was published, until 1994, when Mankin and co-workers reported a single 
point mutation within helix 74 in the 23S rRNA of Halobacterium halobium (Hh).  
Point mutation U2457C (U2438C), Hh (E. coli numbering) was found to confer 
resistance to amicetin (Figure 3.2).11  This study proposed that the binding site of 
amicetin is close to the peptidyl transferase center and that the point mutation 
U2457C (U2438C) perturbs the local rRNA structure thereby disrupting the binding 
site of amicetin.  Point mutations conferring resistance are not exclusive to binding 
sites, as antibiotic resistance maybe effected allosterically.  Additionally, data 
obtained from footprinting experiments reported in this study are inconclusive. 
Ramesh and co-workers conducted NMR experiments and molecular 
modeling studies on amicetin bound to a truncated helix 74 mimic of the 23S RNA, 
based on the resistance mutant found by Leviev and co-workers. 11, 12   They reported 
a  constrained  model  of  amicetin  folding  in  half  (Figure 3.3)  where  its  cytosine  
 
 








moiety stacked and hydrogen bonded to the nucleotide U6 in the 35-mer RNA 
construct, corresponding to U2089 (U2094, U2068), Tth (Hh, E. coli) numbering.  
This folded conformation of amicetin was previously unseen and was drastically 
different from the X-ray structure of crystalline amicetin that showed a linear 
conformation13  This study suggested that the highly constrained conformation is 
stabilized by π-stacking interactions between the aromatic ring of the p-
aminobenzoyl moiety, the cytosine ring of amicetin, and the uracil group, in addition 
to hydrogen bonding between the imino proton of uracil and   cytosine.  Their model 
additionally  suggests  that  further  stabilization  is  achieved  through  an elaborate 
 
 
Figure 3.2 Peptidyl transferase center domain V 







intramolecular hydrogen-bonding network between the sugar and the α-methylseryl 
moiety of amicetin. 
Reports of intramolecular π-stacking on a turn in literature are quite rare.  
Before Ramesh’s report, this binding motif has only been seen in two other 
ribosomal antibiotic (Figure 3.4).  The first  literature precedence was   reported by 
Ramakrishnan and co-workers in the crystal structure of ribosome-bound 
pactamycin.14   The  second was a  computational  model  on a  cross-linked  linezolid 
 
 











analogue.15  In both examples, the molecules are not forced into an energetically 
unfavored conformation. This novel binding motif, while interesting, is highly 
suspect, especially when the high energy penalties are considered.  A much more 
sophisticated technique in structural biology such as x-ray crystallography may be 




3.2 Materials and Methods 
 
3.2.1 Re-Isolation of Amicetin from S. vinaceusdrappus 
 
While studies on the synthesis of amicetin and its derivatives are conducted 
in our laboratory, we sought to express and re-isolate amicetin from its original 
producing actinomycete.  We sought to adapt and modify the original production and 
isolation procedures on a laboratory scale.16, 17 
Streptomyces vinaceusdrappus (ATCC 25511) was grown on a sterile yeast-
malt agar plate and was inoculated into sterilized growth media consisting of yeast 
extract, peptone, and glucose (YPG-broth). An aliquot of the YPG seed culture was 
transferred into the production media containing dextrose, yeast extract, soy and 
various salts, to express amicetin.  The fermentation broth was subjected to a series 
of filtrations to produce the clarified production broth, which was extracted with a 
solution of 30% isopropanol in chloroform, about one-quarter of its volume, and was 
repeated thrice. The crude solid was purified using normal and reverse column 
chromatography.  Amicetin was observed to slowly decompose via solvolysis, 
especially at higher temperatures.  Crude amicetin was then carefully handled, 
purified and stored under dry and cold conditions.  Amicetin was obtained as a white 









3.2.2  Co-Crystallization, Data Collection and Processing  
X-ray Crystallography experiments were done in collaboration with Daniel 
Eiler of the Steitz Group at Yale University.  T. thermophilus 70S ribosomes were 
purified and crystallized as previously published 18   Ribosome complexes were 
obtained by incubating vacant 70S ribosomes with 500 µM amicetin, 20 µM mRNA, 
and 20 µM fMet-tRNAfMet for 24 hours.  Crystals were harvested and flash frozen 
in a nitrogen cryostream.  Details of the crystallization and structure determination 
are provided in the Supplemental Information. 
Data collection was performed at 100 K using synchrotron X-ray radiation at 
beam line 24ID-C at the Advanced Photon Source in Argonne National Laboratory 
(Argonne, IL) and beam line x25 at the National Synchrotron Light Source in 
Brookhaven National Laboratory.  X-ray diffraction data was processed using X-ray 
Detector Software (XDS).19  Refinements, integration and handling of scaled data 
were completed using Collaborative Computational Project programs. 20   Final 
models were built using COOT and refined using PHENIX.21, 22  Ligand model for 
amicetin were built using PRODRG.23   
 
 
3.3  Results 
 
From the crystallographic data, the binding site of amicetin concurs with the 
hypothesis that it binds in the same site and in a similar manner, albeit with some 
differences, as another pyrimidine nucleoside antibiotic, blasticidin S.24, 25  It also 
agrees with the data from previous biochemical studies indicating that it inhibits 
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protein synthesis by inducing a nonproductive conformation on the P-site bound 
tRNA, thereby arresting the peptidyl transferase reaction.   
In the crystal structure of ribosome-bound amicetin (Figure 3.5), the 
antibiotic assumed an extended conformation, contrary to the proposed folded 
conformation suggested in the NMR models.12, 26  The disaccharide portion of the 
molecule, amicetamine, protrudes out into helix 74 with the terminal sugar ring 
stacking on A2450 (A2439), Tth (E.coli) numbering (Figure 3.6).  This affords a 
cation-π interaction between the dimethylamine moiety of the terminal sugar of 
amicetin and the purine ring of A2450 (A2439).  The cytosine moiety of amicetin 
forms a Watson-Crick base-pair with G2262 (G2251) (Figure 3.7), mimicking the 
penultimate 3' cytosine, C75, of a P-site bound tRNA.  In the absence of the P-site 
tRNA, the p-aminobenzoyl moiety forms π-stacking interactions with A2613 (A2602) 
(Figure 3.7).  The terminal hydroxyl group of the α-methylseryl moiety hydrogen 
bonds with the R18 of ribosomal protein L16 (Figure 3.7). 
3.4 Discussion 
3.4.1 Proposed Mechanism of Action and Similarity 
to Blasticidin S 
The binding location and conformation of amicetin bound to the 70S ribosome 
corresponds with previously reported biochemical studies. Our data agrees with the 
primary hypothesis that amicetin binds to the PTC of the ribosome and with 
preliminary observations that it inhibits peptidyl transferase reaction in a similar 
manner as other pyrimidine nucleoside antibiotics such as blasticidin S.2-11 
As was discussed earlier, blasticidin S was one of the first antibiotics to have 

























 Figure 3.7  Important intermolecular contacts of amicetin within its binding site 
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determined by X-ray crystallography.27  The major site mimicked the penultimate 
cytosine of a P-site tRNA and formed an interaction between its guanidine tail and 
the nucleotide base corresponding to A2449 (A2438).28  The cytosine moiety of the 
minor binding site stacks with the cytosine moiety of the major site.  This report 
suggested that blasticidin competes with tRNA binding.27  A more recent crystal 
structure of the 70S ribosome in complex with blasticidin S and a P-site tRNA 
reveals that blasticidin S, rather than competing with the tRNA for binding to the P-
site, it distorts the CCA end of the tRNA by pushing C75 out of its stacking 
interaction, rendering the tRNA in a nonproductive conformation on the ribosome 
(Figure 3.8). Similar to blasticidin S, our data shows (Figure 3.9). that amicetin 
traps the 3' end of a P-site tRNA in the 50S ribosomal subunit by displacing a  P-site 
tRNA’s  penultimate cytosine, intercalating nucleotides C74 and A76, and forming a 
Watson-Crick pair with G2262 (G2251) in place of C75 at the 3’ end of the P-site 
tRNA. This induced nonproductive conformation inhibits the peptidyl transferase 
reaction. 
In addition, amicetin and blasticidin S form similar cation-π interactions 
with A2450 (A2439) and amicetin’s the dimethylamino moiety, as with the 
guanidine tail of blasticidin S (Figure 3.10).  Both basic centers are stacked on the 
aromatic ring of this particular adenosine and appear to be pertinent to the binding 
and activity of the antibiotics.  Any structural change to the guanidine moiety, or its 
deletion from the molecule results in decreased or lost of activity.29  The importance 
of this interaction in amicetin is illustrated by the effect of the resistance mutation 
U2449C (U2438C), Tth (E.coli) numbering, on the local rRNA structure.11, 30  
Changing uracil into cytosine would destabilize the Watson-Crick base pair between 
U2449 (U2438) and A2092 (A2071) present in the wild type ribosome.  This would 
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Figure 3.8  Distortion of the P-site tRNA conformation by blasticidin S in 70S T. 
thermophilus ribosome 
A B 
Figure 3.9  Distortion of the P-site tRNA conformation by amicetin  in 
70S T. thermophilus ribosome 
A) Amicetin’s cytosine overlaps with C75 of the P-site tRNA in the Apo ribosome;
B) amicetin traps the 3' end of a P-site tRNA in a nonproductive conformation by








interfere with amicetin binding, since the mutation would likely affect the position 
of the backbone of U2449 (U2438) and the unpaired A2450 (A2439), disrupting the 
cation-π interaction with the dimethylamino group of the terminal sugar. 
The crystal structure presented here is consistent with observations from 
available biochemical studies on amicetin.  Trapping the P-site tRNA in a non-
productive conformation inhibits peptidyl transferase on puromycin reactions and 
polyphenylalanine synthesis.2, 6  This also provides an explanation on amicetin’s 
ability to stabilize native polysomes.8  Upon completion of the peptide chain at the 
termination codon, the ribosome dissociates from the mRNA, becoming a 
termination ribosome, which readily disassembles  into   individual   ribosomal 
subunit, which can then re-assemble into polysomes, completing the ribosome cycle 
(Figure 3.11).31  Peptidyl transferase inhibitors halt the translation process, causing 
the congestion of ribosomes along the mRNA. This translational “traffic jam” 
prevents the reading of the termination  codon  and  the  subsequent  disassembly  of 
 
Figure 3.10  Cation-π interactions with A2450 (A2439) 









the polysome, supporting amicetin’s proposed mechanism of action-the inhibition of 
peptide bond formation. 
Our data also supports amicetin’s inability to inhibit pre-initiation processes 
like amino acid activation and early elongation steps like L-[13C]-phenylalanyl-RNA 
binding to the ribosomes.2  Amicetin, as shown here, interacts with residues in the P 
loop region, which is at least 100 100 Å away from residues of implicated in 
initiation processes.14, 32  Although amicetin was also reported to interfere with the 
binding of C-A-C-C-A tRNA  mimics  to   isolated 50S ribosomal subunit, it is likely 
due to a lack of a codon-anticodon interaction between full length tRNAs and the 
50S subunit, that is present in the context of the 70S ribosomes.  
Amicetin was also previously reported to inhibit fMethionine release from 
fMet-tRNA-ribosome complex.5  This property of amicetin has not been revisited 
 
 





since its publication in 1970.  Inhibition of fMethionine release mediated by release 
factor RF1 has recently been reported for blasticidin S.25  Svridstiky and co-workers 
proposed that the inhibition of peptide release by blasticidin may be due to steric 
interference of the distorted CCA 3’ end of the P-site tRNA with the GGQ-containing 
region of release factors.  A similar distortion of the P-site tRNA was also observed 
in our crystal structure of amicetin-tRNA-ribosome complex, and may have inhibited 
the RF1-mediated fMethionine release. 
Amicetin’s π-stacking interaction with A2613 (A2602) may be a contributing 
factor in inhibiting fMethionine release. Universally conserved A2613 (A2602) have 
been implicated in peptide release.33 , 34   In vitro experiments on reconstituted 
Thermus aquaticus 50S ribosome subunits and affinity-tag purified E. coli ribosomes 
have shown that A2613 (A2602) of 23S rRNA may be one of the critical residues for 
peptide release.  Release factors trigger peptide release by reorienting A2613 
(A2602) in the PTC. A2613 (A2602) subsequently coordinates with the GGQ motif of 
release factor proteins and activates a water molecule for peptidyl-tRNA 
hydrolysis.33  Superposition of our amicetin-70S structure with previously published 
RF2-70S complex35 shows that amicetin’s cytosine ring occupies the same space as 
A2613 (A2602) in the RF2-70S complex (Figure 3.12).  Upon binding of amicetin 
with the ribosome, A2613 (A2602) is displaced from its interaction with the GGQ 




3.4.2  Differences Between Amicetin and Blasticidin S 
Amicetin’s general structure is quite similar to blasticidin S.  It does, 








benzoyl group attached to the cytosine moiety.  This affords amicetin other 
important contacts with the ribosome that are not available to blasticidin S.  The p-
aminobenzoyl moiety of amicetin forms π-stacking interactions with A2613(A2602). 
This particular interaction is interesting due to its highly dynamic nature 
(Figure 3.13).  In the presence blasticidin S, A2613 (A2602) is slightly shifted from 
from its position in the Apo conformation.  On the other hand, in the amicetin-70S 
structure, A2613 (A2602) is repositioned almost 90o relative to its conformation in 
the Apo 70S ribosome. When this amicetin-70S complex is overlaid with the 
structure of the 70S ribosome with programmed A-site, P-site and E-site tRNAs, 
A2613 (A2602) overlaps with C74 of the P-site tRNA.36   
 
 
3.4.3  Differences with the Solution State NMR Studies 
Our crystal structures are in conflict with the conclusions and observations 




Figure 3.12 Superimposed amicetin-70S ribosome and RF2-70S 
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amicetin-helix 74 mimic complex (Figure 3.14).12, 26, 37  We suspect that the previous 
reports’ method in studying a system that is as complex and dynamic as the 
ribosome’s interaction with molecules such as antibiotics were oversimplified.  While 
NMR can provide useful structural information, using a 29-35mer RNA mimics to 
stand in as helix 74 of the 23S RNA was a reductionist approach to this complicated 
problem. We presume that truncated RNAs are not a practical model for studying 
interactions of antibiotics with ribosome. 
First, the base interactions observed in helix 74 mimics (Figure 3.14), 
employed in the aforementioned studies were quite different from those observed in 
published ribosome crystal structures.36, 38, 39  In the isolated model of the helix 74 
mimic, noncanonical interactions are formed between U6 and U30, as well as 
between A9 and A27, however, in the complete ribosome, these noncanonical 
interactions are absent. Normally, U2089 (U2068) forms a trans Watson-





Crick/Hoogsteen base pair with A2441 (A2430).38, 39  In an attempt to focus on the 
interactions with the speculative binding site from the resistance mutations studies, 
using a truncated rRNA mimic could have resulted in the formation of these 
artificial conformations. 
Secondly, for amicetin to afford the folded conformation as proposed by 
Ramesh, the amide bond between the pyrimidine ring and the aromatic ring has to 
assume a cis amide geometry, which is less favored than the trans conformation by 
an energy difference of 5 kcal/mol.  By assuming a cis amide geometry, it has to 
overcome an energy barrier of 15 kcal/mol.  Overall, that adds up to a total of 20 
kcal/mol energy penalty.  Their model suggested the folded conformation of amicetin 
is compensated with energy gained from both intra and intermolecular interactions, 
specifically with the nucleotide that corresponded to U2089 (U2068) via π-stacking 
interactions and hydrogen bonding.   In our crystal  structure  (Figure 3.15),  U2089  
 A B C 
 
 
Figure 3.14  RNA mimics employed in NMR studies on amicetin 
A) Secondary structure and the corresponding Tth numbering of the 35mer 
section of Helix 74; B) secondary structure of the solution state NMR structure of 
the 35mer Helix 74 mimic; C) putative binding site of amicetin from the solution 














(U2068) is at least 25 Å away from the binding site It is highly improbable for U2089 
(U2068) to undergo such drastic rearrangement and repositioning in the densely 
packed complete 50S ribosomal subunit or 70S ribosome.  Furthermore, electron 




The crystal structure of the antibiotic amicetin in complex with mRNA and 
tRNA on the 70S ribosome from T. thermophilus is presented, demonstrating the 





inhibits peptidyl transferase reaction by trapping the CCA 3’ end of a tRNA into the 
P-site of the ribosome.  Like blasticidin S, amicetin could possibly also inhibit 
peptide termination through its displacement of A2612 (A2602), an important 
nucleotide implicated in peptide release through its interaction with the GGQ motif 
of class 1 release factors.  Our data agrees with most available biochemical data on 
amicetin except for a series of recently published NMR experiments.  Mimics of 
helix 74 are outside the functional context of the ribosome and results in an artificial 
environment that is distinct from that of the native and complete 70S ribosome, 
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3.7  Supplemental Information 
3.7.1  General Experimental Procedure 
Streptomyces vinaceusdrappus (ATCC 25511) was purchased from American 
Type Culture Collection (ATCC) was maintained and propagated per ATCC 
instructions.  Materials for culture growth and propagation were purchased from BD 
Difco™ and Fischer Scientific® and used as received. Optical density (OD600) was 
measured using Biomate 3 (Thermo™).  
Normal phase flash chromatography was performed on Merck silica gel 
Kieselgel 60 (230-400 mesh) from EM Science with the indicated HPLC grade 
solvent.  Fractions were monitored by TLC and visualized by a dual short wave/long 
wave UV lamp. Reverse phase chromatography was performed on packed C-18 
columns using CombiFlash Rf™ (TELEDYNE ISCO) with the indicated HPLC grade 
solvent.  
Melting point was determined using Mel-Temp® Capillary Melting Point 
Apparatus. Infrared Spectra was obtained using Nicolet 380-FT IR Spectrometer 
fitted with a Smart Orbit sample system.  Optical rotations were obtained at 
ambient temperature on a Perkin Elmer Model 343 polarimeter (NaD line)using 
microcell with 1 decimeter path length. Mass spectra were obtained at the 
University of Utah CIF on a Micromass Quattro II (ESI/APCI) for LRMS or an LCT 
XE premier (ESI/APCI-TOF) for HRMS.  1H NMR spectra were recorded on Varian 
Unity-300 and cold probe Inova-500 MHz spectrometers. The chemical shifts (δ) of 
proton resonances are reported relative to CD3OD,\ using the following format: 1, 2  
                                                
 




chemical shift [multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m =  
multiplet, app = apparent, br = broad), coupling constant(s) (J in Hz), integral]. 13C 
NMR spectra were recorded at 150 MHz.   Chemical shifts of carbon resonances are 
reported relative to the deuterated solvent peak. 
 
3.7.2  Production of Amicetin 
Fermentation and production of amicetin from Streptomyces 
vinaceusdrappus (ATCC 25511) was done aspreviously described.3 The culture of 
S. vinaceusdrappus (ATCC 25511) was maintained at 36 °C on a sterile yeast-malt 
extract-glucose agar (4% w/v glucose, 4% w/v yeast extract, 10% w/v malt extract, 2% 
w/v CaCO3, and 12% w/v agar, dissolved in distilled and deionized water; pH 7.2; 
autoclaved at 120 ˚C for 15 min).  After four days, the mycelia grown on the agar 
plate were inoculated in a 500-mL Erlenmeyer flask containing 100 mL of sterile 
yeast-peptone-glucose seed medium (10% w/v yeast extract, 20% w/v peptone, 20% 
w/v glucose, dissolved in distilled deionized water; pH 7.0; autoclaved at 120 ˚C for 
15 min). The flasks were shaken (200 rpm) at 28 ˚C for 2 days.  The seed culture (25 
mL, OD600 of 1.6) was transferred into 2000-mL Erlenmeyer flasks, each containing 
500 mL of the production media (25% w/v glucose, 2.5% w/v yeast extract, 7% w/v 
soybean flour, 5% w/v Na2SO4, 8% w/v CaCO3, 4% w/v KCl, 0.4% w/v KH2PO4; pH 
7.55; autoclaved 120 ˚C for 20 min).  The inoculated production media was shaken 
(200 rpm) and incubated at 28 °C for 5 days.  
                                                
 
2 Hoye, T.R.; Hansen, P.R.; Vyvyan, J. R.  J. Org. Chem. 1994, 59, 4096-4103. 
3 De Boer, C.; Hinman, J. W. U. S. Patent 238,012 July 23,1951. 
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3.7.3  Isolation and Purification of Amicetin 
The production media was vacuum twice filtered to remove the mycelia using 
Whatman filter paper grade 1 and a third time with Whatman filter paper grade 3, 
yielding a brown-colored filtrate.  Without pH adjustment, the clarified filtrate was 
extracted thrice with one-fourth its volume using 30% v/v iPrOH/CHCl3. The 
extracts were combined and concentrated under reduced pressure yielding a 300 mg 
of brown solid of crude amicetin.  The crude solid was taken up in methanol and 
adsorbed into 1 g of celite, and dried under reduced reduced pressure. This process 
was repeated thrice to ensure optimal transfer of the crude material to the adsorbing 
agent.  The crude material was then purified by normal phase flash chromatography 
via gradient elution of 5% v/v MeOH/CHCl3 to 30% MeOH/CHCl3.  Semi-clean 
amicetin was obtained from the 20-30% MeOH/CHCl3 fractions.  The collected 
fractions were concentrated under reduced pressure and were re-adsorbed in celite, 
as previously described.  Re-adsorbed amicetin was subjected to further purification 
by reverse phase chromatography via gradient elution of 5% v/v H2O/CH3CN to 50% 
H2O/CH3CN.  The collected fractions were concentrated under reduced pressure to 
yield an off-white solid, which was triturated with ether to yield pure amicetin as a 
white powder (30 mg) as a white solid. Rf= 0.33 (30% MeOH/CHCl3). 1H NMR (300 
MHz, CDCl3) δ 8.18 (d, J = 7.6 Hz, 1H), 7.98 (d, J = 8.5 Hz, 2H), 7.82 (d, J = 8.6 Hz, 
2H), 5.78 (d, J = 7.6 Hz, 1H), 4.90 (d, masked by H2O, 1H), 3.96-3.73 (m, 4H), 3.43-
3.41(m, 3H), 2.47 (s, 6H), 2.40 (bs, 1H), 2.15 (m, 2H), 1.66 (dd, J = 9.3, 9.3, 2H), 1.37 
(d, J = 6.0 Hz, 3H), 1.31, (s, 1H), 1.25 (d, J = 6.3 Hz, 3H) ppm. 13C NMR (125 MHz, 
CDCl3) δ 177.8, 164.8, 157.3, 146.2, 143.9, 130.3, 129.6, 120.5, 98.8, 96.1, 84.6, 78.4, 
75.0, 74.6, 71.8, 70.2, 69.1, 67.3, 66.9, 64.7, 60.9, 42.3, 31.0, 27.7, 25.2, 22.7, 19.6, 
































3.7.5  Complex Formation and Crystallization 
70S T. thermophilus ribosomes were purified and crystallized as previously 
described.4 Purified 70S ribosomes were diluted with a buffer solution [5 mM Hepes 
(pH 7.5), 50 mM KCl, 10 mM NH4Cl, and 10 mM Mg(OAc)2 ] to a final concentration 
of 10 mg/mL.  70S ribosomes crystals werer grown at 19°C via sitting-drop vapor 
diffusion by mixing 3 µL of the ribosome sample with 3.5-4.5 µL of the crystallization 
solution [2.9% PEG 20K, 9% methyl-2,4-pentanediol (MPD), 175 mM L-arginine, and 
100 mM Tris–HCl (pH 7.6)]. Concentration of MPD was increased to 40% in stabilize 
the crystals, upon addition of 500 µM amicetin.  70s ribosomes were also co-
crystallized with mRNA (20 µM) and fMet-tRNAfMet (20 µM).  The crystals were flash 
frozen in a nitrogen cryostream at 80 K after 24 hours of equilibration.  
 
                                                
 
4 Polikanov, Y. S.; Blaha, G. M.; Steitz, T. A. Science 2012, 336, 915-918. 
CHAPTER 4 
BIOLOGICAL EVALUATION OF AMICETIN ANALOGUES 
4.1 Background 
The persisting global problem of tuberculosis (TB) and the inadequacy of the 
current drug treatments have led to our recent interest in developing new TB 
therapies.  As previously discussed, we sought to employ amicetin (Figure 4.1),1, 2  an 
underutilized pyrimidine nucleoside antibiotic as a possible drug lead;  using its 
structural features to design analogues that are active against Mycobacterium 
tuberculosis and noncytotoxic to mammalian cells.  Our efforts were also guided by 
other aminoacyl nucleoside antibiotics and TAN 1057 (Figure 4.1), a 
dihydropyrimidinone antibiotic.3 
A review by Fox proposed that aminoacyl nucleosides capable of inhibiting 
protein synthesis have an accessible amino acid moiety (Figure 4.1, blue) attached 
to a carrier nucleoside (Figure 4.1, red), and another basic center at the end of the 
molecule (Figure 4.1, green).4  These functional groups were thought to afford the 
efficient binding of the molecules to the ribosomes, providing their biological activity 
and inhibitory properties against protein synthesis.  In addition to this, 
Lichtenthaler proposed that the spatial rearrangement and the distance created by 
the molecular spacer or linker between the nucleobase and the amino acid 
(Figure 4.1, black) is essential for maintaining inhibitory function.5  
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In contrast, TAN 1057, a ribosomal antibiotic that neither has a sugar moiety 
nor a formal nitrogenous base is known to be active against Methicillin-resistant 
Staphylococcus aureus (MRSA) and inhibits protein synthesis.3  TAN 1057, however, 
has a dihydropyrimidinone that acts as a cytosine-mimic, as well as two basic 
centers (urea and ß-homoarginine).15  
Considering TAN 1057’s simplified structure relative to other pyrimidine 
nucleoside antibiotics, we speculate that amicetin analogues with simpler scaffolds 
can also exhibit the desired biological activity as long as the general pharmacophore 
is preserved. We sought to develop simplified amicetin with the general 
pharmacophore: a cytosine base, a linker, a cationic tail, and another cationic cap 
region (Figure 4.2).  
Our approach to analogue design preserves the cytimidine portion of 
amicetin, which contain both the required nucleobase, cytosine, and the aminoacyl 
cap region.  This allows for a focused SAR  study  on  the  disaccharide  of  amicetin.  
 
 





We chose   to   replace  the  disaccharide  with nonhydrolyzable linkers to explore 
possible variations of cationic tails, as well as variations of spacer length and 
flexibility.  Substituting the sugar moiety also simplifies the synthesis of potential 
analogues.  Drawing inspiration from the common structural features observed in 
pyrimidine nucleoside antibiotics and TAN 1057, we began to design and synthesize 
our analogues prior to solving the crystal structure of ribosome-bound amicetin. 
4.2 Materials and Methods 
4.2.1 Biological Evaluation of Amicetin Analogues 
Amicetin analogues were prepared by Hariprassada Reddy Kannareddy of 
the Looper Research Laboratory.  Compounds were assayed against M. tuberculosis 
H37Ra and mammalian CEM-TART leukemia cells using an MTT Assay.6, 7  The 
antimicrobial spectrum of the analogues were determined against B. subtilis, E. coli, 
A. baumanii, and C. albicans.   Protein synthesis inhibition was measured by 
luciferase readout using the Promega™ E. coli S30 Extract System. Assays were 
Figure 4.2 General design of amicetin analogues 
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done in triplicate. Data were processed using GraphPad™ Prism 6.  Detailed 
procedures are provided in the Supplemental Information. 
4.2.2 Co-Crystallization, Data Collection and Processing 
X-Ray Crystallograpy Experiments were done in collaboration with the Steitz 
Group at Yale University.  T. thermophilus 70S ribosomes were purified and 
crystallized as previously published. 8   Ribosome complexes were obtained by 
incubating vacant 70S ribosomes with analogue 1 (1 mM) and analogue 5 (3 mM) for 
24 hours.  Crystals were harvested and flash frozen in a nitrogen cryostream. 
Details of the crystallization are provided in the Supplemental Information. 
Data collection was performed at 100 K using synchrotron X-ray radiation at 
beam line 24ID-C at the Advanced Photon Source in Argonne National Laboratory 
(Argonne, IL) and beam line x25 at the National Synchrotron Light Source in 
Brookhaven National Laboratory.  X-ray diffraction data was processed using X-ray 
Detector Software (XDS).9  Refinements, integration and handling of scaled data 
were completed using Collaborative Computational Project programs. 10   Final 
models were built using COOT and refined using PHENIX.11, 12  Ligand model for 
amicetin were built using PRODRG.13   
4.3 Results 
4.3.1 Biological Properties of Amicetin Analogues  
Our preliminary screening has produced six analogues (Figure 4.3) that 
exhibited antimycobacterial activity, measured as half maximal inhibitory 
concentration (IC50), in the low micromolar  concentrations (Figure 4.4, Table 4.1). 
Analogue 3 is the most active with an IC50 of 0.98 µM against M. tuberculosis H37Ra 
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Figure 4.3 Amicetin analogues with antimycobacterial activity 

















































































Table 4.1  Summary of biological activity of amicetin analogues 
Compound M. tuberculosis 
H37Ra IC50 (µM) 
Protein Synthesis 
% Inhibition at 50 µM 
CEM-TART 
IC50 (µM) 
amicetin 0.24 100   4.5 
1 8.2 77 > 100 
2 19 61 > 100 
3 0.98 99 > 100 
4 7.4 94 > 100 
5 22 42 > 100 
(ATCC 25177).  All six analogues exhibited inhibition  of  protein   synthesis directly 
proportional to their respective antimycobacterial activity (Table 4.1).  The most 
potent analogue, compound 3, inhibited protein synthesis with an IC50 of 3.8 µM.  
These compounds exhibited limited cytotoxicity (Table 4.1) against CEM-
TART leukemia cells (AIDS Research and Reference Reagent Program, NIAID, 
NIH), IC50 >100 µM. All compounds tested, including the active analogues, exhibited 
a narrow spectrum of antimicrobial activity, and are inactive against B. subtilis  
(ATCC 6633), E. coli (ATCC 25922),  A. baumanii (ATCC 19606),  and C. albicans. 
(ATCC 90028).  
4.3.2  Crystal Structures of Amicetin Analogues Bound to  
70S T. thermophilus Ribosomes 
Structures of analogues 1 and 5 bound to the 70S ribosomal subunit of 
Thermus thermophilus (Tth) occupy the same binding pocket of amicetin in the 
peptidyl transferase center of the 70S T. thermophilus ribosome as amicetin 
(Figure 4.5).  Amicetin, analogue 1 and analogue 5 share a similar extended 
conformation with slight variations while the configuration of analogue 5 in the 
binding site deviates significantly from the other two, especially with respect to the 
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latter’s propylprolinyl group (Figure 4.6).  Unlike the respective aminohexopyranose 
and aminopiperidyl moieties of amicetin and analogue 1, which the propylprolinyl 
tail of analogue 5 swerves into a crevice  away  from  the  exit tunnel.  The basic 
groups of amicetin and analogue 1 sits on top of the exit tunnel, while the prolinyl of 
analogue 1 docks into a different crevice. 
Analogue 1, which is more potent, has a closer binding motif to amicetin than 
analogue 5, and has all the ribosomal interactions reported on amicetin (Figure 4.7, 
Figure 4.8).  Both analogues form the Watson-Crick GC pair through their cytosine, 
π-stacking interaction through their p-aminobenzoyl, and hydrogen bonding through 
their aminoacyl.  Unlike analogue 1, analogue 5 does not form cation-π intercations 
with the ribosome through its cationic tail. 
 
 
Figure 4.5 Shared binding site of amicetin (yellow) and analogues 1 (magenta) 
















Figure 4.7  Key interactions of analogue 1 with the  70S T. Thermophilus 
ribosome  
 
Figure 4.6  Overlapped binding conformations of amicetin:  amicetin (yellow), 




4.4  Discussion 
 
4.4.1  Structure Activity Relationship of Amicetin Analogues 
 
with Respect to Antimycobacterial Activity 
 
To test our hypothesis, 20 amicetin analogues in addition to cytimidine and 
amicetin  (Figure 4.9) were assayed against M. tuberculosis H37Ra. Based on the 
following set of compounds an apparent structure activity relationship can be 
inferred.  In line with our hypothesis, both basic centers are needed for activity,  as 
shown by cytimidine, and analogues 6 to 12 being devoid of activity.  Although 
analogue 8 technically has two basic centers, it appears to be at least 3 atoms short 
when laid side by side with blasticidin S, not to mention its molecular spacer is an 
alkynyl chain which has very little freedom of motion which could affect its binding 
affinity.  
As previously discussed, Lichtenthaler proposed that the spatial 
rearrangement and the distance created by the molecular spacer between the 
nucleobase and the  amino  acid  is  essential  for  maintaining  inhibitory  function.5 
 
 










Figure 4.9 Amicetin analogues 
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In spite of having an aminoacyl group, a cytosine, and a second basic center, 
analogues 13 to 20 are all devoid of any antimycobacterial activity, which 
essentially supports this hypothesis. The right molecular spacer is needed for 
efficient binding and activity. We presume that the molecular spacers of these 
compounds are too short (analogues 13 to 17) or too long (analogues 18 to 20) to 
properly mimic the conformation of the dimethylamino group of amicetin.  The 
overall architecture of the spacers and cationic tails also affects antimycobacterial 
Figure 4.9 (continued…) 
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activity.  Methyl groups, carboxyl groups and phenyl rings in analogues 13 to 15 
and analogues 18 to 20 are not tolerated, which may be due to a specific and tight 
binding pocket (vide infra). Antimycobacterial activity appears to be favored by 
having the combination of a more flexible alkyl group and a terminal primary amine. 
The most active of the compounds, analogue 3 (IC50 of 0.98 µM), contains n-butyl as 
its linker and 4-aminopiperidyl as its cationic tail. A less flexible linker such as 2-
butynyl in   analogue 1, or a tertiary amine such as analogue 4, leads to a ten-fold 
decrease in activity with analogue 1 and 4 having IC50 values of 8.2 µM and 7.4 µM 
respectively. The least active of the synthesized compounds were analogues 2 and 5, 
with IC50 values of 19 and 22 µM, respectively. The drastic loss of activity displayed 
by analogue 2 further illustrates that the right molecular spacer and basic group is 
needed for antimycobacterial activity.  Analogue 2 has a rigid alkynyl group and 3° 
amine, the combination of which lowered its activity 20-fold, relative to analogue 1 
and 80-fold, relative to amicetin.  Analogue 5 has a flexible but shorter n-propyl 
group and a 2° amine which afforded a lower antimycobacterial property.  
We suspect and have confirmed via co-crystallization with 70S ribosomes that 
these active analogues share a similar binding conformation and binding site with 
amicetin (vide infra).  The appropriate length and flexibility of molecular spacers 
allows these molecules to adopt a conformation analogous to amicetin (Figure 4.10). 
However, the absence of any activity on compounds 16 and 18, which are close 
analogues to active compounds 5 and 4, respectively, somehow contradicts this 
supposition.  Analogue 18 has a flexible triethylene glycol (TEG) linker in place of 
the 1-n-butyl-(4-(N,N’-dimethyl)piperidyl group in 4, while analogue 16 has a 
threonine moiety in place of the proline group in 5.  One could expect the TEG 
analogue and threonine analogue to  exhibit  antimycobacterial  activity  similar  to 
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analogue 4 and 5, respectively, by simply examining the aligned structures of these 
molecules (Figure 4.11).  However, data from our MTT assay show otherwise.  Either 
the TEG side chain was unable to generate a stable binding conformation for 
analogue 18, or other factors, such as permeability, may be affecting its activity.  In 
addition, it is unclear why proline in analogue 5 is more favored than threonine in 
analogue 16. The differences in activity may be due to differences in the binding 
affinity of these molecules to a very specific binding pocket. 
At this point, we cannot rule out other possible factors (i.e., cell wall 
permeability and efflux mechanisms) influencing the inefficacy of three quarters of 
analogues presented here. Nevertheless, we have observed a general structure 
activity relationship among our analogues that agrees with our proposed simplified 
pharmacophore.  In addition to the required nucleobase, the two basic centers at 
both ends of the molecule are needed for activity.  Appropriate length and flexibility 
of the molecular spacer appears to be essential for proper positioning of the cationic 
tail, and therefore important for antimycobacterial activity.  For the cationic tail, 
primary amine groups are more favored than their amine counterparts, presumably 
Figure 4.10 Aligned structures of amicetin and analogue 3 
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due their ability to form stronger hydrogen bonding or cationic interactions.  
  
 
4.4.2  Amicetin Analogues as Protein Synthesis Inhibitors 
 
Members of the aminoacyl nucleoside class of antibiotics are known to be protein 
synthesis inhibitors.14  To elucidate the mechanism of action of our compounds, we 
tested our analogues for protein synthesis inhibition using a cell-free translation 
assay.  We used an in vitro prokaryotic protein expression system, which employs 
S30 E. coli extracts, the plasmid pBESTluc™ DNA containing the eukaryotic firefly 
luciferase gene, luc, as well as the necessary proteins for both transcription and 
translation of luciferase (Figure 4.12). Luciferase is the enzyme that produces 
bioluminescence in fireflies through the oxidation of luciferin to oxyluciferin. The 
light produced is easily measured using a luminometer, and is directly proportional 
to the amount firefly luciferase protein synthesized. Thus, light output is an 
indication of the level of protein synthesis. For the purposes of prelimnary 









Figure 4.12 Inhibition of luciferase translation 
The inhibitory properties observed in this assay correlate well with anti-
mycobacterial activity and SAR of these compounds (Figure 4.13). Analogue 3 was 
found to be the best inhibitor, exhibiting 99% inhibition of protein synthesis, 
followed by analogue 4 at 94% inhibition.  Analogue 1 gave modest inhibition at 
77%, while analogue 2 and 5 were the weakest inhibitors at 61% and 42%. A full 
inhibition curve was measured for analogue 4 and amicetin (Figure 4.14).  The IC50 
of analogue 3 for protein synthesis inhibition was  3.8 µM,  while  the  IC50  of 
amicetin was 1.6 µM.  The trend we  have  observed  supports  our  assumption  that 
molecules achieve their antimycobacterial properties by inhibiting translation.  The 
significance and correlation of these observations with respect to their interaction 






















4.4.3  Narrow Antimicrobial Spectrum of Amicetin Analogues 
None of the amicetin analogues exhibited any activity against other test 
microorganisms.  Our compounds are inactive against gram-positive B. subtilis, 
gram-negative E. coli and A. baumanii, and opportunistic fungi C. albicans.  All 
compounds tested negative for any activity even at 100 µM of antibiotic.  The narrow 
spectrum of activity observed among the analogues was expected, since our parent 
molecule, amicetin, is selectively effective against mycobacteria and gram-positive 
species such as S. aureus and B. subtilis, but is essentially ineffective against gram-
negative species.15  However, both amicetin and our active analogues were found to 
inhibit translation in cell-free E. coli ribosome.  This suggests that other factors such 
as poor drug uptake due to cell wall permeability may be cause for the observed 
resistance in our analogues. On the other hand, amicetin is known to be active 
against B. subtilis, resistance of our analogues to this species was not expected.  It is 
possible, however, that the specific strain we used for the assay is intrinsically 
resistant since amicetin-resistant B. subtilis strains have been identified.16    
The selective antimicrobial activity of our compounds is particularly 
interesting since the use of narrow spectrum antibiotics is generally favored in 
clinical practice.  Potentially, the use of amicetin analogues in the treatment of TB, 
which requires a long and intensive regimen of antibiotics, will circumvent 
resistance selection in nontargeted pathogens.  
4.4.4 Selective Cytotoxicity of Amicetin Analogues 
One important characteristic of a good antimicrobial agent is selective 
toxicity- that is the growth of the infecting organism is inhibited while the cells of 
the host remains largely unaffected.17  We tested the compounds from our library 
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against CEM-TART leukemia cell to determine if our antimycobacterial agents are 
selective for M. tuberculosis over mammalian cells (Table 4.2).  All compounds 
showed no appreciable cytotoxicity against CEM-TART leukemia cell lineage18  even 
at a maximum concentration of 100 µM. Amicetin is less cytotoxic to mammalian 
cells compared with other antibiotics  of  its  class.  We  were  hoping to improve 
selectivity with our compounds.  With respect to IC50 values, we have found all 
analogues, but most especially analogue 4, to  be  more  selective  than amicetin. 
Amicetin’s selectivity index ratio with respect to mammalian cells and mycobacteria 
is about 19.  Selectivity is greatly improved by analogue 4 whose selectivity index 
ratio is greater than 100. 
4.4 .5 Structures of Analogue 1 and 5 Bound to the  
70S T. thermophilus Ribosomes 
Based on similar inhibitory patterns and nonsynergistic inhibitory responses, 
members of the pyrimidine nucleoside class of antibiotics were believed to be 
competing for identical sites within the peptidyl transferase center (PTC) of the 
ribosome.19  We postulate that our analogues possibly bind to the PTC of the 
blasticidin S.20, 21  To investigate this, analogues 1 and 5 were co-crystallized  with 
Table 4.2 Comparison of cytotoxicity data vs. antimycobacterial activity 
Compound % Growth Inhibition of 
CEM-TART at 100 µM 
CEM-TART IC50 Mtb H37Ra IC50 
amicetin 100 4.5 0.24 
1 24 > 100 µM 8.2 
2 27 > 100 µM 19 
3 18 > 100 µM 0.98 
4 26 > 100 µM 7.4 
5 31 > 100 µM 22 
  
246 
the 70S subunit of the ribosome of Thermus thermophilus (Tth).  Analogues 1 and 5 
occupy the same binding site and similar conformation as amicetin (Figure 4.6, vide 
infra). Analogue 1 closely resemble the binding conformation of amicetin compared 
to 5 (Figure 4.6, Figure 4.7A and Figure 4.7B vide infra). It forms a Watson-Crick 
base pair between the cytosine moiety and the guanine base of G2262 (G2251), Tth, 
(E. coli) numbering.  The carboxyl group of α-methylserine forms a hydrogen bond 
with the guanidine of R18 (L16 ribosomal protein). In addition, the hydroxyl group 
of α-methylserine also forms a  hydrogen bond with the carboxyl of E16 and with the 
phosphate group of G2506 (G2495).  The adenine base of A2613 (A2602) π-stacks 
with p-aminobenzoyl of amicetin.  The aminosugar moiety forms a cation-π 
interaction with the nucleobase of A2450 (A2439).  
The binding conformation of analogue 5 differs from the two with respect to 
the some key interactions. The π-stacking interaction between p-aminobenzoyl of 
analogue 5 and A2613 (A2602) appear to be more skewed than analogue 1.  
Analogue 5 also does not have the same hydrogen bond network; only its hydroxyl 
group from its α-methylserine forms polar contacts with the phosphate of G2506 
(G2495).  In addition, the cation-π interaction with A2450 (A2439) is absent in 
analogue 5.  Hydrogen bonding between the prolinyl group and the phosphate of 
C2085 (C2064) replaces this cation-π interaction. - 
Our crystal structure supports the observed trend in biological activity (anti-
mycobacterial property and inhibition of protein synthesis observed among the 
analogues.  The absence of these key interactions could explain the inactivity of our 
analogues. Having only one basic center could eliminate either the hydrogen 
bonding interaction with the E16-V17-R18 sequence of the L16 ribosomal protein or 
the cation-π interaction with A2450 (A2439).  The same inference could be made for 
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analogues that have molecular spacers of inappropriate length. The absence of the 
cation-π interaction in analogue 5 likely resulted in its weaker binding to the 70S 
ribosome and much lower activity compared to the other active analogues. 
The strength of the binding energy appears to be important for better activity 
and is reflected in our SAR.  Stronger cation-π interaction is afforded by having a 
primary amine than by having a tertiary amine.  While the exact values for our 
substituents are not reported, a possible explanation can be derived from the 
electronic interactions and binding energies of ammonium cations and benzene.   
The gas phase binding energy between a benzene ring and an ammonium ion 
decreases with each succeeding methylation (Table 4.3).22 From this, one can predict 
that the binding energy of 4-aminopiperidyl group with the adenine of A2450 
(A2439) would be  stronger  than  the  dimethyl  analogue.  The   binding   energy of  
cation-π interaction also depends on distance and conformation of the ion and the  π- 
system; between adenine group and a protonated primary amine the value could be 
anywhere from 9 to 16 kcal/mol.23  Amicetin is four times more active than analogue 
1 despite having a 3° amine for its cationic tail presumably because its aminosugar 
moiety overlaps better with A2450 (A2439) than the aminopiperidyl group of 1 
(Figure 4.15).  Additionally, having a more flexible molecular spacer (alkyl vs. 
alkynyl) between the cytosine group and the cationic tail allows the molecule to 
adopt a conformation that affords stronger cation-π interactions.  
 
 
Table 4.3 Experimental binding energies of cation-π interactions 
 






While electronic arguments could explain the observed SAR afforded by 
cation-π  interactions,  we   cannot   rule   out   the   possible   contribution   of steric 
interactions  in  the  observed  SAR.  Our  crystal  structure  shows  a  rather tight 
binding pocket for amicetin and its analogues, specifically in the A2450 (A2439) 
region.  In this case, having a bulky methyl group (i.e., amicetin, analogue 2, and 
analogue 4) in place of hydrogens (i.e., bamicetin, analogue 1, and analogue 3) in the 
amino end of the moleculer results in steric repulsions with the phosphate  backbone 
of A2450 (A2439), affording a lower binding affinity presumably eventually resulting 
in lower antimycobacterial activity.   
The strength of π-stacking interaction between p-aminobenzoyl moiety and 
A2613 (A2602) (Figure 4.16) maybe important for activity.  Energies of π-stacking 
interactions could range from 1.6 to 2.4 kcal/mol, and are largely dependent on the 
electrostatics and orientation of the aromatic ring.24, 25 The aromatic ring in amicetin 
overlaps with A2613 in an off-center, face-parallel manner.  The stacking appears to 
be more skewed in analogue  1  and analogue 5. The differences in stacking 
orientation could also contribute to the trend in activity observed.  Better overlap 
Figure 4.15  Comparison of cation-π interactions of amicetin (yellow), analogue 1 
(magenta), and analogue 5 (cyan) 
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between the aromatic rings contributes to a better binding interaction between the 
antibiotic and the ribosome, leading to better activity.  
The hydrogen bonding network formed between the α-methylserine moiety 
and residues of L16 in amicetin   and in  analogue 1 and 5  may also explain the 
decrease in overall antimycobacterial activity with respect to amicetin.  Literature 
precendence have established the importance of the α-methylserine moiety. 26 
Inhibition of translation is decreased by 10-fold in the absence of the aminoacyl 
group. Our crystal structures show that hydrogen bonding interactions in amicetin 
are more extensive compared to the other two (Figure 4.7A and Figure 4.7B, vide 
infra) and thus could result in an overall higher binding affinity to the ribosome, and 
better biological activity. 
 Aside from antimycobacterial activity and inhibition of protein synthesis, our 
analogues displayed selective cytotoxicity against mycobacteria over mammalian 
Figure 4.16  Comparison of π-stacking interactions of amicetin (yellow), 
analogue 1 (magenta), and analogue 5 (cyan) 
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cells.  The observed selectivity is particularly interesting, considering that the 
binding site of our analogues, the peptidyl transferase center, is highly conserved in 
prokaryotes and eukaryotes.  Without discounting other mechanisms of inherent 
resistance (i.e., efflux pumps and cell wall permeability) present in eukaryotes, 
specially mammalian cells, we presume that the key interactions of our analogues 
with the prokaryotic ribosome is not observed in the eukaryotic system.  When the 
crystal structures of the ribosome-bound analogues were superimposed with the 
crystal structure of empty 80S S. cerevisiae ribosomes, S. cerevisiae (E. coli) 
numbering (Figure 4.17),27 it appears that certain interactions are not favored in the 
tight binding pocket of the yeast ribosome.  Steric repulsion between the cytosine 
moiety of amicetin and its analogues with G2620 (G2252) is observed in the 
superimposed structures. (Figure  4.18).  In addition, misalignment of the cytosine 
moiety with G2619 (G2251), preventing it to form a proper GC pair (Figure 4.19).    
The α-methylserine moiety also appears to be bumping into the QQG 
sequence of L ribosomal protein, and the phosphate of A2864 (A2596) (Figure 4.20). 
In addition to this, A2808 (A2439) is located further away by at least 1 Å preventing 
strong binding contacts (Figure 4.21).  A2971 (A2602) is also positioned several 
angstroms away to form any stable π-stacking intercations (Figure 4.22).  We also 
compared its conformation with the Apo-70S T. thermophilus ribosomes, due to the 
fact that its assume different conformations and orientations in every crystalline 
complex. A2971 (A2602) orientation in both yeast and Apo-70S T. thermophilus 
ribosomes are very different from the orientation in our crystal structures 
(Figure 4.23). Based solely on our crystallographic data, it is hard to conclude on 
















Figure 4.18  Steric replulsion with G2620 (G2252) in superimposed structures of 
amicetin (yellow), analogue 1 (magenta), and analogue 5 (cyan)  




Figure 4.17 Superimposed structures of amicetin (yellow), analogue 1 (magenta), 
















Figure 4.19  Misalignment observed in the GC pair in superimposed structures of 
amicetin (yellow), analogue 1 (magenta), and analogue 5 (cyan)  




Figure 4.20  Steric replulsion with residues Q112-G113-G114 
  in superimposed structures of amicetin (yellow), analogue 1 (magenta), and 











Figure 4.21  Absence of cation-π interactions with A2808 (A2439)  in 
superimposed structures of amicetin (yellow), analogue 1 (magenta), and 






Figure 4.22  Absence of π-stacking interactions with A2971 (A2602)  in 
superimposed structures of amicetin (yellow), analogue 1 (magenta), and 
analogue 5 (cyan) with 80S S. cerevisiae ribosome 
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4.5  Conclusion 
We have identified amicetin analogues exhibiting antimycobacterial activity 
against M. tuberculosis H37Ra and limited cytotoxicity against mammalian cells 
CEM-TART leukemia cell lineage.  Analogues were found to inhibit protein 
synthesis. Crystal structures of ribosome-bound amicetin and representative 
analogues provide insight into their structure activity relationships and biological 
activity. This report presented our initial efforts in the discovery of amicetin anti-
tubercular agents.  Continued efforts are on going towards the synthesis and in 
depth biological evaluation of new compounds. 
Figure 4.23  Comparison of A2971 (A2602)  in superimposed structures of 
amicetin (yellow), analogue 1 (magenta), and analogue 5 (cyan) with  
80S S. cerevisiae ribosome (light gray) against Apo 70S T. thermophilus  
ribosome (purple) 
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4.7  Supplemental Information 
4.7.1  General Experimental Procedures 
Test organisms were obtained from the American Type Culture Collection 
(ATCC).  Each organism was grown in their respective broth media according to 
Clinical Laboratory Standards Institute (CLSI) methods and published procedures.1, 
2 Chemicals and other growth supplies were purchased from commercial sources 
(Sigma Aldrich and Fischer Scientific). Library screening and assays were performed 
in 96-well plates. Absorbance measurements were measured on a Multiskan FC 
plate reader (Fisher Scientific, Waltham, MA). Luminescence measurements were 
performed on a Microbeta Trilux Liquid Scintilation and Luminescence Counter. 
 
 
4.7.2  M. tuberculosis Susceptibility Testing 
Mycobacterium tuberculosis H37Ra (ATCC 25177) was grown in 7H9 
medium with ADC supplement (Remel, Lenexa, KS).  Colorimetric 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was employed to 
measure the growth inhibition of M. tuberculosis H37Ra (ATCC 25177) following a 
modified procedure from published methods.2, 3  Test compounds were dissolved in 
DMSO to produce stock solutions at 2 mM concentration; effective working 
concentration of 100 µM.  Two-fold  serial  dilution  plates  of  each  compound  were 
                                                
 
1 Ferraro, M. J.; Craig, W. A.; Dudley, M. N.; Eliopoulos, G. M.; Hecht, D. W.; 
Hindler, J.; Reller, L. B.; Shelodon, A. T.; Swenson, J. M.; Tenover, F. C.; Testa, R. 
T.; Weinstein, M. P.; Wikler, M. A. 5th edition. Wayne: NCCLS; 2000. 
2 Koch, M.; Bugni, T. S.; Pond, C. D.; Sondossi, M.; Dindi, M.; Piskaut, P.; 
Ireland, C. M.; Barrows, L. R. Planta Med. 2009, 75, 1326-1330. 
3 Foongladda. S.; Roengsanthia, D.; Arjrattanakool, W.; Chuchottaworn, C.; 
Chaiprasert, A.; Franzblau, S. G. Int. J. Tuberc. Lung Dis. 2002, 6, 1118-1122.  
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prepared for growth inhibition curves; effective working concentration from 100 µM 
to 390 nM. 200 µL of ADC enriched 7H9 medium containing M. tuberculosis  cultures 
were dispensed at approximately 10,00,000 cells per well. Each plate contains 4 wells 
of noninoculated media as no-growth control, 4 wells of DMSO as growth control, and 
8 wells of rifampicin as positive control. One µL of test compound (in DMSO) was 
added to the rest of the plate in triplicate. Final well volume was 200 µL. The test 
plate was incubated for four days at 37 °C,  after which,  11 µL of sterile MTT (5 mg/
mL in PBS) was added and was further incubated overnight. Insoluble purple 
formazan product formed from the metabolism of MTT by viable M. tuberculosis was 
then solubilized by the addition of 50 µL of a solubilization solution (5 % SDS w/v, 50 
% DMF v/v, 45 % H2O v/v). Cell viability was measured as the absorbance at 570 nm 
(A570). All data were corrected against no-growth control wells. Percentage inhibition 
was calculated as the fraction of the average absorbance of the test wells over the 
corrected average absorbance of the growth (DMSO) control wells, subtracted from 
unity and multiplied by 100.  Standard deviation was computed for error analysis. 
Growth inhibition curves were fitted and half-maximal inhibitory concentrations 
(IC50) were obtained by nonlinear regression analysis using GraphPad™ Prism 6.   
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4.7.4 Antimicrobial Spectrum 
Each test organism was inoculated and grown in their respective broth 
media: Mueller-Hinton II media (Difco BD, Franklin Lakes, NJ) for Escherichia coli 
(ATCC 25922); MOPS buffered RPMI-1640 (NCCLS 2007) for Acinetobacter 
baumannii (ATCC 19606), Bacillus subtilis (ATCC 6633), and Candida albicans 
(ATCC 90028).1 Each plate contains 4 wells of uninoculated media as no-growth 
control, 4 wells of DMSO as growth control, and 8 wells of purchased (Sigma 
Aldrich), organism-appropriate antibiotic as positive control: kanamycin (E. coli), 
gentamycin  (B. subtilis), and itraconazole (A. baumannii and C. albicans). The 
remaining wells received 1 µL of the test compound from the same dilution plate 
prepared for the TB assay. For the B. subtilis plate 11 µL of sterile MTT (5 mg/mL in 
PBS) was added. Final well volume is 200 µL. Plates were incubated overnight at 
37oC. Minimum inhibitory concentration (MIC), the lowest concentration of test 
compound in which complete growth suppression was noted, was determined for all 
test organisms except for B. subtilis, whose data was processed similarly as M. 




4.7.5 Cytotoxicity Assay 
In vitro cytotoxicity assay was performed as previously described.4 CEM-
TART cells (AIDS Research and Reference Reagent Program, NIAID, NIH) were
grown and maintained in culture media consisting of RPMI (Hyclone), 20% FBS 
(Hyclone), and CellGro antibiotics/mycotics (Mediatech, Manassess, VA). CEM-TART 
cells were dispensed at approximately 20,000 cells per well. Each plate contains 8 wells 
of noninoculated media as no-growth well, 8 wells of doxorubicin as positive control, 
and 8 wells of DMSO growth well as negative control. Test compounds (1.0 µL), from 
the same dilution plate prepared for the TB assay, were assayed in triplicate. Plates 
were incubated in a waterjacked incubator with 5% CO2 at 37oC for 3 days.  After 
incubation, 11 µL of 5 mg/mL MTT was added. The plate was further incubated for 
2-3 hours. The plates were shaken for 5 minutes on a microplate shaker and the 
medium was aspirated. 150 µL DMSO was added to the formazan precipitate. Cell 
viability was measured as A570. Percent inhibition was determined similarly as M. 
tuberculosis H37Ra. 
4.7.6  Protein Synthesis Inhibition Assay 
Analogues 1 to 5 were assayed for inhibition of prokaryotic translation using 
the commercially available E. coli S30 system (Promega). Protein production was 
monitored via a luciferase readout. Reactions were performed as described by the 
manufacturer. Stock solutions of test compounds were prepared by dissolving the 
analogues in DMSO to a final concentration of 2.5 mM for the preliminary screening; 
4 Noro, J. C.; Barrows, L. R.;  Gideon, O. G.;  Ireland, C. M.; Koch, M.; 




effective working concentration of 50 µM. Similarly, analogue 3 and amicetin were 
diluted to 5.0 mM and two-fold serial dilutions were made for a dose-response curve; 
effective working concentration from 100 µM to 781 nM. Nuclease-free water and 
streptomycin (10 mg/mL) were used as blank and positive control, respectively. 
Reactions were performed in triplicates. In vitro  transcription/translation reactions 
were assembled by mixing  20 µL of S30 Premix, 15 µL of S30 extract, 5.0 µL of 
complex amino acids, 1.0 µL of pBESTluc plasmid, 8.0 µL of nuclease-free water, and 
1.0 µL of test compound. Reactions were incubated at 37 °C for 60 min.  The 
reactions were stopped by placing the microcentrifuges on ice for 5 min. 
Subsequently, 100 µL of Steady-Glo Reagent (Promega) was added to wells 
containing 5.0 µL of translation reaction and 95 µL distilled water. Luminescence 
readings obtained on Luminescence measurements were performed on a Microbeta 
Trilux Liquid Scintilation and Luminescence plate reader. Percentage inhibition, 
dose-response curve and IC50 data were obtained as described in the TB assay 
 
 
4.7.7 Complex Formation and Crystallization 
70S T. thermophilus ribosomes were purified and crystallized as previously 
described.5 Purified 70S ribosomes were diluted with a buffer solution [5 mM Hepes 
(pH 7.5), 50 mM KCl, 10 mM NH4Cl, and 10 mM Mg(OAc)2 ] to a final concentration 
of 10 mg/mL.  70S ribosomes crystals werer grown at 19°C via sitting-drop vapor 
diffusion by mixing 3 µL of the ribosome sample with 3.5-4.5 µL of the crystallization 
solution [2.9% PEG 20K, 9% methyl-2,4-pentanediol (MPD), 175 mM L-arginine, and 
100 mM Tris–HCl (pH 7.6)]. YfiA protein (59 µM) was added to stabilize the head  of 
                                                
 
5 Polikanov, Y. S.; Blaha, G. M.; Steitz, T. A. Science 2012, 336, 915-918. 
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the 30S ribosomal subunit. Concentration of MPD was increased to 40% in stabilize 
the crystals, upon addition of  analogue 1 (1 mM) and analogue 5 (3 mM).  The 
crystals were flash frozen in a nitrogen cryostream at 80 K after 24 hours of 
equilibration.  
 
